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Breast cancer is the most common cancer in women worldwide. The 
development and clinical progression of breast cancer are well defined with invasion 
and metastasis as the main causes of death. Substantial evidence have demonstrated 
that heparan sulphate and its sulphation status are involved in many biological 
processes of breast cell malignant transformation and cancer progression, such as cell 
proliferation, adhesion, migration, invasion and metastasis. Nevertheless, depending 
on the tumour microenvironment, heparan sulphate may act as a promoter or inhibitor 
in tumour growth and progression. Targeting heparan sulphate in breast cancer 
treatment therefore is still one of the challenges in breast cancer research. A better 
understanding of the effects of differentially sulphated heparan sulphate on cancer cell 
behaviours is important for the development of these molecules as therapeutic targets 
for breast cancer. 
The present study examined the effects of sulphation status of heparan sulphate 
on modulating the biological behaviours such as cell proliferation, adhesion, 
migration and invasion in breast epithelial and cancer cells. Diverse regulatory 
functions of differentially sulphated heparan sulphate in breast cancer in vitro 
biological processes were also explored.  
Reduction in heparan sulphation in breast cancer cells was demonstrated to 
inhibit breast cancer cell proliferation. The inhibitory effect could be rescued by 
addition of porcine intestine mucosa-derived heparan sulphate (HS-PM), but not of 
highly sulphated bovine kidney derived heparan sulphate (HS-BK). Undersulphation 
also disturbed cell cycle progression in breast cancer cells. Reduction in heparan 
sulphation in breast cancer cells was shown to increase cancer cell adhesion and 
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formation of focal adhesion complex with upregulation of FAK and paxillin at both 
gene transcript and protein levels. The increment in adhesion could be completely 
blocked by exogenous HS-BK and partially blocked by HS-PM. Results also showed 
that inhibition of heparan sulphation as well as the presence of HS-BK, both led to a 
significant reduction in cell migration. In contrast, HS-PM was able to block 
inhibitory effect on migration. Reduction in HS sulphation also inhibited breast cancer 
invasion in vitro. 
The present study also showed loss of function of HS3ST3A1 by siRNA 
silencing in MCF-12A cells impaired heparan sulphation. Evaluation of in vitro cell 
proliferation, adhesion, migration and invasion after silencing HS3ST3A1 in 
MCF-12A cells indicated phenotypic changes in the cells with a low proliferation rate 
and low adhesiveness, but higher mobility and invasiveness.  
In order to elucidate the molecular networks following silencing of HS3ST3A1, 
genomic gene expression profiles after silencing HS3ST3A1 in MCF-12A cells were 
analyzed by Affymetrix GeneChip. Differentially expressed probe sets (186 genes) 
were identified. Among these genes, of particular interest were cell-cycle related 
genes and cell-ECM communication genes. Most of the cell cycle related genes were 
down-regulated and the cell-ECM communication genes were dysregulated. This gene 
expression profile was in accordance with the phenotypic changes observed in 
MCF-12A cells after silencing HS3ST3A1. 
The study increased the knowledge of the function of undersulphation in heparan 
sulphate in human breast cancer and epithelial cells regarding cell growth and 
progression. The study also broadened understanding of the function of 
structure-specific heparan sulphation by HS3ST3A1 in cell phenotypic changes. 
Furthermore, the gene expression profiling analysis revealed gene expression pattern 
Summary 
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or “gene fingerprint” after silencing HS3ST3A1 in the regulation of the phenotypic 
changes in breast epithelial cell by 3-O-sulphation HS, which could serve as the basis 
for assessing different gene functions in breast cancer progression in the future.      
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1.1 Introduction of breast cancer  
 
Breast cancer is a malignant tumour that arises from epithelial cells lining the 
ducts and lobules of breast. It occurs in both men and women, although male breast 
cancer is rare as the male breast is a rudimentary structure. 
The mammary gland is a structurally dynamic organ, varying with age, 
menstrual cycle and reproductive status. Structurally it contains a branched 
tubuloalveolar system. The mammary gland has about 12 to 20 breast lobes. Fibrous 
suspensory ligaments radiating out from the nipple separate these lobes by 
collagenous connective tissue. Each lobe drains into separate lactiferous ducts and 
from there into lactiferous sinuses that narrow and converge on the nipple. Within the 
lobes are varying amounts of adipose tissue. Each lactiferous duct is lined by a 
two-cell layered cuboidal-low columnar or epithelium with a sparse discontinuous 
outer layer of myoepithelial cells and a basal lamina. In the non-pregnant state, the 
mammary gland consists of lactiferous ducts, each ending in a group of blind saccular 
evaginations, named alveoles.  
At puberty, circulating estrogen (in the presence of prolactin) stimulates the 
development of the lactiferous ducts and the enlargement of the surrounding fat tissue 
Progesterone stimulates the formation of new alveolar buds, replacing old, regressing 
buds, which eventually disappear at the end of ovarian cycle. These cyclic changes 
are repeated during the menstrual cycles. 
During pregnancy, the mammary gland comes under the influence of oestrogen 
and progesterone. Prolactin and placental lactogen, in the presence of estrogen, 
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progesterone and growth factors, stimulate the development of lactiferous ducts and 
secretory alveoli at the ends of the branched ducts. During lactation, the lactiferous 
duct system and the lobular alveolar tissue are fully developed and functional. 
Prolactin stimulates secretion by alveolar cells. These hormones cause a further 
branching of the ductal system which ends in clusters of saccules, named alveoli. In 
humans, approximately 200 alveoli are surrounded by a connective tissue to form a 
lobule. The lobule is the basic functional unit for milk production. About 25 lobules 
are packaged to form a lobe. Luminal epithelial cells of ducts and alveoli are 
precursors of myoepithelial cells, which migrate to the basal region of the lining 
epithelium. The epithelial-myoepithelial conversion also occurs in the mature 
mammary gland. This understanding of breast anatomy is important because breast 
lumps including cancer develop mostly within the ducts and glands. Malignant 
transformation of breast epithelial cells from noncancerous to precancerous and 
cancerous stages is a multistep disease process with progressive genetic and 
phenotypic alterations. Numerous factors have been reported to contribute to breast 
malignant transformation, including chemical carcinogens, genetic susceptibility, 
dysregulation of oncogenes and dietary habits. 
1.1.1 Epidemiology of breast cancer  
According to the NCI SEER Cancer Statistics Review, the age-adjusted 
incidence rate of breast cancer is 127.8 per 100,000 women per year in USA. These 
rates are based on cases diagnosed in 2000-2004 from 17 SEER geographic areas. It is 
estimated that 178,480 women will be diagnosed with breast cancer and 40,460 
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women in USA will die of the disease in 2007 (Ries et al., 2007). The American 
Cancer Society (ACS) has a higher estimation with 240,510 new cases of breast 
cancer expected to be diagnosed among women in the United States: 178,480 invasive 
breast cancers and 62,030 cases of in situ breast cancer (Fritz et al., 2000; American 
Cancer Society, 2007). 
Though breast cancer incidence rates have been reported to be different between 
Asian and Caucasian populations (Leung et al., 2002; Chia et al., 2005; Shen et al., 
2005) there is a rapid rise in female breast cancer incidence in rapidly developing 
Asian countries including Singapore. The current age-adjusted breast cancer incidence 
rate in Singapore is 54.9 per 100,000 women per year during the 5-year period of 
1998–2002, from just 20 per 100 000 women in 1968–1972, increasing by 
approximately 3 folds from year 1968 (Seow et al., 2004). Many researchers believe 
that adoption of a "Westernised" lifestyle in Singapore which includes a combination 
of decreased parity, delayed childbearing, diet rich in saturated fats, early menarche 
and a sedentary lifestyle pattern has been associated with increased incidence of 
breast cancer (Ng et al., 1997; Gago-Dominguez et al., 2003; Chia et al., 2005; Chew 
et al., 2006; Ursin et al., 2006; Sim et al., 2006).  
1.1.2 Risks of breast cancer 
Breast cancer is the most common cancer among women in Singapore, affecting 
about 1000-1100 women annually. However there is no single underlying cause of 
breast cancer. Research has revealed a complex interplay of factors such as hormonal, 
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reproductive, genetic, environmental, dietary and other factors can cause breast cancer. 
Some of the known risk factors include:  
1) Early menarche, late menopause and long duration of menstruation (Kato et 
al., 1988); 
2) Nulliparity or delayed first childbirth (e.g. >30 years at first child birth) 
(Menes et al., 2007); Additional child birth is positively related to breast 
cancer. Having one child was not associated with a decrease in breast 
cancer risk. But each additional birth was found to reduce breast cancer risk 
by 14% in women who were 40 and older (Andrieu et al, 2006) 
3) Genetic susceptibility. Since the discovery of the BRCA1 and BRCA2 
genes, much attention has been focused on characterizing the genetic risk of 
breast cancer. It is typically estimated that mutations in BRCA1 and 
BRCA2 account for 15%–25% of the familial breast cancers (Easton et al., 
1993; Ford et al., 1995; Yang and Lippman, 1999; Balmain et al., 2003). 
Other genetic association with breast cancer have also been reported (Walsh 
et al., 2006; Walsh and King, 2007); 
4) Hormone    Use of hormone replacement therapy (Tavani et al., 1997; 
Coombs et al., 2005). Studies of breast cancer have consistently found an 
increased risk associated with elevated blood levels of endogenous estrogen, 
clinical indicators of persistently elevated blood estrogen levels, and 
exposure to exogenous estrogen plus progestin through 
hormone-replacement therapy and the use of oral contraceptives. In 
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experimental animals, estrogen treatment leads to the development of 
mammary tumors（Clemons and Goss, 2001;Fournier et al., 2005); 
5) Family history of breast cancer, especially the first degree females 
(Collaborative Group on Hormonal Factors in Breast Cancer., 2001); 
6) History of atypical epithelial hyperplasia on breast biopsy (Dupont and 
Page, 1985; Hartmann et al., 2005); 
7) Obesity (Kuhl, 2005; Carmichael, 2006);  
8) Cigarette smoking (Couch et al., 2001; Terry and Rohan, 2002); 
1.1.3 Classification of breast cancer  
Clinically, TNM (primary tumour, regional lymph nodes, distant metastasis) 
classification system is recommended by American Joint Committee on Cancer 
(AJCC) (Singletary and Connolly, 2006) to assess a breast cancer patient’s prognosis 
and help doctors to make treatment decisions.  
Stage 0:  Carcinoma in situ (non-invasive cancer). 
Stage I:  Tumour is small (≤ 2 cm), and cancer has not spread to the lymph nodes. 
Stage II: Tumour is small, but cancer has spread to the lymph nodes; OR tumour is 
moderate in size (2 to 5 cm), with or without lymph node involvement; OR 
tumour is large (over 5 cm), but cancer has not spread to the lymph nodes. 
Stage III: Tumour is large, and cancer has spread to the lymph nodes; OR tumour is 
of any size, but lymph node involvement is substantial; OR tumour is of 
any size, but cancer has spread to chest wall or skin. 
Introduction 
 7
Stage IV:  Cancer has metastasized beyond the axillary lymph nodes to other parts 
of the body. 
1.1.4 Diagnosis of breast cancer 
Diagnosis of breast cancer is made through a process called triple assessment, 
which includes clinical examination, imaging procedures (e.g., mammography, breast 
ultrasonography, magnetic resonance imaging [MRI scan]), and biopsy of a mass 
detected by physical examination or mammography (Berg et al., 2004). Systematic 
screening by means of clinical examination and mammography results in early 
diagnosis of breast cancer and a 25 to 30 percent decrease in mortality (Kerlikowske 
et al., 1995; Karesen et al., 2002; Dillon et al., 2005).  
1.1.4.1 Clinical breast examination 
Research on clinical breast examination plus mammography found that clinical 
breast examination contributed to breast cancer detection independent of 
mammography (Barton et al., 1999).   
1.1.4.2 Mammography 
Mammography now is the most popular examination method. It is non-invasive 
and easy to perform. The benefit value of mammography is higher in women with a 




Ultrasonography has been widely used in the screening of those with a palpable 
breast lesion, and ultrasonography now is also used for guiding fine needle aspiration. 
Recent research found that the combination of ultrasonography and mammography is 
significantly better than either modality used alone, together resulting in 9% more 
breast cancers detected (Benson et al., 2004).  
Ultrasonography has also been considered as a screening tool for younger 
women who are at high risk for breast cancer because their breast tissues are more 
dense compared with their older cohort. 
1.1.4.4 Magnetic Resonance Imaging (MRI) 
MRI as a screening test for breast cancer was first reported in the 1980s. Studies 
using MRI in high-risk women report that MRI is significantly more sensitive than 
mammography. In a recent study of high-risk women, MRI was found to be better at 
ruling out breast cancer but more likely to produce false-positive results. The 
American Cancer Society recently recommended that women at high risk of breast 
cancer undergo annual MRI screening as an adjunct to mammography beginning at 
age 30 (Saslow et al., 2007). 
1.1.4.5 Positron-emission tomography 
Positron-emission tomography (PET) scanning is an imaging method based on 
increased glucose utilization by malignant cells. It provides a quantitative evaluation 
of in vivo biodistribution of a radioactive tracer, such as the glucose analog 
fluorine-18–labeled 2-fluoro-2-deoxy-D-glucose (FDG) (Wahl et al., 1991). In the 
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evaluation of suspicious breast lesions, PET scanning has been found to be 
remarkably sensitive and specific for breast cancer detection (Wahl et al., 2004). 
1.1.4.6 Biopsy  
Biopsy and cytopathological examination are also widely accepted diagnostic 
methods and most of the time are deemed as the “gold standard” in the diagnosis of 
breast cancer based on the histopathologic or cytologic features. Today, fine-needle 
aspiration or core needle biopsy is still the standard step in “triple assessment” 
(Chaiwun and Thorner, 2007). Ultrasound-guided core needle biopsy and stereotactic 
directed biopsy have become important diagnostic tools, especially for women with 
suspicious but non-palpable breast masses. 
1.1.4.7 Biomarkers 
Apart from the above methods, detections for specific tumour markers such as 
CEA and CA153 tissue polypeptide antigen (TPA) are also the common examination 
methods for breast cancer screening (Soletormos et al., 1996; Meisel et al., 1998; 
Duffy, 1999; Soletormos et al., 2004). 
1.1.5 Treatment of breast cancer 
1.1.5.1 Locoregional therapy  
Locoregional therapy is mainly surgery and surgery is still the primary treatment 
for breast cancer. Depending on the tumour size, part or all of the breast may be 
removed. However removal of the whole breast, called radical mastectomy, is rarely 
performed today due to its severe physiologic and psychological disadvantages. 
Modified radical mastectomy is more widely accepted as the “standard” surgery 
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procedure today (Punglia et al., 2007). Lumpectomy is also performed if the breast 
cancer is only a “non-invasive ductal carcinoma” or “ductal carcinoma in situ”.  
Locoregional radiation therapy is an integral part of breast-conserving treatment. 
It is also adopted in those who can not receive surgery. This radiation therapy is more 
often used in the prophylactic prevention of recurrence of breast cancer after the 
surgery. Clinical investigations have shown that post-mastectomy radiotherapy 
reduces the incidence local and regional recurrences by 50 to 75 percent (The Early 
Breast Cancer Trialists' Collaborative Group, 1995; Whelan and Levine, 2005; Gebski 
et al., 2006). 
1.1.5.2 Systemic therapy 
Systemic therapy uses medications to treat cancer cells throughout the body. 
Systemic treatments include chemotherapy, hormonal therapy and biological therapy.  
1.1.5.2.1 Chemotherapy 
Chemotherapy is usually administered after surgery in women with operable 
breast cancer to reduce the risk of recurrence (Goldhirsch et al., 2005). However, for 
women with large tumours, preoperative chemotherapy now called neoadjuvant 
chemotherapy is also performed to shrink the size of the tumour. Research finding has 
shown that the efficacy of adjuvant and neoadjuvant chemotherapy is the same. 
Several different chemotherapy regimens may be used. However, the use of 
anthracyclines and taxanes in adjuvant chemotherapy is now increasingly becoming 
standard clinical practice in many countries (Singletary, 2003; Trudeau et al., 2005), 
in view of the superior efficacy of sequential epirubicin followed by 
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cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) (Goldhirsch et al., 2006; 
Verma and Clemons, 2007). 
1.1.5.2.2 Hormonal treatment 
Hormonal therapy has a well-established role in treatment of oextrogen 
receptor-positive invasive breast cancer (Early Breast Cancer Trialists' Collaborative 
Group, 1998). Until recently tamoxifen was the most commonly used agent in the 
hormonal therapy in premenopausal and postmenopausal women (Carlson et al., 
2006). Recent evidence showed that aromatase (oextrogen synthetase) inhibitors are 
superior to tamoxifen as anti-oextrogen therapy (Carlson et al., 2006). These clinical 
studies include both second line trials after disease progression on tamoxifen and 
first-line trials where aromatase inhibitors were compared directly to tamoxifen 
(Eiermann et al., 2001; Poole and Paridaens, 2007).  
1.1.5.2.3 Biological therapy 
An increased understanding of the biology of breast cancer has led to the 
identification of novel therapeutic targets such as the HER-2/neu protein (human 
epithelial growth factor receptor 2, also known as c-erbB-2,). Amplification and/or 
overexpression of the HER2/neu gene are in ~30% breast cancers and is associated 
with a poor prognosis (Tuma, 2006; Ferretti et al., 2007). Herceptin (also known as 
trastuzumab) is a monoclonal antibody against the HER-2/neu oncogene protein, 
which was first found to inhibit the proliferation of tumour cells in which HER-2 was 
overexpressed. Published results from three large clinical trials suggest that patients 
with early-stage disease benefit significantly from Herceptin (Piccart-Gebhart et al., 
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2005; Romond et al., 2005; Tuma, 2006; Ferretti et al., 2007).  
Although significant advances have been achieved in breast cancer early 
detection, diagnosis and medical treatment, the death rate is still high. The vast 
majority of breast cancer related mortality is due to metastasis to distant organs, such 
as bone, lung and liver with bone being the most preferential distant metastasitic site. 
Metastasis is a complicated multiple-step process which includes uncontrolled 
cell proliferation and detachment from the primary tumour mass, invasion of 
cancerous cells through the basement membrane, intravasation into the blood vessels, 
survival in the blood circulation by escaping immuno-surveillance, re-attachment to 
and extravasation out of the blood vessel wall, colonization to the target organ and 
continuation of uncontrolled cell growth and neovascularization (Chambers et al., 
2002; Klein, 2003). Hence metastasis requires a cascade of sequential steps 
containing proper coordination of cell adhesion, motility and growth (Minn et al., 
2005; Gupta and Massague, 2006). 
Over the past few decades, advances in molecular and cell biology have 
elucidated the molecular steps in cancer metastasis. The metastatic cascade requires 
sequential interactions between cell-cell and cell-extracellular matrix (ECM). The 
central components of these extracellular interactions are proteoglycans, which are 
present at the cell-ECM interface or in the ECM of virtually all kinds of cells. 
Proteoglycans have been widely shown to have crucial regulatory roles in normal 
physiological processes, such as embryogenesis, as well as in pathophysiological 
conditions such as tumourigenesis and progression. 
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1.2 Proteoglycan and glycosaminoglycans (GAGs) 
Proteoglycans are very large macromolecules, consisting of a core protein 
covalently linked with complex glycosaminoglycans (GAGs). The structural 








Fig. 1.1 Structure of the GAG linkage to protein in proteoglycans 
 
Glycosaminoglycans are unbranched, highly sulphated polysaccharides 
containing repeating disaccharides (typically repeating 40-100 times), containing 
hexosamine and hexuronic acid (GlcA or IdoA). They are modified by epimerization 
and sulphation during synthesis in the Golgi apparatus. Thus GAG is a finely 
structured chain with distinct sulphation patterns which have specific binding 
affinities to different proteins and growth factors as well as cytokines. 
There are four classes of GAGs based on the differences in GAG disaccharide 
composition, epimerization and sulphation pattern, namely, heparan sulphate 
(HS)/heparin, chondroitin sulphate (CS)/dermatan sulphate (DS), keratan sulphate 
(KS) and hyaluronic acid (HA, also called Hyaluronan) (Kjellen and Lindahl, 1991; 
Esko and Selleck, 2002, see Table. 1).  
HS/Heparin is synthesized as a polymer of repeating disaccharide of hexuronic 










(disacharides of GAG)n tetrasacharide linker 
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below). The difference between HS and heparin is that heparin is more highly 
sulphated than heparan sulphate (Coombe and Kett, 2005).  
CS and DS share the same biosynthetic precursor. CS chains always contain 
glucuronic acid while DS can have iduronic acid whose presence actually is sufficient 
to define the GAG as a DS more than a CS. CS is usually categorized on the basis of 
the position of sulphation of the hexosamine such as C-4S, C-6S and C-4, 6 S. 
KS is relatively distinct from all of the other GAGs. It is shorter and possesses 
galactose instead of an uronic acid in the repeating disaccharide. It can contain 
branching fucose residues and may be end-capped by various sugars, such as sialic 
acids (Funderburgh, 2000).  
HA is unique in that it is synthesized at the plasma membrane and is not 
attached covalently to a core protein. It is also a very large polymer with molecular 
weights up to 100kDa -10,000kDa (Fraser et al., 1997; Weigel et al., 1997). 
Apart from HA, synthesis of all GAGs including the HS/Heparin and CS/DS 
occur in the Golgi apparatus and is initiated by formation of the tetrasaccharide linker, 
Xylose-galactose-galactose-glucuronic acid with the xylose covalently linked to a 
serine residue on the core protein. The repeating disaccharide of CS/DS is glucuronic 
acid and N-acetylgalactosamine whereas in HS/Heparin, is glucuronic acid and 
N-acetyl glucosamine. Thus the backbone of HS/Heparin is a linear polysaccharide of 
the disaccharide glucuronic acid-β1-4 N-acetyl glucosamine whereas the 
corresponding product of CS/DS is a linear polysaccharide of the disaccharide 
glucuronic acid-β1-3 N-acetylgalactosamine.  
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The newly synthesized backbone chain is then subjected to a series of 
modification by different enzymes. These modifications generate along the GAG 
chains specific structures which render the GAGs diverse functions. These 
modifications are most clearly known in the synthesis of HS/Heparin (see detail 
Section 1.3 below). 
Proteoglycans are also classified according to the localization of their core 






Table 1.1 Structure of disaccharide: heparan sulphate, chondroitin sulphate, 
dermatan sulphate, keratan sulphate and hyaluronic acid  (Adapted from Kjellen 




GlcN and GlcUA or IdUA 
N and O sulphation (C2,3,6) 
 




Link sulphate at 4 or 6 C of GalNAc 
 
β-1,3 glycosidic linkage 
 
Dermatan sulphate: 
IdoA with some GlcUA 
Sulphation at 4 or 6 C of GalNAc 






Type I: GlcNAc and Gal (no 
UA) 
Sulphation on C6 of Gal or HexN 
 
β-1,4 glycosidic linkage 
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Table 1.2 Classification of proteoglycans on the basis of their localization 
and type of core protein. (Based on Waddington and Embery, 2001; 
Delehedde et al., 2001) 




ECM HA, CS, KS 225-250 aggrecan, 
versican 
Collagen-associated CS, DS, KS 40 decorin, 
biglycan 
fibromodulin 
Basement membrane HS 120 perlecan 







heparin, CS  
 
17-19 serglycin 
(CS, chondroitin sulphate; DS, dermatan sulphate; KS, keratan sulphate; HA, 
hyaluronic acid; HS, heparan sulphate) 
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1.3 Heparan Sulphate Protoglycan (HSPG) 
1.3.1 Introduction of HSPG 
Heparan sulphate proteoglycans (HSPGs) are highly sulphated proteoglycans 
with the basic structure consisting of a core protein covalently linked with heparan 
sulphate glycosaminoglycan (HS-GAG) chains (Esko and Selleck, 2002; Whitelock 
and Iozzo, 2005; Sasisekharan et al., 2006). They are expressed virtually in all kind of 
mammalian cells and ubiquitously distributed on the surface of mammalian cells and 
in the extracellular matrix (ECM).  
Based on its core protein, HSPGs can be classified into several types. The major 
family of HSPGs is syndecan which is anchored to the cell surface via a 
transmembrane domain. Glypican，another family of HSPGs, is GPI-anchored to cell 
surface. The third group of HSPGs is perlecan, agrin and the hybrid HSPG/collagen 
type XVIII, which are secreted into the ECM (Iozzo, 2005). Studies have revealed 
that, due to different core proteins, syndecans have four isoforms (syndecan 1, 2, 3, 
and 4) and glypicans have six isoforms (glypican 1, 2, 3, 4, 5, and 6) (Esko and 
Selleck, 2002; Whitelock and Iozzo, 2005; Sasisekharan et al., 2006). 
Heparan sulphate glycosaminoglycans (HS-GAG) are unbranched and highly 
acidic chains of polysaccharide. They consist of repeating β1-4 linked disaccharide 
units, D-glucosamine and glucuronic/idouronic acid (Esko and Selleck, 2002; 
Whitelock and Iozzo, 2005; Sasisekharan et al., 2006). These disaccharide units are 
substituted with acetyl and/or sulphate groups at various positions of the sugar circle 
(Aikawa et al., 2001; Shriver et al., 2002; Nakato and Kimata, 2002; Grobe et al., 
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2002; Liu and Pedersen, 2006; Mulloy and Rider, 2006). Such substitutions along the 
HS-GAG chains render a defined acetylation and sulphation pattern and make 
HS-GAGs a heterogeneous mixture at the whole level. Through the long unbranched 
and heterogeneous structure of HS-GAG chains, HSPGs can interact with a variety of 
proteins such as extracellular matrix proteins, enzymes, growth factors, and cytokines 
as well as their receptors (Esko and Selleck, 2002). Thus HSPGs can exert a critical 
role in modulating cell functions such as cell proliferation, adhesion, migration, 
invasion and angiogenesis (Jiang and Couchman, 2003; Segev et al., 2004; Sanderson 
et al., 2004; Farach-Carson et al., 2005; Hacker et al., 2005; Iozzo, 2005; Coombe 
and Kett, 2005; Cool and Nurcombe, 2006; Jenniskens et al., 2006; Van et al., 2006; 
Vives et al., 2006). To better understand the relationship between the function of HS 
and its complicated structure, it is necessary to understand the biosynthesis of HS. 
1.3.2 Synthesis of HS 
HS synthesis is a non-template driven process and involves multi-steps that 
occur in a specific and sequential manner. These steps involve many different 
enzymes in the endoplasmic reticulum (ER) and Golgi apparatus in the cells (Esko 
and Selleck, 2002; Whitelock and Iozzo, 2005; Sasisekharan et al., 2006).  
Cells begin HS synthesis by building up blocks with monosaccharide and 
sulphate through specialized transporter in the plasma membrane. Sugars are activated 
by nucleotide consumption in the cytosol to form UDP-sugars. At the same time, 
sulphate is also activated and transported to the ER and Golgi by recruiting free 
sulphate groups into 3’-phosphoadenosine 5’-phosphosulphate (PAPS) (Esko and 
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Selleck, 2002; Whitelock and Iozzo, 2005; Sasisekharan et al., 2006). PAPS is the 
universal donor of sulphate to all sulphotransferases, both in the Golgi apparatus and 
the cytosol. 
The HS chain is initiated at a tetrasaccharide linker [GlcA β1,3 –Gal β1,3 –Gal 
β1, 4 -Xyl-β1-O-(Ser)] which is covalently linked with the core protein at the Ser 
residue via the Xylose residue. The core proteins have a consensus peptide sequence 
of Ser-Gly/Ala-X-Gly (where X stands for any amino acid) at the GAG-protein 
attachment site. The tetrasaccharide linkage is formed by stepwise addition of each 
UDP-sugar residue to the serine residue of the core protein by respective 
glycosyltransferases: xylosyltransferase (XyT-I), galactosyltransferase I (GalT-I), 
galactosyltransferase II (GalT-II), and glucuronyltransferase I (GlcAT-I) (Esko and 
Selleck, 2002; Whitelock and Iozzo, 2005; Sasisekharan et al., 2006). 
After completion of the synthesis of the tetrasaccharide, the addition of the fifth 
monosaccharide determines if the GAG chin becomes HS/heparin or CD/DS.  In 
HS/Heparin, the fifth sugar is a N-acetylated glucosamine (α-GlcNAc) added by the 
key enzyme α-N-acetylglucosaminyltransferase I (GlcNAcT-I) (Fritz et al., 1994), 
whereas in CS/DS, it is GalNAc which is added by 
β-N-acetylgalactosaminyltransferase I (GalNAcT-I) (Rohrmann et al., 1985; 
Nadanaka et al., 1999). HS elongation then proceeds by the action of 
glycosyltransferases (GlcNAc-TII and GlcA-TII), which add 1,4-GlcA and 
1,4-GlcNAc units in alternating sequence to the nonreducing end of the growing 
polymer. These unbranched chains contain typically 40-100 times repeating 
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disaccharides [GlcA-GlcNAc]n (Esko and Selleck, 2002). The exostosin (EXT) 
family of genes encodes this α-glycosyltransferase involved in heparan sulphate 
biosynthesis. Five members of this family have been cloned to date in human: EXT1 
(Ahn et al., 1995), EXT2 (Le Merrer et al., 1994), EXTL1 (Wise et al., 1997), 
EXTL2 (Wuyts et al., 1997), and EXTL3 (Van et al., 1998). After that, the nascent 
HS polymer is subjected to consecutive modification by substrate-specific enzymes. 
These modifications include N-deacetylation and N-sulphation of GlcNAc, C5 
epimerization of GlcA to form iduronic acid (IdoA), 2-O-sulphation of IdoA and 
GlcA residues, as well as 6-O-sulphation and 3-O-sulphation of glucosamine (Lindahl 
et al., 1998; Aikawa et al., 2001; Shriver et al., 2002; Grobe et al., 2002; Nakato and 
Kimata, 2002; Liu and Pedersen, 2006; Mulloy and Rider, 2006). N-deacetylation and 
N-sulphation of GlcNAc are catalyzed by the dual functional enzyme N-deacetylase 
and N-sulphotransferase (NDST). C5- epimerization is exerted by the C5- uronyl 
transferase (C5 epimerase) and O- sulphation is catalyzed by different O- 
sulphotransferases at the specific positions of the disaccharide. These 
sulphotransferases are named according to the sugar residue position they sulphate. 
HS2ST sulphates the 2-O position of uronic acid, whereas HS3ST and HS6ST 
enzymes sulphate the 3-O or 6-O positions of glucosamine, respectively (Lindahl et 
al., 1998). The first modification is the N-deacetylation and N-sulphation of GlcNAc 
which is catalyzed by the bifunctional N-deacetylase/N-sulphotransferase (NDST). 
N-sulphation is important in that it is a signal for other modification. Thus 6-O- 
sulphation occurs preferentially on N-sulphated glucosamine or on N-acetylated 
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glucosamines that are immediate neighbors of an N-sulphated glucosamine (Habuchi, 
2000). Similarly C5 epimerization of glucuronic acid to iduronic acid only occurs in 
the uronic acid linked to an adjacent N-sulphated glucosamine (Habuchi, 2000). 
Iduronic acid may be 2-O-sulphated as long as it is flanked on both sides by 
N-sulphates. The 3-O sulphation of glucosamine residues of HS-GAG chain is a rare 
but important modification in HS synthesis such as for the anticoagulant activity of 
HS/Heparin (Dementiev et al., 2004; Petitou and van Boeckel, 2004). The difference 
between HS and heparin widely used clinically is that in heparin over 85% of 
glucosamine are N-sulphated, while in HS N-sulphation is only 40-50%. 
Due to the fine structure of the HS chain, all of the enzymes, except C5 
epimerase and 2-O- sulphotransferase (Habuchi, 2000; Forsberg and Kjellen, 2001; 
Kusche-Gullberg and Kjellen, 2003; Habuchi et al., 2004), have distinct isoforms for 
unique substrate preference with selective expression level in different kinds of cells. 
Nowadays almost every isoform of the sulphation enzymes has been cloned and 
isolated (Pikas et al., 1998; Kusche-Gullberg and Kjellen, 2003; Habuchi et al., 2004). 
There are four isoforms of NDSTs, three isoforms of 6-O- sulphotransferases and 
seven isoforms of 3- O- sulphotransferase (Habuchi, 2000; Kusche-Gullberg and 
Kjellen, 2003).  
The synsthesis of heparan sulphate is such a highly coordinated process that 
cells with loss of any such enzyme would result in impaired heparan sulphate 
synthesis (Forsberg and Kjellen, 2001). Many researches have demonstrated that cells 
lacking full capacity to transport sulphate have diminished sulphation (Esko et al., 
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1986). Cells lacking of a specific glycosyltransferase (Bai et al., 1999), with 
deficiency of an enzyme for transportation or formation a particular substrate, such as 
EXT (Stickens et al., 2005), UDP-Gal (Nakamura et al., 2002) or PAPS (Dejima et al., 
2006), C5-epimerase (Li et al., 2003; Feyerabend et al., 2006), or specific 
sulphotransferase, such as 2-O sulphation (Bai and Esko, 1996; Merry et al., 2001), 
N-sulphation (Bame and Esko, 1989; Humphries et al., 1999), 6-O sulphation (Pratt et 
al., 2006), have been found to possess a limited capability to synthesize or to  
sulphate HS glycosaminoglycans. 
1.3.3 Function of HS 
From the synthetic processes of heparan sulphate proteoglycan, biological 
functions of HSPGs are dictated largely by the specific structure of heparan sulphate 
chains, their pattern of sulphation and their core proteins as well as cooperation with 
cytokines, extracellular matrix proteins, enzymes, protease inhibitors, growth factors 
and other molecules (Bernfield et al., 1999; Lander and Selleck, 2000; Iozzo, 2001; 
Esko and Selleck, 2002; Nakato and Kimata, 2002). 
Sulphation modifications occur non-uniformly throughout the heparan sulphate 
chain, thus forming peculiar sulphation patterns with the concomitant presence of 
highly sulphated domains (S-domain) and under-/ non-sulphated domains. These 
sulphation patterns create binding specificity for different substrates. One of the best 
studied examples is the interaction between FGF-2 and heparan sulphate. This 
interaction requires at least some degree of 2-O sulphation, and a chain length of at 
least octasaccharide of heparan sulphate. For FGF-2 binding to its receptor FGFR, 
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there must also be 6-O sulphation. Both 2-O-sulphate and 6-O-sulphate groups of 
heparan sulphate are essential for the ternary formation of HS-FGF2-FGFR (Aviezer 
et al., 1994; Pye et al., 1998; Jemth et al., 2002; Harmer, 2006) and FGF2 signaling. 
Modifications of sulphation at specific position of HS are important modulating steps 
in physiological as well as pathophysiological conditions in cells. For example, 
heparan sulphate 6-O-endosulphatase (Sulf) is exosulphatase which remove 
6-O-sulphate groups from the non-reducing-end glucosamine residues within heparan 
sulphate (Dhoot et al., 2001) (Lai et al., 2003). Research has showed that Sulf 
functions as a negative regulator of FGF signaling and FGF2-dependent angiogenesis 
by disrupting the FGF2-FGFR1-heparan sulphate ternary complex formation (Wang 
et al., 2004) which inhibited both tumour growth and tumour angiogenesis in 
xenografts in mice induced by Sulf-1 over-expressing MDA-MB-468 breast cancer 
cells (Narita et al., 2006). 
Degradation is an additional functional variation of HS GAGs, since variable 
stability and turnover of GAGs may depend upon their susceptibility to enzymatic 
degradation. Heparan sulphate cleavage is by the ß-D-endoglucuronidase, heparanase 
(HPSE), which acts via a hydrolytic mechanism to cleave glycosidic bonds in heparan 
sulphate. Degradation of the ECM such as the heparan sulphate (Eccles, 1999) is a 
key aspect of tumour cell migration, invasion and metastasis (Edovitsky et al., 2004). 
Core proteins in HS proteoglycans also exert functions through interactions with 
other molecules, especially when these HS proteoglycans are involved in the 
formation of extracellular matrix. Cell surface proteoglycans, syndecans and 
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glypicans generally function by the interaction with extracellular matrix as receptors 
or facilitators for cell adhesion (Woods et al., 1998). Syndecan-4 is a peculiar 
transmembrane heparan sulphate proteoglycan present together with β1-integrins in 
focal adhesion on different substrates (fibronectin, laminin, vitronectin, or type I 
collagen) (Saoncella et al., 1999a; Woods and Couchman, 2001). 
Thus, the detailed positions and degree of sulphation and stability of HS GAGs 
as well as the core proteins provide a variety of specificities for functions, including 
cell proliferation, adhesion, migration and invasion as well as other biological 
processes, such as angiogenesis. 
1.3.3.1 HS and cell proliferation / growth 
HSPG in cell proliferation has been well established. Interaction of HSPG and 
FGF-2 in cell proliferation has been well studied. As mentioned above, FGF-2 exerts 
its effect though the binding of its receptor and HS glycosaminoglycan with both 2-O 
and 6-O sulphation. FGF-2 is an important growth factor in regulating cell 
proliferation (Spivak-Kroizman et al., 1994). FGFs mediate their cellular responses 
by binding to FGF receptors and activating a family of four receptor tyrosine kinases 
(RTKs) (Jaye et al., 1992) which eventually leads to stimulation of intracellular 
downstream signaling pathways such as activation of the Ras/MAP kinase signaling 
pathway that cause cell proliferation, cell differentiation, cell migration, cell survival 
and cell shape (Spivak-Kroizman et al., 1994; Kouhara et al., 1997). It has been 
shown that FGF-2 is a mitogen for breast cancer T47D, MCF-7 and BT-20 cells 
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(Karey and Sirbasku, 1988; Peyrat et al., 1991). The stimulation effect of FGF-2 on 
MCF-7 cell proliferation was completely abolished after heparinase treatment which 
degraded HSPG or was significantly inhibited by chlorate treatment which removed 
the sulphate group in the HS chains (Delehedde et al., 1996). These results have 
demonstrated that HSPG plays a crucial role in modulating FGF-2 induced 
proliferation in breast cancer cells. Removal of the 6-O sulphation in pancreastic 
cancer cells by over-expression of Sulf resulted in reduced anchorage-dependent and 
-independent cell growth as well as invasion by blocking FGF-2 signaling pathway 
(Li et al., 2005). Previous studies have elucidated that addition of exogenous highly 
sulphated HS-GAGs such as heparin (Majack and Clowes, 1984) as well as lower 
sulphated HS-GAGs (Forsten et al., 1997) inhibited FGF-2 mediated proliferation of 
smooth muscle cells. Exogenous heparin has also been reported to inhibitF FGF-2 
induced proliferation in endothelial cells (Giraux et al., 1998). Recently, studies also 
showed that inhibition of HS-GAGs synthesis abrogated FGF-2-induced mitogenic 
response in bovine aortic endothelial cells (Fujiwara and Kaji, 1999).  
In addition to FGF, HSPGs have also been reported to participate in regulation 
of other growth factors. Sulf over-expression in head and neck squamous cell 
carcinoma cell lines inhibited the signaling activities of HS-dependent epidermal 
growth factor, resulting in repression of tumour growth and cell migration (Lai et al., 
2003; Lai et al., 2004). It has been reported that syndecan-4 regulates protein levels of 
the endothelial growth factor receptors (erb-B2 and -B3) in a colon cancer cell line 
(Isabel et al., 2001). Moreover, syndecan-2 can bind and regulate the signaling of 
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tumour growth factor-β (Chen et al., 2004). Syndecan-1 is also implicated in 
hepatocyte growth factor signaling. Binding of hepatocyte growth factor to 
syndecan-1 induced activation of PI3-kinase and mitogen-activated protein kinase 
pathways (Seidel et al., 2000; Derksen et al., 2002). 
The significance of glypicans (GPC) in tumour growth was identified in breast 
cancer and pancreatic cancer. GPC-3 functioned predominantly as growth inhibitor 
and modulator of cell survival and inducer of apoptosis (Filmus and Selleck, 2001), 
while GPC-1 was a promoter of cell growth (Filmus, 2001). GPC-1 was found over 
expressed in breast cancer and modulated mitogenic effect of growth factors in breast 
cancers (Matsuda et al., 2001). It was also found GPC-1 was over-expressed in 
pancreatic cancer both by the cancer cells and the stroma cells (Kleeff et al., 1998). 
Silencing its expression by anti-sense treatment reduced the response of pancreatic 
cell to growth factors such as FGF-2 and EGF (Kleeff et al., 1999). On the contrary, 
GPC-3 expression was silenced in breast cancer due to its promoter hypermethylation 
(Xiang et al., 2001). Over-expression GPC-3 in breast cancer induced apoptosis 
(Gonzalez et al., 1998). It has been established that GPC-1 is a key tumour-promoting 
HSPG while GPC-3 acts as a tumour suppressor. 
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1.3.3.2 HS and cell adhesion 
HSPGs are expressed on almost every cell surface and in the extracellular 
matrix. Many researches have demonstrated that HSPG are involved in cell 
cytoskeletal remodeling, adhesion and focal adhesion. Over-expression of syndecan-1 
has been shown to promote cell spreading in in vitro and in vivo models of breast 
cancer, which suggested that syndecan-1 promoted tumourigenesis by regulating 
tumour cell spreading and adhesion (Beauvais and Rapraeger, 2003; Burbach et al., 
2004) as well as proliferation, and angiogenesis. Syndecan-2 has also been shown to 
be involved in cell adhesion. Fibroblasts overexpressing syndecan-2 form 
filopodia-like membrane protrusions, and a role for syndecan-2 in cell motility has 
also been shown (Fears et al., 2006). Addition of exogenous soluble recombinant 
syndecan-2 ectodomain to brain microvascular endothelial cells increased cell–cell 
interactions on matrigel (Fears and Woods, 2006). However, when syndecan-2 was 
overexpressed in colorectal cancer-derived cells, the cells showed a flattened 
appearance with loss of cell–cell contacts, lamellipodial or filopodial membrane 
protrusions, and increased migration across the transwell membrane (Contreras et al., 
2001).  
The best evidence for a specific role of syndecans in cell adhesion comes from 
studies of Syndecan-4 in focal adhesion formation. Syndecan-4 is a transmembrane 
heparan sulphate proteoglycan present together with integrins in focal adhesions on 
different substrates (fibronectin, laminin, vitronectin, or type I collagen) (Woods and 
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Couchman, 1994). Specific stimulation with antibodies against the ectodomain of 
mouse syndecan-4 promoted focal adhesion assembly (Saoncella et al., 1999). Woods 
et al.(2000) found when glycosaminoglycan chains of syndecan-4 binds to 
recombinant heparin binding fragment of fibronectin, syndecan-4 redistributes into 
forming focal adhesions. Mahalingam et al. (2007) found that cellular adhesion 
responses to the heparin-binding (HepII) domain of fibronectin require N- sulphated 
glucosamine in the HS. In the more complex response of focal adhesion formation 
through syndecan-4, both N-sulphation and glucosamine 6-O-sulphation were 
required. Moreover, interactions with the HepII domain of fibronectin required for 
activation and stability of FAK and to maintain fibroblast cell survival 
(Wilcox-Adelman et al., 2002). Evidence has also shown that the sulphation pattern 
influenced cell adhesion to different substrate. For example, Keller et al. (1989) 
reported sodium chlorate inhibited the binding of 3T3 cell to fibronectin. 
Undersulphation by sodium chlorate inhibited C6 glioma cell adhesion to fibronectin, 
laminin and collagen IV (de Aguiar et al., 2002).   
1.3.3.3 HS and cell migration  
HS is known to play a role in cell migration. Research findings have strongly 
suggested that function of HS in cell migration depends on specific cell type and HS 
structural motifs in the sequence. Intact HSPGs have been reported to promote stable 
focal adhesion that may retard cell migration in endothelial cells (Moon et al., 2005). 
Nurcombe et al. (2000) showed that HS preparations that were known to be specific 
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for FGF-1 (HS-GAG A)) or FGF-2 (HS-GAG-B) have different function in cell 
migration in MCF-7 and MDA-MB-231 breast cancer cells. Combination of 
FGF-1/HS-GAG-A induced greatest migration in MDA-MB-231 cells and MCF-7 
cells. Although increases in motility were seen on HS-GAG-A or FGF-1 alone, the 
effects of their combination were synergistic and led to significant greater migratory 
speeds. In contrast, the motility was only slightly increased when adding the 
combination of FGF-2 and HS-GAG-B. 
HS core protein is also involved in cell migration. Overexpressing full-length 
core protein of syndecan-4 in CHO-K1 cells results in increased focal adhesion 
formation and decreased cell motility (Longley et al., 1999). 
Disturbance in HS sulphation has also been demonstrated to influence cell 
migration. Lacking of 2-O sulphation in 2-O-sulphotransferase mutant 
Caenorhabditis elegans caused specific cell-migration defects of the gonad leader 
cells and of hermaphrodite-specific neurons (Kinnunen et al., 2005). Sodium chlorate 
treatment of brain endothelium cells or monocytes significantly reduced 
transendothelial migration. In addition, enzymatic removal of heparan sulphate chains 
also inhibited monocyte transendothelial migration (Floris et al., 2003). On the other 
hand increasing 6-O-sulphation by overexpressing a dominant positive Sulf 
significantly increased invasion through Matrigel and migration of vascular smooth 
muscle cell compared to control cells (Sala-Newby et al., 2005). 
1.3.3.4 HS and cell invasion 
Metastasis of tumour cells is a multistep cascade. A tumour cell invades into 
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tissues by first degrading extracellular matrix constituents including fibronectin, 
collagens, laminins and HSPGs. Highly sulphated heparin and heparan sulphate have 
been demonstrated significantly enhanced melanoma cell invasion in vitro into 
Matrigel (Brunner et al., 1998). The enhancement of tumour cell invasion was due to 
a stimulation of plasminogen activation by the sulphated glycosaminoglycans. 
Results from the ex vivo experiment using MCF-7 cells transfected with 
heparanase cDNA have also demonstrated that HS is associated with tumour invasion. 
When the transfected MCF-7 cells were injected into the mammary pad of nude mice, 
it showed enhanced tumour growth and invasion compared with tumours produced by 
mock-transfected cells (Cohen et al., 2006). Further more, when heparanase was 
silenced by using either ribozymes or siRNA, both human breast carcinoma 
(MDA-MB-435) and mouse melanoma (B16-BL6) tumour cells were found reduced 
invasion and adhesion in vitro and were less metastatic in vivo (Edovitsky et al., 
2004).These findings were recently confirmed independently by a Chinese group in 
MDA-MB-435 breast cancer cells (Zhang et al., 2007c). These findings suggested 
that heparanase may facilitate tumour invasion by degrading HSPG in the cell 
extracellular matrix and basement membrane. 
Transfection of mouse mammary tumour cells with anti-sense mRNA for 
syndecan-1 resulted in an epithelial to mesenchymal transformation and increased 
invasion (Leppa et al., 1991; Leppa et al., 1992). Overexpression of syndecan-1 in 
syndecan-deficient myeloma cells remarkably inhibited cell invasion (Liu et al., 1998). 
These results indicate syndecan may be a tumour suppressor. 
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1.3.3.5 HS and angiogenesis 
Angiogenesis is a coordinated multicellular process for the formation of new 
blood vessels from the existing vasculature and is necessary for tumour growth. 
HSPGs have long been implicated in these processes. HS sequester, stabilize and 
protect growth factors such as VEGF from inactivation and thus promote 
angiogenesis in tumours. VEGF is a specific mitogen for vascular endothelial cells in 
vitro and angiogenic factor in vivo (Ferrara, 1996; Ferrara and Gerber, 2001). The 
optimal binding of VEGF to heparin/heparan requires 6-O-sulphation of glucosamine 
(Ono et al., 1999) although 2-O-, 6-O-, and N-sulphation of HS contributed to the 
strength of the VEGF165 interaction (Robinson et al., 2006). Removal of 
6-O-sulphate group from HS resulted in the significant loss of binding to VEGF165. 
However, knock-down of the expression of Sulf in normal endothelial cells by siRNA 
reduced VEGF165 (one short type of VEGF) mediated angiogenic response (Narita et 
al., 2006).  
Syndecans have also been shown to be involved in tumour angiogenesis. In an 
in vivo model of breast cancer in which breast cancer cells were co-injected with 
syndecan-1-expressing fibroblasts into the mouse flank, enhanced tumour growth and 
increased tumour vascularization was observed (Maeda et al., 2004; Maeda et al., 
2006). Syndecan-2 was highly expressed in the microvasculature of mouse gliomas. 
When its expression was down-regulated in mouse brain microvascular endothelial 
cells, formation of capillary tube-like structures in vitro was reduced (Fears et al., 
2006). Heparanase has also been found to facilitate angiogenesis as it degrades HSPG 
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in the basement membrane, librating endothelial cell to invade and migrate toward 
angiogenic factors (Elkin et al., 2001).  
1.3.4 3-O sulphation in HS 
Many research findings have verified that HS functions are dependent on 
specific sulphation as HS binds to a variety of growth factors, cytokines, signaling 
molecules and ECM proteins (Sasisekharan et al., 2006; Mulloy and Rider, 2006). 
Here gives a brief literature review on 3-O sulphation in HS. 
3-O sulphation of glucosamine residues of HS-GAG chain is a rare but 
important modification of HS synthesis. Until today, at least seven isoforms of 
3-O-sulphotransferases (3-O-STs) have been identified and partially characterized 
(Liu et al., 1996; Liu et al., 1999; Shworak et al., 1999; Xia et al., 2002; Lin, 2004). 
They are 3-O-ST-1 (HS3ST1), 3-O-ST-2 (HS3ST2), 3-O-ST-3A (HS3STA), 
3-O-ST-3B HS3STB), 3-O-ST-4 (HS3ST4), 3-O-ST-5 (HS3ST5) and 3-O-ST-6 
(HS3ST6). The success in cloning and characterization of HS 3-O-sulphation 
enzymes increased the understanding for the mechanisms of generating HS with 
defined sequences and the sequence-specific function. 
One of the most studied enzymes, 3-O-sulphotransferase (3-O-ST, now known 
as 3-O-ST-1, HS3ST1) converts non-anticoagulant heparan sulphate into 
anticoagulant heparan sulphate, which is widely used in clinic and well known as 
heparin (Dementiev et al., 2004; Petitou and van Boeckel, 2004). Blood coagulation is 
a cascade involving a series of reactions which results in the activation of factor Xa 
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that is the key player in formation of a blood clot. The anticoagulant heparin sulphate, 
by interacting with antithrombin, which undergoes conformational change in its 
structure, inhibits activation of factor Xa as well as other proteases in the blood 
coagulation cascade (Olson and Bjork, 1994). Thus as an anticoagulant, heparan 
sulphate can stop blood coagulation. 
Modification of 3-O-sulphation in anticoagulant heparan sulphate by 3-O-ST-1 
determines the formation of specific HS binding sequences for ligands such as 
antithrombin and thus influences HS function. The preference of substrate and 
production of antithrombin-binding motif by 3-O-ST-1 suggest the possibility that 
other heparan sulphate 3-O-sulphation enzymes may function in a similar way. By 
controlling production of other important HS fine motifs, these enzymes may also 
play important roles in HS functions. For example, 3-O-ST-5 has been found to 
synthesize antithrombin-binding motif along HS chain which exhibits anticoagulant 
activity (Xia et al., 2002). But this AT-bind structure is different from what is 
produced by 3-O-ST-1. Research findings have demonstrated that 3-O-ST-5 has a 
broader substrate specificity compared with that of 3-O-ST-1 (Mochizuki et al., 2003; 
Chen et al., 2003; Duncan et al., 2004; Chen and Liu, 2005). 3-O-ST-5 sulphates 
glucosamine units that are linked to a glucuronic acid (or iduronic acid) as well as 
2-O-sulphated iduronic acid units, thus the HS motif also has the function of 
promoting herpes simplex virus 1 into target cells (Chen et al., 2003; Duncan et al., 
2004; Chen and Liu, 2005). 
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Research has also revealed that 3-O-ST-2 (Chen and Liu, 2005), 3-O-ST-3A 
(Moon et al., 2004b), 3-O-ST-3B (Moon et al., 2004a), 3-O-ST-4 (Chen and Liu, 
2005), and 3-O-ST-6 (Xu et al., 2005) can generate herpes simplex virus 1(HSV-1) 
gP-binding motif which serves as an entry receptor for the virus (Shukla et al., 1999; 
Xu et al., 2005) but none of these 3-O-sulphation enzymes can produce anticoaglutant 
HS motif. These biochemical studies have greatly contributed to our knowledge of the 
function of HS3STs based on their respective substrate preferences and the resultant 
HS structures, but their biological functions, including those of 3-OST-3A is still 
unknown. 
In summary, HSPGs have multifaceted functions in the regulation of cell growth, 
adhesion, migration, tumourigenesis and progression. As mentioned above, in some 
instances, HSPGs can sequester growth factors away from their cell surface receptors, 
hindering signaling. Whereas in other cases, HSPGs can participate in a ternary 
complex with the growth factors, promote growth factor binding with its receptor 
resulting in enhanced signaling. The discrepancy among the different studies 
reiterates the notion that whether HSPG and its sulphation are pro-or anti- factors in 
cell growth and tumour progression is dependent on the microenvironment of cell 
HSPG and its specific binding ligands such as growth factors. Targeting heparan 
sulphate in breast cancer treatment therefore is still one of the challenges in breast 
cancer research. A better understanding of the effects of differentially sulphated 
heparan sulphate on breast cancer cell behaviour is important for the development of 
these molecules into potential therapeutic targets for breast cancer. 
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1.4 RNAi technology 
1.4.1 Introduction of RNAi 
RNA interference (RNAi) is a general term given to a gene-silencing regulation 
process that is induced by double-stranded RNA (dsRNA) in sequence-specific 
degradation of complementary mRNA or by inhibiting translation (Fire et al., 1998).  
Double-stranded RNA-mediated interference has recently emerged as a 
powerful tool to silence gene expression in human cells. Over the past 2 decades since 
RNAi was first discovered (Napoli et al., 1990), the possibility of RNA interference is 
one of the most exciting new technologies in functional genomics. RNA interference 
has been not only proven to be an invaluable research tool in basic science, allowing 
much more rapid characterization of the function for known genes, but more 
importantly, this new technology accelerates the discovery of novel genes involved in 
disease processes and it gives promising clinical results that may lead to novel 
therapies in the future. 
1.4.2 Mechanism of RNAi 
The mechanism of RNAi has been investigated by both biochemical and genetic 
approaches. RNA interference is mediated by small interfering RNAs (siRNAs) 
which are intracellularly generated from long endogenous microRNA (miRNA) or 
exogenous double-stranded RNA molecules (dsRNAs). RNAi relies on a multi-step 
intracellular pathway which can be roughly divided into two phases, the initiation 
phase and the effector phase.    
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In the first phase, the long, double-stranded RNA (dsRNA) is recognized and 
cleaved by Dicer, an ribonuclease (RNase) III enzyme, to form short 21–23 nt 
duplexes (small interfering RNA, siRNA) with a symmetric 2 nt overhang at the 
3’-end and a 5’-phosphate and 3’-hydroxy group (Zamore et al., 2000; Elbashir et al., 
2001; Bernstein et al., 2001).     
In the second phase, the produced siRNAs are incorporated into the multiprotein 
complex, RNA-induced silencing complex (RISC). A helicase in RISC unwinds the 
duplex siRNA by peeling of the sense strand of the siRNA and this complex becomes 
activated with the single-stranded siRNA. The antisense strand of the siRNA is then 
hybridized perfectly to its complementary mRNA in the cells. The RISC complex 
cleaves the target mRNA, 10 nucleotides from the 5’ end of the incorporated 
siRNA–target mRNA duplex. Due to the generation of unprotected RNA ends, the 
target gene mRNA rapidly degrades. Hence, expression of the targeting gene was 
decreased. 
1.4.4 RNAi and cancer  
Cancer is viewed as a multi-step disease. According to the established model of 
oncogenesis, to become a cancer cell, normal cell must undergo several essential 
alterations in cellular physiology which includes uncontrolled proliferation, resistance 
to apoptosis, angiogenesis, invasion and metastasis (Hanahan and Weinberg, 2000). 
Currently, cancer research are using different technologies to understand biological 




Traditionally, gene function in cancer has been studied using animal knockout 
models. RNA interference offers a number of advantages over the traditional systems, 
including ease of use, high specificity and efficacy in nearly any biological system, 
and the ability to perform large-scale screening for gene functions. Since RNAi 
mechanism has high specificity and efficiency in down-regulating gene expression, 
this methodology has been widely used in recent years in studying the function of 
genes in cancer, as loss of function indicates a specific effect exerted by the gene 
(Gartel and Kandel, 2006; Gaither and Iourgenko, 2007; Fuchs and Borkhardt, 2007).  
So far, various genes have been knocked-down using RNAi technique in 
different tumour cell lines in vitro as well as in vivo mouse models. By such an easy 
and convenient way, scientists have been able to study the profound biological 
consequences following the knockdown of their expression. These genes include 
oncogenes/supressors, anti-apoptosis or pro-apoptotic genes, telomerase, growth 
factors and their receptors, signaling molecules and as well as a panel of other genes 
(Devi, 2006; Gartel and Kandel, 2006; Chang, 2007). Our understanding of function 
of genes and their interactions has changed dramatically with the development of 
RNAi systems.   
Introduction 
 39
1.4.4 RNAi and proteoglycans 
RNAi has also been used to investigate the functions of those genes involved in 
the synthesis of proteoglycans. Using siRNA to silence the genes involved in the 
synthesis of proteoglycans has been studied in various species. Table 1.3 summarizes 
the currently known studies targeting different proteoglycan related genes in different 
species and systems. 
Unfortunately, our current knowledge about the roles of one specific gene in 
cancer development is insufficient to describe the behaviours of tumours and predict 
the outcome of potential therapeutic effects. Therefore, the process of multiple genes 
especially that exert their functions synergistically in the same pathway in cancer 
models will improve the understanding of their function in cancers.  Since their 
advent in the mid-1990s, DNA microarrays have been the choice for genome-wide 
expression analysis (see below, Genomic Microarray introduction part). The 
synergistic effect from the combined usage of RNA interference and the whole 
genomic expression profiling by microarray analysis is providing researchers with 
vast amounts of information. When comprehensively analyzed, the outcomes from the 
combination of these two new methodologies will provide a unique opportunity to 
annotate the unknown genes as well as the “known” genes together with their 
interactions in pathways occurring in cancer cells (Laflamme and Robichaud, 2007). 
As a result, it is much easier to understand the function of any given gene that 
interacts with a number of different partners within specific pathways in cancer 
progression (Williams et al., 2003; Jazag et al., 2005; Sachse et al., 2005).
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Table 1.3 Studies in knockdown of expression of proteoglycan related genes in different species and systems. 
Target Cell type Results Reference 
Glypican-1  Lymphoblastoid cells Enhanced BMP signaling (O'connell et al., 2007) 
 Turkey myogenic satellite cells Decreased myogenic satellite cell proliferation (Zhang et al., 2007a) 
Syndecan-1 T lymphocytes mainly of the CD4+ cells Reduced CyPB-induced p44/p42 MAPK activation  
and consequent migration and adhesion, 
(Pakula et al., 2007) 
 Mouse embryonic fibroblasts Ras-ERK signaling pathway (Li et al., 2006) 
 Breast cancer MDA-MB-231 cells Disrupted alpha(v)beta(3)-dependent cell spreading and migration (Beauvais et al., 2004) 
 Keratinocytes Decreased cell adhesion   (Ogawa et al., 2007) 
 Breast cancer T47D cells Inhibited carcinoma cell mitogenesis   (Su et al., 2007) 
 B82L mouse fibroblasts Inhibited cell attachment and spreading on vitronectin (McQuade et al., 2006) 
Syndecan-2 Human embryonic kidney cells Inhibited filopodia and spine formation (Lin et al., 2007) 
 Human osteosarcoma cells Inhibited chemotherapy-induced apoptosis. (Orosco et al., 2007) 
Syndecan-4 Dendritic cell Decreased dendritic cell motility (Averbeck et al., 2007) 
 HeLa cells Syndecan-4 behaves as CXCL12 receptor in p44/p42 pathways (Charnaux et al., 2005) 
 Lymphoblastoid cells Decreased BMP signaling in LCLs (O'connell et al., 2007) 
 Vascular smooth muscle cells VSMC Reduced DNA synthesis and ERK pathway (Rauch et al., 2005) 
Glypicans (Dally) Drosophlia Inhibited Hedgehog signal transduction (Desbordes and Sanson, 2003) 
Perlecan  Prostate LNCaP cells Decreased SHH signaling  (Datta et al., 2006; Marker, 2007) 
 Murine malignant melanoma B16-F10 cells Blocks tumour growth and angiogenesis  (Adatia et al., 1997) 
 Human colon carcinoma cells Inhibition of tumour growth and neovascularization (Sharma et al., 1998) 
 prostate cancer C4-2B cells  Reduces cell adhesion in vitro and tumour growth in vivo (Savore et al., 2005) 
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Table 1.3 Studies in knockdown of expression of proteoglycan related genes in different species and systems (Cont’d) 
Target Cell type Results Reference 
beta4GalT7  Drosophila Inhibited the development of wing and leg  (Nakamura et al., 2002) 
6-OST(dHS6ST) Drosophlia Caused embryonic lethality and disruption of  
the primary branching of the tracheal system 
(Kamimura et al., 2001) 
3-OST Drosophila  Inhibited Notch signaling (Kamimura et al., 2004) 
2-OST C. elegans Inhibited cell migration  (Kinnunen et al., 2005) 
3-OST-3B Peripheral blood T lymphocytes and Jurkat 
T cells 
Inhibited of ERK pathway and migration  
and integrin-mediated adhesion 
(Vanpouille et al., 2007) 
Sulf-1 Human umbilical vein endothelial cells 
HUVEC 
Increased proliferation and enhanced downstream signaling (Narita et al., 2006) 
 Breast cancer cell MDA-MB-468 cells Increased autocrine activation of ERK  (Narita et al., 2007) 
 Ovarian cancer  Enhancedcisplatin-induced cytotoxicity (Staub et al., 2007) 
HPSE B16 mouse melanoma cells Decreased in VEGF and p38 phosphorylation  (Zetser et al., 2006) 
 Hepatocellular carcinoma Inhibited the invasion, angiogenesis and metastasis of  
human hepatocellular carcinoma 
(Zhang et al., 2007b) 
 Breast carcinoma cells Reduced invasion and adhesion in vitro (Zhang et al., 2007c) 
 Breast cancer MDA-MB-231 cells  Reduced invasion and adhesion in vitro (Edovitsky et al., 2004) 
 Breast cancer MDA-MB-231 cells Inhibited tumour metastasis and angiogenesis  (Ilan et al., 2006) 
 Myeloma cell lines Decreased syndecan-1 gene expression (Mahtouk et al., 2007) 
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1.5 Genomic microarray 
The Human Genome Project (HGP) completely sequenced the human genome 
(Venter et al., 2001; Lander et al., 2001; Collins et al., 2003). This advent job has 
provided a tremendous list of genes in human. However, deciphering the functions of 
all these genes has proven to be another even more difficult job compared with the 
HGP itself. Fortunately, the availability of microarray, which was first introduced in 
1995 (Schena et al., 1995), has proven to be an indispensable tool for biologists who 
are trying to identify the functions of all of these genes.  
1.5.1 What is microarray?  
A microarray is typically defined as a collection of microscopic spots which are 
referred to as probes containing a single species of a nucleic acid and representing the 
genes of interest, immobilised on a solid support (normally nylon, glass, silicon) in a 
highly parallel manner forming an array, hence the term. This technology is based on 
the hybridization between labeled targets derived from a biological sample and the 
probes (Southern et al., 1999). The targets, normally mRNA, extracted from 
biological samples and labelled with a detectable molecule or dye such as a 
fluorophore, Cy3 or Cy5, are hybridized to the microarray probes. The hybridization 
signal emitted by the labeling dye represents the relative mRNA expression level of 
the corresponding gene in the sample. The signals are detected, acquired, quantified, 
integrated and digitalized with dedicated software, creating a “gene expression 
profile” or “molecular portrait” for all of the genes in the samples (Duggan et al., 
1999). The resultant digital data are then further deep-mined by sophisticated 
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softwares to obtain useful information such as differential gene expression and 
pathways. 
The most widely used microarrays are Affymetrix GeneChips 
(http://www.affymetrix.com). Affymetrix GeneChips are high density oligonucleotide 
microarrays. The probe is fabricated by in situ light-directed chemical synthesis from 
phosphoramidite nucleotide monomers directly on a quartz wafers , which combines 
solid-phase chemical synthesis with photolithographic fabrication techniques,  also 
known as photolithography, widely employed in the semiconductor industry (Fodor et 
al., 1991; Fodor et al., 1993; Lockhart et al., 1996; Lipshutz et al., 1999).  
The group of probes corresponding to a given gene is known as the probe set. 
Affymetrix GeneChip microarrays utilize approximately 11-20 such probe pairs to 
interrogate a single transcript sequence. For each probe, there is also a mismatch 
sequence for each probe wherein the mismatch has a single nucleotide mutation 
compared with its corresponding probe. These are designated Perfect Match (PM) and 
Mismatch (MM) probes, respectively. The mismatch probes serve as a control for 
non-specific hybridization and increase the signal-to-noise ratios. 
Affymetrix GeneChip Human Genome U133 Plus 2.0Array (HG-U133 Plus 2.0) 
comprises 1,300,000 unique oligonucleotide features covering over 47,000 transcripts 







1.5.2 Microarray applications  
The applications of microarrays in breast cancer researches have increased 
dramatically since the introduction of microarray. The main applications of 
microarrays in breast cancer studies are to: 
1)  Identify genes that are differentially expressed between breast tumour and 
normal breast tissues or cells as well as the drug-treated or stimulated and 
non-intervened samples. 
2)  Identify and categorize new subtypes of breast cancer (molecular tumour 
classification) on the basis of gene expression pattern--- gene signature, or gene 
portrait,  
3)  Develop a classifier on the basis of gene signature, allowing the better 
evaluation of prognosis and more accurate prediction of patient response to a 
particular treatment and eventually tailoring treatment for the individual patient, 
known as “personalized medicine”. 
1.5.3 Microarray data analysis 
1.5.3.1 Differential gene expression 
With thousands of genes explored simultaneously, microarray profiling 
generates vast amounts of biological data. These enormous amounts of data require 
computational analysis and visualization for biological function interpretation. A 
plethora of automated data mining softwares are now available to evaluate microarray 
data ranging from the simple fold-change for identifying differentially expressed 
Introduction 
 45
genes, to complex computational algorithms for tumour classification. The most 
commonly used software packages are Affymetrix’s own Microarray Analysis Suite 
or GeneChip Operating Software (MAS 5.0 or GCOS ) (Affymetrix, 2001; 
Affymetrix Inc, 2002), DNA-Chip Analyzer (dChip) (Li and Wong, 2001a; Li and 
Wong, 2001b), and the so-called Robust Multichip Analysis(RMA, Irizarry et al., 
2003a; Irizarry et al., 2003b), with other deep data mining tools like GeneSpring 
(Silicon Genetics, Redwood City, CA, USA) (Chu et al., 2001) which can be linked to 
public databases.  
1.5.3.2 Exploratory data analysis  
It is more valuable to use clustering techniques such as hierarchical clustering, 
Principal Component Analysis (PCA) in conjunction with pathway analysis software 
for understanding the biological function of gene expression. 
Hierarchical Clustering is an analytic algorithm to reduce the complexity of data 
sets by classifying genes into categories with similar expression manners. All genes 
start as an individual cluster, then the clusters with nearest distance are merged into a 
new cluster, such calculation repeated till a clustering tree structure is set up. 
Hierarchical cluster analysis is usually used near the end of microarray data analysis 
to identify genes that are co-regulated. D-chip and GeneSpring have hierarchical 




Principal components analysis (PCA) is a statistical technique for determining 
the key variables in a multidimensional data set by reducing the dimensionality into 
three most significant variances, known as principal components, that must be 
considered in the microarray analysis. PCA can be used not only in classifying 
samples with a similar expression pattern, e.g. related to a specific treatment or 
phenotype. It can also be used in identifying the interested genes that are most 
important for the differences between the groups (Yeung and Ruzzo, 2001). 
GeneSpring has the Principal Component Analysis function. 
1.5.3.3 Functional analysis 
Gene Ontology (GO) is widely accepted for gene function analysis. It consists 
of three categories, biological process, molecular function, and cellular component. 
The classification for the differentially expressed genes based on the GO Ontology 
category will list co-regulated genes and thus provides a tool that is able to highlight 
some pathways hidden in the data. GO analysis tools are collected by the Gene 
Ontology Consortium. One can also get access to NetAffx GO Mining Tool (Cheng et 
al., 2004) in Affymetrix website. 
1.5.3.4 Pathway analysis 
Genes are working together in a cascade of networks. As a result, analyzing the 
microarray data in a pathway perspective could lead to a higher level of understanding 
of gene functions. PathwayStudio (Nikitin et al., 2003) is a network exploring 
bioinformatics software which comes with ResNet Core, a database of more than 
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50,000 validated facts and 1000+ reconstructed pathways, which can be extended to 
over 800,000 facts available in the ResNet™ 4.0 database. It includes a pathway 
simulation module to explore the dynamic behavior of pathways and new tools for 
building relevance networks and connectivity maps from the microarray expression 
data, and Ariadne’s MedScan Reader™ biomedical  literature browser. MedScan 
Reader enables the viewing and automated extraction of scientific facts from 
biomedical literature, including MEDLINE abstracts, journal articles and other source 
references.  
In summary, microarray technology is a versatile technology that allows global 
analysis of gene expression patterns simultaneously. Many tools are being developed 
to assist with the analysis of such high throughput data. This technology can identify 
novel gene-gene interactions and gene pathways. Combination with the recently 
emerged siRNA gene silencing technology, microarray technology will have an 
increasingly important role in the post-genomic era. 
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1.6 Scope of study 
The transformation from breast normal epithelial cell to malignant cell 
phenotype and breast cancer progression involves multiple steps including 
uncontrolled cell proliferation, detachment from the primary tumour mass, invasion of 
cancerous cells through the basement membrane, intravasation into and extravasation 
out of the blood vessels and colonization to the target organ, and continuation of 
uncontrolled cell growth and neovascularization (Couldrey and Green, 2000; Hanahan 
and Weinberg, 2000; Lu and Kang, 2007). These processes require sequential 
interactions between cell-cell and cell-extracellular matrix (ECM). The central 
components of these interactions are proteoglycans, which are present at the 
cell-ECM interface and in the ECM. Heparan sulphate is one kind of GAGs. Any 
change in heparan sulphate will influence these processes in the malignant 
transformation and cancer progression. 
 
Hypothesis: The main hypothesis is that HS sulphation status is involved in the 
regulation of breast cancer behaviours. To support this hypothesis: (a) Inhibition of 
HS or addition of exogenous differentially sulphated HS should affect biological 
activities of breast cancer cells. (b) Alteration in expression of sulphation transferase 
HS3ST3A1 should have some effect on cellular behaviours of breast epithelial and 
cancer cells. 
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The objectives of the present study are to: 
1) Examine the effects of undersulphation in GAG induced by sodium chlorate in 
breast cancer cell lines in vitro. 
2) Investigate the effects of differentially sulphated exogenous heparan sulphate on 
the biological activities of breast cancer cell lines in vitro.  
3) Evaluate the expression level of HS3ST3A1 in breast cancer cells and normal 
breast epithelial cells in vitro and in breast benign and cancer tissues in vivo.  
4) Study the function of HS3ST3A1 in breast epithelial cells with regard to: 
(a) Changes of cell phenotype such as cell proliferation, adhesion, migration and 
invasion after specifically knockdown of this gene by using siRNA.  
(b) Differentially expressed genes after silencing HS3ST3A1 expression by using 
microarray analysis.  
(c) Possible mechanic pathways involved in phenotypic alterations after silencing 
HS3ST3A1 expression in MCF-12A cells. 










CHAPTER  2  
 
 
MATERIALS AND METHODS 
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2.1 Materials and reagents 
Cell culture flasks and 6 well plates were bought from Nalge Nunc (Nalge Nunc 
International, Rochester, NY, USA). Petri dishes, 96-well plates and migration 
transwells were purchased from Corning (Costar, Corning, NY, USA). Bovine serum 
albumin (BSA), epidermal growth factor (EGF), cholera toxin, insulin, hydrocortisone, 
sodium chlorate and crystal violet were purchased from Sigma-Aldrich (Sigma, 
St.Louis, Mo, USA). Foetal bovine serum (FBS) was purchased from Hyclone 
(Hyclone, Logan, UT, USA). OPTI-MEM I medium was purchased from Invitrogen 
(Invitrogen, Carlsbad, CA, USA). Extracellular proteins fibronectin and collagen type I 
were purchased from BD Bioscience (Becton Dickinson & Company, Bedford, MA, 
USA). BioCoat Cell Environments, Matrigel TM invasion chamber were also bought 
from BD Bioscience.  
Heparan sulphate from porcine intestinal mucosal (HS-PM) and heparan sulphate 
from bovine kidney (HS-BK) were all purchased from Sigma-Aldrich Chemicals 
(Sigma Chemical Co., St.Louis, MO, USA). 
The anti-heparan sulphate chain antibody (clone F58-10E4, mouse 
immunoglobulin M [IgM] ) was purchased from Seikagaku (Seikagaku Corp., Tokyo, 
Japan). 
FAK rabbit polyclonal antibody C-20 was from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). The anti-FAK C-20 polyclonal antibodies were raised against 
peptides corresponding to amino acids 1033–1052 mapping at the C terminus of human 
FAK. Mouse monoclonal anti-paxillin, anti-FAK and anti-F11R were obtained from 
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BD Bioscience. Fluorescein isothiocyanate (FITC)-phalloidin and all 
fluorescence-conjugated secondary antibodies were purchased from Molecular Probe 
(Molecular Probe, Inc., Eugene, OR, USA). 
Sodium chlorate was prepared as a stock concentration of 3 M in double distilled 
water and stored at -20°C.  The chemical was further diluted in FBS-free culture 
medium immediately before use. 
Ambion's Silencer™ siRNA Transfection Kit was brought from Ambion. The kit 
contains siPORT transfection agents, siPORT™ Amine Transfection Agent and 
siPORT™ Lipid Transfection Agent. The kit also includes GAPDH synthetic siRNA 
and its corresponding scrambled control siRNA (siRNA Transfection II Kit. Catalog #: 
1631, Ambion, Inc., Ambion, Austin, TX, USA). 
2.2 Cell culture 
MCF-12A (ATCC: CRL-10782), MCF-7 (ATCC: HTB-22), MDA-MB-231 
(ATCC: HTB 26), T47D (ATCC: HTB-133) and ZR-75-1 (ATCC: CRL 1500) cell 
lines were obtained from American Tissue Culture Collection (ATCC, Manassas, VA, 
USA). The MCF-12A cell line is a spontaneously immortalized and non-tumorigenic 
mammary epithelial cell line. It was derived from the mortal cell line MCF-12M which 
was established from the tissue taken at reduction mammoplasty from a nulliparous 
patient with fibrocystic breast disease that contained focal areas of intraductal 
hyperplasia (Paine  et al., 1992). The characteristics of MCF-12A breast epithelial cell 
line and culture condition are well established. MCF-12A cells were cultured in a 1:1 
mixture of Dulbecco's modified Eagle's medium and F12 medium (DMEM-F12, 
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Invitrogen, Carlsbad, CA, USA) supplemented with 5% FBS, hydrocortisone 
(0.5 µg/ml), insulin (10 µg/ml), epidermal growth factor (20 ng/ml), cholera toxin (100 
ng/ml), and 40 µg/ml gentamicin (Invitrogen, Carlsbad, CA, USA). MDA-MB-231 and 
MCF-7 breast cancer cells were routinely maintained in DMEM with phenol-red and 
supplemented with 7.5% FBS, 2 mM glutamine, and 40 µg/ml gentamicin.  T47D and 
ZR-75-1 breast cancer cells were routinely maintained in RPMI 1640 medium with 
phenol-red and supplemented with 7.5% FBS, 2 mM glutamine, and 40 µg/ml 
gentamicin. 
2.3 siRNA transfection 
For siRNA transfection, MCF-12A cells were cultured in the maintaining 
medium with antibiotics. The transfection was carried out using reverse transfection 
method as recommended by Ambion (Ambion, Inc., Ambion, Austin, TX, USA). 
Briefly, MCF-12A cells transfected with siRNA and siPort Amine mixture while the 
cells were still in suspension (i.e. after trypsinization and prior to plating). Transfection 
parameters include MCF-12A cell number, amount of transfection agent siPort Amine, 
exposure time of transfection agent to MCF-12A cells, and siRNA quality. Several 
experiments were designed to optimize these transfection parameters. Optimization of 
transfection was performed using Ambion's Silencer™ siRNA Transfection Kit.  
2.4 Blyscan assay for glycosaminoglycan level analysis 
MCF-7 cells were cultured with or without 30 mM sodium chlorate for 48 hrs. 
The culture medium was collected. The cells were collected by directly scratching with 
a cell scraper in 500 μl cold PBS. The cell lysates were then sonicated for 20 s. Twenty 
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μl of the medium and the sonicated cell lysates were removed and kept at -80 °C for 
protein analysis. 
The crude glycosaminoglycans were precipitated by adding 1.3% potassium 
acetate in 95% ethanol at -20°C overnight after boiling for 10 min. The pellet was 
digested with 2 mg pronase at 55°C for 16 hrs.  After inactivating the pronase by 
boiling for 10 min, the supernatant was collected by centrifugation at 14,000 x g for 15 
min. These supernatant was again precipitated overnight at -20 °C with 1.3% potassium 
acetate in 95% ethanol before the total glycosaminoglycans were collected by 
centrifugation at 14,000 x g for 15 min. Sulphated glycosaminoglycan content was 
determined with the Blyscan TM kit (Sulphated Glycosainoglycan Assay, Biodye 
science, Newtownabbey, Northern Ireland, UK) according to the manufacturer's 
instructions. The Blyscan assay is a quantitative dye-binding method for the 
measurement of sulphated proteoglycans and GAGs. The assay is based on the specific 
binding of the cationic dye, 1, 9-dimethyl methylene blue to sulphated GAGs. Briefly, 
100 µl of medium supernatant or re-suspended GAGs solution was mixed with 1 ml 
Blyscan dye and incubated for 30 min at room temperature with gentle shaking to allow 
a precipitable complex to form. The proteoglycan–dye complex was precipitated by 
centrifugation for 10 min at 13 000 rpm and the supernatant was removed. The bound 
dye was dissolved in 1 ml dissociation reagent for 20 min and the absorbance was 
measured at 562 nm. A standard curve using standard GAG samples was made during 
each quantitation. The coefficient of the linear regression for the standard curve was 
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0.98 or greater. All samples were run in duplicates. The final results were calculated as 
μg sulphated GAG per μg protein.  
2.5 Measurement of cellular DNA content with propidium iodide (PI) by flow 
cytometry 
1.5 x 105 cells were grown in 6-well plates for 24 hrs and serum-starved for 
overnight using 2% FBS-containing DMEM before being treated with 30 mM sodium 
chlorate serum-containing media. At various time points after treatment, the cells were 
harvested and stained with propidium iodide (PI) in Vindelov’s cocktail [10 mM Tris 
HCl (pH 8), 10 mM NaCl, 50 mg PI/litre, 10 mg/litre ribonuclease A, and 0.1% Nonidet 
P-40] for 1 h at 4°C in the dark. The stained cells were analyzed and the fluorescence 
was collected in a linear scale using the FACS Calibur flow cytometer (Becton 
Dickinson, Lincoln Park, NJ, USA) running the CellQuest software with excitation 
wavelength of 488 nm. At least 10000 events were collected for each sample. The DNA 
distribution in cell cycles (FL2-A parameter) was analyzed by the ModFit software 
(Beckton Dickson, Mountain View, CA, USA).  
2.6 Confocal laser scanning microscopy 
2.6.1 Antibody staining in culture cells 
Cells were grown on acid-etched coverslips for 24 hrs before treatment with and 
without 30 mM sodium chlorate. For staining HSPG, cells were fixed using 
Sainte-Marie's fixative as this gives better preservation of glycosaminoglycans 
(Tuckett and Morriss-Kay, 1988). Cells were blocked for 1 h at room temperature in 
blocking solution (PBS containing 10% FBS) and then stained with anti-HSPG 
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monoclonal antibody 10E4 (1:100 dilution). The cells then were washed with PBS and 
incubated with Alexa-488 conjugated secondary goat anti-mouse IgM antibody (1:400 
dilution) 
For staining paxillin and focal adhesion kinase (FAK) and F-actin, the cells were 
fixed with 4% paraformaldehyde in PBS for 10 min and permeabilized for 10 min with 
0.2% Triton X-100 in PBS. Cells were blocked for 1 hr at room temperature in blocking 
solution (PBS containing 10% FBS). The cells were then incubated with anti-paxillin 
monoclonal antibody or anti-FAK polyclonal antibody in PBS containing 2% FBS at 
4°C overnight, washed, and further incubated at room temperature for 1 hr with 
Alexa-568 conjugated secondary goat anti-mouse or goat anti-rabbit IgG antibody 
(1:200 dilution)  and with fluorescein isothiocyanate (FITC)-conjugated phalloidin 
(for F-actin, 1:50 dilution) for 1 h at room temperature.  
For staining cells on the fibronectin-coated coverslips, the coverslips were first 
coated with 20 μg/ml fibronectin at 4°C overnight and blocked with 1% BSA at room 
temperature for 1 hr. The coverslips were air-dried in the culture hood. MCF-7 cells 
were treated with 30 mM sodium chlorate for 48 hrs and re-plated onto the 
fibronectin-coated coverslips for 2 hrs with or without (control) sodium chlorate. The 
cells were then processed as above. 
All coverslips were mounted on slides with Vectashield fluorescent mounting 
medium containing 4, 6-diamidino-2-phenylindole (DAPI) nuclear stain (Vector 
Laboratories, Burlingame, CA, USA). Stained cells were viewed and examined by 
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using an Olympus FluoView FV1000 Laser Scanning Confocal Microscope (Olympus, 
Melville, NY, USA). 
2.6.2 Evaluation of apoptotic nuclear morphology 
Briefly, cells were treated with 30 mM sodium chlorate for 48 hrs. Cells were then 
washed with phosphate-buffered saline (PBS). Cells were then fixed with 4% 
paraformaldehyde for 15 min. After washing, cells were incubated in DAPI at a final 
concentration of 10 µg/ml at room temperature for 15 min. Nuclear morphology was 
then examined with a Zeiss LSM510 confocal microscope (Carl Zeiss, Göttingen, 
Germany).  
The apoptotic cells were recognized on the basis of nuclear condensation and 
DNA fragmentation including chromatin condensation, segmentation of nuclear 
chromatin of irregular size in DAPI stained cells under confocal microscope. The 
apoptotic index was expressed in percentage as positive cells per 100 cancer cells 
assessed in 10 high power fields, where apoptotic index (AI) = Number of apoptotic 
cells counted /Total number of nuclei ×100%. 
2.7 In situ hybridization of HS3ST3A1 on breast cancer patients 
2.71 Patients and tumors 
Formalin-fixed, paraffin embedded tissue sections from matched normal and 
invasive ductal breast cancer tissues of 22 patients were obtained from Department of 
Pathology, Singapore General Hospital (SGH). Clinicopathological information 
collected included patient age, tumor size, ER, PR and cerB2 status, and lymph node 
metastasis. 
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2.7.2 HS3ST3A1 in situ RNA probes preparation 
Conventional PCR was run for amplification of HS3ST3A1 gene using the 
following primers: Forward, 5’-ttgggcgagtctaagacgat-3’ (Accession No.NM_006042, 
524-543), Reverse, 5’- aggccaggggactcttcttc-3’ (NM_006042, 1138-1157). The PCR 
product was cloned into a pDrive cloning vector (Qiagen, Hilden, Germany). The 
cDNA template was sequenced to confirm insert identity and orientation. The probe 
was then generated and digoxigenin-labelled using DIG RNA labelling kit (Roche 
Applied Science, Mannheim, Germany) according to the manufacturer’s instructions. 
Briefly, equivalent of 1 μg of insert DNA was digested to linearize the template. SP6 or 
T7 RNA polymerase was used to produce antisense or sense probes respectively. To 
synthesize riboprobes, in a total volume 20 μl reaction, the following were added:  
1 μg  linearized plasmid DNA  
2 μl  10 x DIG RNA labeling mix,  
2 μl  10 x Transcription buffer,  
2 μl  20 U/μl RNA polymerase (SP6 or T7 ) 
Add sterile RNase free double distilled water 
The reaction was allowed for 2 hrs at 37° C before RNase-free, DNase I was add to 
remove template DNA for 15 min at 37° C. The reaction was stopped by adding 2 μl 
0.2 M EDTA (pH 8.0). The probes were purified by ethanol precipitation to remove 
unincorporated nucleotides. The probes were diluted in hybridization buffer and 
stored at ~80 °C till usage. 
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2.7.3 In situ hybridization of HS3ST3A1 on breast cancer patients 
In situ hybridization was carried out in RNase-free procedures. Section slides 
were de-paraffinized and de-waxed by immersing in fresh xylene for 5 min with two 
changes and re-hydrated in graded series of ethanol of 100% ethanol, followed by one 
change of 90%, 70% and 50% respectively (each change lasting for 60 s). After fixation 
with 4% paraformaldehyde in PBS for 10 min and permeabilization with 20 μg/ml 
proteinase K for 20 min at room temperature, the slides were post-fixed for 5 min at 
room temperature with 4% paraformaldehyde in PBS. The slides were then washed 
with PBS containing 0.1% Tween-20 and acetlylated for 10 min using 0.25 % acetic 
anhydride in 0.1M Triethanolamine-HCl pH 8.0. After wash again, the slides were 
incubated in pre-hybridization solution at 70°C for at least 2 hrs to block non-specific 
binding sites. The slide then incubated with hybridization buffer containing 
digoxigenin-labeled HS3ST3A1 RNA probe (1 μl probe per 100 μl hybridization 
solution) at 70°C overnight in a humid chamber. After that the slides were washed with 
1 x SSC containing 50% formamide for 30 min at 65 °C and then with NTE  buffer 
(500 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 7.5) for 10 min at 37°C. The slides were 
added 20 μg/ml RNase A to digest any single-stranded (unbound) RNA probe for 30 
min at 37°C in NTE buffer. The slides were washed once with NTE for 10 min at 37°C 
and then with 2 x SSC for 20 min and with 0.2x SSC for 20 min at 65°C twice before 
blocked in 20% HISS/MABT solution ( 20% heat inactivated sheep serum in 100 mM  
Maleic acid, 150 mM NaCl, 0.1% Tween-20, ph 7.5) for 1 hr. The slides were then 
incubated with sheep anti-DIG-alkaline phosphatase (1: 2500, Roche Applied Science, 
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Mannheim, Germany) overnight in a humid chamber. After washing, the substrate 
NBT/BCIP solution (Roche) was added. The reaction was carried out in a humid 
chamber for 48-72 hrs in the dark until the color development was optimal and then the 
color reaction was stopped by washing out the NBT/BCIP solution and slides were 
fixed in 4% formaldehyde. Coverslips were mounted on the slides with mounting 
media (Vector Laboratories, Burlingame, CA, USA).No counter-staining was carried 
out and negative controls were performed by using sense probes.   
2.7.4 Analysis of in situ hybridization of HS3ST3A1  
To analyse the staining intensities, a semi-quantitative method was used as 
described in (Koo  et al., 2006). The scoring was represented by the percentage of 
positive cells x staining intensity (IPS). The intensity of staining is classified from a 
range of 0 = no expression, 1+ = weak expression, 2 + = moderate expression, 3+ = 
strong expression. The maximum IPS will be 300.  
2.8 Western Blot 
2.8.1 Extraction of protein 
For Western blotting analysis of integrin, FAK and paxillin, MCF-7 cells were 
cultured with or without 30 mM sodium chlorate for 48 hrs. The cells were re-seeded 
onto fibronectin–coated (20 μg/ml) flask for 2 hrs. The cells were washed three times 
with ice-cold PBS, then lysed in cold lysis buffer (50 mM HEPES, 150 mM NaCl, 1% 
Triton X-100, 5 μg/ml pepstatin A, 5 μg/ml leupeptin, 2 μg/ml aprotinin, 1 mM PMSF, 
100 mM sodium fluoride and 1 mM sodium vanadate, pH 7.5) and left standing on ice 
for 20 min. For analysis of  F11R in MCF-12A cells, the cells were lysed in RIPA 
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buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP40, 0.25% Na-deoxycholate, 5 
μg/ml pepstatin A, 5 μg/ml leupeptin, 2 μg/ml aprotinin, 1 mM PMSF, 100 mM sodium 
fluoride and 1 mM sodium vanadate, pH 7.5). After removal of cell debris by 
centrifugation at 13,000 rpm for 20 min,  the protein supernatant were collected and 
aliquoted and stored at -80°C until use. 
The concentration of the protein was determined by using bicinchoninic acid 
(BCA) protein assay kit (Pierce, Rockford, IL, USA). Briefly, 25 μl of serial diluted 
standards and 25 μl of unknown sample (normally 5 times dilution, 5 μl of collected 
protein diluted in 20 μl lysis buffer) was pipetted into 96-well plate. Subsequently, 200 
μl of the BCA reagent mixture solution (50 units of Bicinchoninic Acid Solution with 1 
unit of 4% (w/v) CuSO 4 • 5H2O Solution) was added to each well and mixed well. The 
plate was incubated at 37°C for 30 min and the absorbance was read at 562 nm. The 
concentration of protein in each sample was quantified by normalizing to the standard 
curve. The mechanism of BCA kit is that under alkaline pH conditions, the cysteine, 
cystine, tryptophan, tyrosine, and the peptide bond in the protein could reduce the Cu2+ 
to Cu1+ in the Cu2+-protein complex. The reduction is proportional to the amount of  
the protein in the sample. The Bicinchoninic acid forms a purple-blue complex with 
Cu1+ in alkaline conditions, which has a maximum absorbance at 562 nm. BCA assay 
has several advantages over other protein quantitation assays such as Biuret, Lowry and 
Bradford assay. These advantages include a more stable color complex, tolerance of 
higher concentration of detergents and a broad range of protein concentrations. 
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 2.8.2 Preparation of separating gel 
Spacers and glass were washed and wiped with 70% ethanol. Separating gel (10%) 
was prepared with N, N, N', N'-Tetramethylethylendiamin (TEMED) and ammonium 
persulfate (APS) (Bio-Rad, Hercules, CA, USA) added in the final step (Refer to Table 
2.7.1). The gel mixture was then quickly added into the space between the spacer and 
glass without causing any air bubble. Double distilled water was slowly overlaid on the 
gel to make an even surface of the gel. The gel was allowed to polymerize for at least 
half an hour. 
2.8.3 Preparation of stacking gel 
Waiting until the separating gel was completely polymerized, poured off the 
over-lay water. The mixture of stacking gel (4%) was added onto top of the separating 
gel. The teflon comb was carefully inserted into the stacking gel to make sure that no air 
bubbles were trapped under the comb. Waiting for another half an hour to allow the 
stacking gel to polymerize before gently pulled out the comb. Distilled water was 
squirted into the wells to wash out the remaining unpolymerized acrylamide.  
Table 2.1 Formula of separating and stacking gel for Western blot 
Separating gel Stacking gel 
solutions 10% solutions 4% 
dd H2O 2.785 ml dd H2O 2.165 ml 
1 M Tris pH8.5 3.75 ml 1 M Tris pH 6.8 375 μl 
30% Acrylamide 3.3 ml 30% Acrylamide 400 μl 
10% SDS 100 μl 10% SDS 30 μl 
10% APS 50 μl 10% APS 20 μl 
1.0 mm   
spacer 
TEMED 15 μl TEMED 10 μl 
 Total volume 10 ml Total volume 3 ml 
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2.8.4 Separating protein in the SDS-PAGE gel 
The protein lysate was mixed with 5x sample buffer containing 5% 
β-mercaptoethanol (β-ME) and heated at 100°C for 10 min for reducing gel. For 
non-reducing gel, the protein lysate was mixed with 5x sample buffer without the 
β-ME and was not heated.  Precision Protein Standards marker (Bio-Rad, Hercules, 
CA, USA) was added into a lane to indicate the molecular weight of protein. Twenty 
μg of the samples were loaded into the well of the stacking and run until the 
bromophenol blue in sample buffer reached the bottom of the separating gel. 
2.8.5 Transfer of protein to PVDF membrane 
A “gel-sandwich” was made on a semi-dry transfer cassette. From the bottom of 
the cassette to the top, lay a Whatman’s paper, PVDF membrane (Amersham 
Biosciences, Freiburg, Germany) which was soaked in methanol for 10 s and 
equilibrated in transfer buffer for 10 min, SDS-PAGE gel, another piece of 
Whatman’s paper sequentially. Each layer of the “gel-sandwich” was rolled over by a 
glass band to remove any air bubbles that may be trapped. The process of protein 
transfer was run for 50 min at 15 v voltage.  
2.8.6 Incubation with primary and secondary antibody 
After the transferring, the membrane was gently rinsed 2 times in TBST buffer 
(10 mM Tris-HCl, pH 7.5,150 mM NaCl, 1% Tween-20). Then the membrane was 
incubated with 5% non-fat milk for 1 hr at room temperature to block the non-specific 
binding sites. The membrane was incubated with different primary antibodies diluted 
in the 5% non-fat milk at room temperature for 1 hr or at 4°C overnight. The 
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membrane was washed 3 times in TBST buffer, each for 10 min, before re-probed 
with horseradish peroxidase (HRP) conjugated secondary antibodies (1:1000 to 
1:10000, diluted in the 5% non-fat milk) for 1 hr at room temperature. The membrane 
was again washed with TBST for 2 times before adding of the ECL. For β-actin 
blotting, membrane was stripped with stripping buffer containing 62.5 mM Tris– HCl 
(pH 6.7), 2% SDS and 100 mM β-mercaptoethanol at 55 °C for 30 min and re-probed 
with monoclonal mouse anti-actin antibody for normalization of protein loading.  
 2.8.7 Band development by Enhanced Chemiluminescence (ECL) 
Enhanced Chemiluminescence substrates (ECL Western Blotting Detection Kit, 
Amersham Pharmacia, Germany) was mixed in a 1:1 ratio according to the product 
insertion and added onto the membrane which was placed on a backbone film. The 
membrane together with the backbone was wrapped with cling wrap film carefully. 
The whole package was then placed in a film cassette. One piece of film was exposed 
to the membrane for 1-5 min to obtain optimal results.    
2.8.8 Densitometric analysis of the band intensity 
The bands on the film indicating the protein size and the expression level were 
scanned with a densitometer (Imaging Densitometer, Model GS-710, Bio-Rad, CA, 
USA). The intensity of the bands were measured with the Quantity-one Image 
Analysis software (Bio-Rad, version 4.62). The ratio of the intensity of the bands 
relative to β-actin was then calculated and used to quantify the expression level of the 
protein.   
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2.9 Quantitative real time polymerase chain reaction (qPCR)  
2.9.1 Extraction of total RNA 
Total RNA was extracted from monolayer cells grown in the 6-well plate with a 
commercially available RNeasy mini kit (Qiagen, Hilden, Germany). All the principal 
reagents were provided in the kit. The extraction process was following the protocol 
provided in the user manual of the kit. Briefly, cells growing in monolayer in the 
6-well plates were first washed completely with cold 1 x PBS to remove any 
remaining medium. The cells were then lysed by adding of 350 μl buffer RLT 
containing 1% β-ME. The cell lysates were collected by a cell scraper and further 
homogenized by passing through a 27# gauge for 5 times. Subsequently, the cell 
lysates were mixed well with 1 volume of 70% RNase-free methanol and transferred 
into a RNeasy MiniElute spin column in a 2 ml collection tube. The column was then 
centrifuged for 15 s at maximium. After discarded the flow through, 350 μl Buffer 
RW1 was added to the column to wash the membrane by centrifugation. RNA was 
then treated with 10 μl ribonuclease (RNase)-free deoxyribonuclease I (DNaseI, 
2.7 Kunitz units/ μl, Qiagen, Hilden, Germany) diluted in 70 μl buffer on the column 
at room temperature for 15 min to remove all trace of genomic DNA. The column was 
further washed by 500 μl Buffer RPE by centrifugation for 2 times. Finally, 32 μl 
RNase-free water was pipetted directly onto the center of the silica-gel membrane in 
the Minielute column and allowed to soak the membrane for 1 min before eluting the 
RNA by centrifugation for 1 min at maximum speed. Concentration and purity of 
RNA were measured by a spectrophotometer (Biophotometer, Eppendorf, Humburg, 
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Germany) in a 1-cm pass-length quartz cuvette. All RNA preparation had an OD260: 
OD280 ratio between 1.8 and 2.1.  
2.9.2 Synthesis of first strand cDNA  
Complementary DNA (cDNA) was synthesized from 2 µg DNA-free total RNA 
with random hexamer primer and SuperScript III reverse transcriptase (Invitrogen Life 
Technologies, Carlsbad, CA, USA).  Briefly, 2 µg RNA was mixed with 1 µl random 
hexamer primer (50 ng/μl) and 1 µl of dNTP (10 mM stock), topped up with 
DEPC-treated H2O to 13 µl, followed by centrifugation and heating at 65ºC for 5 min. 
The mixture was immediately put on ice for at least 3 min. Subsequently, 4 µl of 5 x 
first strand reaction buffer, 1 µl of Rnase inhibitor, 1 µl SuperScript III reverse 
transcriptase and 1 µl DEPC-treated H2O were added to make up the total reaction 
volume of 20 µl. The content was mixed thoroughly before allowed to react at 50 ºC for 
1 hr. Immediately after the reaction, the mixture was heated at 70 ºC for 15 min to 
inactivate the SuperScript III, and the resultant cDNA was then diluted 1:10 with 
DEPC-treated H2O and aliquoted and stored at -20°C until use. 
2.9.3 Quantitative real time polymerase chain reaction (qPCR) 
Real time PCR was performed with the Light Cycler System (Roche, ID, USA), 
using the QuantiTect SYBR Green PCR kit (Qiagen, Hilden, Germany). Primers were 
designed using the PRIMER3 software (http://www.genome.wi.mit.edu) and the 
BLASTn version 2.2.16 (http://www.ncbi.nlm.nih.gov/blast) was used to compare the 
obtained sequence against the non-redundant nucleotide database to make sure the 
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primer was specific. Then the primers were sent out for commercial synthesis 
(synthesized by First Base, Singapore) as following: 




Primers (5’-3’)        Span range   Amplicon 
length (bp) 





HS3ST3B1 NM_006041 F: 5’- ctggcttcaggcaaggagat-3’  




ITGB1 NM_002211  
 
F: 5'- ctgcgagtgtggtgtctgtaa-3’ 





FAK NM_005607 F: 5'- tggacgatgtattggagaagg-3' 






NM_002859 F: 5'- ccacacataccaggagattgc-3’ 




β-actin NM_001101 F: 5’- ggcatgggtcagaaggatt-3’ 




36B4 NM_001002 F: 5'- ctgttgcatcagtaccccatt-3'    




The total volume of real time PCR reaction was 10 μl containing 1 μl of the 
diluted cDNA , 0.5 μl forward primer, 0.5 μl reverse primer (each of 10 μM stock) and 
5 μl QuantiTect SYBR Green Master solution and 3 μl DEPC-treated H2O. According 
to the manufacturer's instructions of the QuantiTect SYBR Green Master solution kit, 
the cycle parameters of the real time PCR consisted of four programs: 
Program 1: Denaturation of the template cDNA and activation of the polymerase. 
The mixture was preincubated at 95 °C for 15 min for 1 cycle to activate the 
recombinant Taq DNA polymerase. 
Program 2: Amplification of the target gene. Cycle parameters were set as 
following: denaturation at 94 °C for 15 s, annealing for 25 s (annealing temperature 
depending on primers, but the primer design in such a way that the annealing 
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temperature normally is 60°C), extension at 72 °C for 12 s, 35 - 45 cycles.. 
Fluorescence was detected at the end of the annealing step of each cycle to monitor the 
progress of amplification.  
Program 3: Melting curve analysis. To examine if there was primer-dimer or 
non-specific amplification, melting-curve analysis was performed immediately after 
the amplification. The melting curve analysis parameters were set as the following: 
denaturation at 95 °C for 0 s by a temperature transition rate of 20 °C /s, incubation at 
65 °C for 15 s, and heating up to 95°C with transition rate of 0.1 °C/s. Melting-curve 
was plotted as the first negative derivative of the fluorescence versus temperature 
[-d(F)/dT] by the LightCycler data analysis software. A single, narrow and sharp peak 
normally means a specific amplication. 
Program 4: Cooling the rotor and thermal chamber: Temperature was decreased 
to 40 °C for 30 s to cool the system. 
 2.9.4 Agarose gel electrophoresis for the qPCR product 
The qPCR product was also checked by agarose gel electrophoresis to exclude 
the possibility of non-specific amplification. After the qPCR amplication, the 
amplified products were acquired by a short spin with capillaries inverted into 
eppendorf tubes. 5 μl of the qPCR product was mixed with 1μl of loading dye 
(Blue/Orange 6x loading dye containing 15% Ficoll 400, 0.03% bromophenol blue, 
0.03% xylene cyanol FF, 0.4% orange G, l0 mM Tris-HCL pH 7.5 and 50 mM EDTA) 
and electrophoresed on 1% agarose gel in the presence of ethidium bromide in TAE 
buffer (40 mM Tris-acetate, 1 mM  EDTA, pH 8.1-8.3) or TBE buffer ( 89 mM 
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Tris-Boric acid, 2 mM EDTA, pH 8.1-8.3) to further verify the product specificity. 
The band was viewed by Gel Documentation Image Analysis System V6.03 
(ChemiGenuis SynGene, Cambridge, UK). 
 2.9.5 Gene expression analysis of qPCR data 
The 2-ΔΔCt method was used to calculate fold changes in the expression levels of 
the genes (Livak and Schmittgen, 2001). Threshold cycle (Ct) was determined as the 
cycle number at which the SYBR fluorescence signal in the sample first exceeds the 
level of background noise and becomes exponential which reflects the amplification 
copies of interested gene, using the second-derivative maximum method of the 
LightCycler software.  
ΔCt is equal to the difference in threshold cycle for target gene and reference 
gene (Ct, target – Ct, reference) in one group. Subsequently, the ΔΔCt values were calculated 
by subtracting the ΔCt value of untreated control from that of the treated group at 
same time point: ΔΔCt = (Ct, target-Ct, referencer) treated- (Ct, target-Ct, referencer)control.  
Relative quantification of the fold changes in gene expression were calculated 
by using the formula: fold change = 2-ΔΔCt  
2.10 Proliferation assay 
Proliferation assay was done by MTS method or crystal violet method. For crystal 
violet method, in 96-well plates, 4 x 103 MCF-7 cells or 2 x 103  MDA-MB-231 cells 
per well in 200 μl volume were seeded in serum-containing media in the presence or 
absence of 30 mM sodium chlorate and incubated for 24, 48, 72, 120 and 168 hrs. 
Medium was changed every 48 hrs. For the study of the effect of different exogenous 
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HS species on MCF-7 cell growth and MDA-MB-231 cell growth, 6 x 103 MCF-7 cells 
or MDA-MB-231 cells per well in 200 μl volume were seeded in serum-containing 
media in the presence or absence of 30 mM sodium chlorate with or without the 
exogenous HS and incubated for 72 hrs. Cell number was determined using crystal 
violet assay. Briefly, at each experimental time point, cells were washed with 
phosphate-buffered saline (PBS), fixed in 4% formaldehyde for 15 min and stained 
with 0.25% crystal violet in 20% methanol in PBS for 30 min. After washing again, 
crystal violet was released with 1% sodium dodecyl sulfate (SDS) for 1 hr. Absorbance 
was read at 595 nm using a plate reader. Growth was measured as compared to a 
standard curve of cells grown in serum-containing media. 
For MTS assay, after 72 hrs post-transfection of HS3ST3A1 siRNA in MCF-12A 
cells, MTS method was used to determine the cell number. MTS assay was performed 
using the CellTiter 96 Aqueous non-radioactive proliferation assay (MTS, Promega 
Corp., Madison, WI, USA) which is a colorimetric method for determining the number 
of viable cells in proliferation assays. The main components in the assay are the 
tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 
-2-(4-sulfophenyl)-2H-tetra-zolium (MTS) and phenazine methosulfate. MTS is 
bioreduced due to the mitochondrial activity in the cells into a soluble formazan which 
can be measured directly at 490 nm. The quantity of formazan is directly proportional 
to the number of living cells in culture. 
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2.11 Adhesion assay  
96-well cell culture plates were coated with fibronectin (20 µg/ml) and collagen I 
(20 µg/ml) in 100 μl volume in PBS at 4°C overnight. Wells were then washed with 
PBS and the unbound sites were blocked with 100 μl 1% BSA for 1 hr at 25°C. Wells 
were then washed twice with PBS again and air-dried in the hood and stored in 4°C for 
later use. Cells are harvested with 0.02% EDTA and 0.25% trypsin. Cells were 
re-suspended in cell growth medium without FBS and re-seeded at a concentration of 1 
× 105 MCF-7 cells and MDA-MB-231 cells per well in 96-cell plates or  8 × 104  
MCF-12A cells per well in 100 μl volume in 96-cell plates and allowed to attach for 30 
min at 37°C in a humidified incubator containing 5% CO2. The cell number was 
determined as in Section 2.10 (Proliferation assay). 
2.12 Migration assay 
Migration assay was performed by two methods. One is using wound scratching 
model. The other is using a commercially available transwell. For the “wound 
scratching” model, MCF-7 cells or MDA-MB-231 cells were seeded in 6-well plates 
and grown to confluence in the presence or absence of 30 mM sodium chlorate with or 
without different HS species. The number of seeded cells was selected so that the 
culture will become confluent 48 hrs after seeding. The scratch wound in the confluent 
cell monolayer was made using a sterile 200 μl-yellow plastic pipette tip. And the cells 
were continued to culture with medium containing 2% FBS in the presence or absence 
of 30 mM sodium chlorate. Wound closure was monitored every 4 hrs and 
photographed using Nikon Digital Sight DS-L1 camera (Nikon, Melville, NY, USA). 
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The distance between the wound edges was measured. These experiments were 
repeated at least three times. The distance migrated was given by the difference 
between the initial wound width and the wound width at each of the monitored time 
points.   
For migration assays performed by Costar transwell insert (8-µm pore size). 
MCF-12A cells are harvested with 0.02% EDTA and 0.25% trypsin after 72 hrs 
post-transfection of HS3ST3A1 siRNA in MCF-12A cells. Cells were re-suspended in 
DMEM/F12 medium containing 0.1% BSA (Sigma-Aldrich) without FBS. Cells were 
seeded at a concentration of 5 × 104/well in 100 μl volume in the upper chamber of the 
transwell. The lower chamber was filled with 600 μl MCF-12A cell full growth 
medium containing 15% FBS as chemoattractant. Cells were allowed to migrate for 16 
hrs at 37°C in a humidified atmosphere containing 5% CO2. Non-migrated cells on the 
upper side of the membrane were removed with a cotton swab. Migrated cells attached 
to the lower side of the membrane were fixed and stained with 0.5% crystal violet in 
20% methanol in PBS for 30 min. The cells were counted using a light microscope at 
100x magnification (Nikon, Melville, NY, USA). Each data point represents the mean 
of five independent microscopic fields in three independent experiments (15 fields). All 
migration assays were performed on three separate experiments, run on duplicates. 
2.13 Invasion Assay 
Cell invasion assay was carried out using BD BioCoat Cell Environments, 
MatrigelTM invasion chamber.  MCF-7 cells and MDA-MB-231 cells were harvested 
after 48 hrs culture in the presence or absence of 30 mM sodium chlorate in 
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serum-containing media. MCF-12A cells are harvested with 0.02% EDTA and 0.25% 
trypsin after 72 hrs post-transfection of HS3ST3A1 siRNA. Cells were re-suspended in 
each growth medium containing 0.1% BSA (Sigma-Aldrich) without FBS. Cells were 
seeded at a concentration of 1 × 105/well in 100 μl volume in the upper well of the 
invasion chamber.  The lower chamber were filled with 600 μl full growth medium 
containing 15% FBS as chemoattractant. Cells were allowed to invade for 24 hrs at 
37°C in a humidified atmosphere containing 5% CO2. The matrigel and the 
non-invaded cells in the upper well were removed with a cotton swab. Invaded cells 
attached to the lower side of the membrane were fixed and stained with 0.5% crystal 
violet in 20% methanol in PBS for 30 min. The cells were counted using a light 
microscope at 100x magnification (Nikon). Each data point represents the mean of five 
independent microscopic fields in three independent experiments (15 fields). The 
invasion assays were performed in duplicates on three separate occasions. 
 
2.14 Gene expression profiling using GeneChipTM Microarray 
2.14.1 RNA preparations 
For RNA preparations, MCF-12A cells were transfected with HS3ST3A1 siRNA 
for 48 hrs. Total RNA was extracted with RNeasy Mini kit (Qiagen, Hilden, Germany) 
as in Section. RNA was also treated with ribonuclease (RNase)-free deoxyribonuclease 
I (DNaseI) to remove all trace of genomic DNA. 
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2.14.2 Preparation of Labeled cRNA and Array Hybridization 
All procedures were performed according to the instructions from Affymetrix 
(Santa Clara, CA).  
2.14.2.1 First Strand Synthesis 
Total RNA (2.5 μg) was converted into first-stranded cDNA by using SuperScript 
II reverse transcriptase (Invitrogen Life Technologies, Carlsbad, CA, USA) and an 
T7-(dT)24 primer. T7-(dT)24 primer sequence:5´- 
GCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24 - 3´  
The steps taken were: 
1. Primer hybridization:  
• 2.5 μg      Total RNA  
•  (Variable)    Nuclease free H2O (to complete 1st strand final reaction volume of           
11 μl ) 
• 1 μl        T7-(dT)24 primer (50 ng/μl )   
2. Incubation at 70ºC for 10 min 
3. Sample was quickly spun down and put on ice to avoid the re-naturing the 
RNA 
4. Addition of  
• 4 μl    5X First strand cDNA buffer  
• 2 μl    0.1 M DTT  
• 1 μl    10 mM dNTP mix  
• 1 μl    RNAsin (RNase inhibitor) 
   And the mixture was spun down and incubated at 42ºC for 2 min 
5. And Addition of  1 μl Superscript II 
6. Mixed well and incubated at 42ºC for 1 hr 
7. Centrifuged briefly and placed on ice 
2.14.2.2  Second Strand Synthesis 
To synthesize second strand, the following steps were taken: 
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 Addition of the following in an Eppendorf tube: 
• 91 μl  DEPC treated H2O 
• 30 μl  5 x Second strand buffer  
• 3 μl 10 mM dNTP mix 
• 1 μl   E.Coli DNA Polymerase I (10 U/μl) 
• 1 μl E.Coli DNA Ligase (10 U/μl ) 
• 1 μl   RNAse H (2 U/μl) 
 
1. Final Volume: 150 μl  
2. Gently tapped the tube to mix the content and, briefly centrifuged down 
3. Incubated at 16ºC for 2 hrs  
4. Addition of 2 μl (10 U) T4 DNA Polymerase 
5. Incubated for 5 min at 16ºC  
6. Reaction was stopped with 10 μl of 0.5 M EDTA 
 
2.14.2.3 Clean Up of Double Stranded cDNA 
To remove the unbound dNTP and enzymes, the yield double stranded cDNA was 
cleaned up by the following steps: 
1. Addition of 600 μl cDNA binding buffer 
2. Mixed by vortexing for 3 s 
3. Application of 500 μl of the solution to cDNA Clean Spin Column 
4. Centrifuged at 13,000 rpm for 1 min  
5. Reloaded the remaining mixture and repeated the centrifugation 
6. Transferred the column into a new 2 ml Collection tube 
7. Addition of 750 μl cDNA Wash buffer 
8. Centrifuged for another 1 min at 13,000 rpm  
9. Discarded the flow-through 
10. Opened the column cap and re-centrifuged for 5min at 13,000 rpm to dry the 
membrane 
11. Transferred the column into a new 1.5 ml Collection tube 
12. Addition of 14 μl Elution buffer and centrifuged for 1 min at 13,000 rpm to 
elute the “clean-up” double stranded cDNA 
Materials and Methods 
 75
13. Retaining the elution. 
2.14.2.4 Synthesis of Biotin-Labeled cRNA  (cRNA in-vitro transcription, IVT) 
The double stranded cDNA was used as template to generate biotin-labeled cRNA 
in vitro with the EnZo BioArray High Yield Transcript Labling Kit (Enzo Diagnostics, 
Inc. Farmingdale, USA). 
To make IVT Master Mix , the following steps were taken at room tempature: 
1. Addition of the following  
• 12 μl     double stand cDNA 
• Variable Nuclease free H2O (final reaction volume of 40 μl ) 
•  4 μl      10x  IVT Labeling Buffer  
• 12 μl      IVT  Labeling NTP Mix 
•  4 μl      IVT  Labeling Enzyme Mix 
• Total Volume  40 μl 
2. Incubated at 37°C for 16 hours 
3. Proceeded to Cleanup and Quantification of Biotin-Labeled cRNA or cRNA 
was kept at -20°C until use. 
2.14.2.5 Cleanup and Quantification of Biotin-Labeled cRNA 
To remove the unbound Labeling NTP and enzymes, the following steps were taken 
and the yield cRNA was cleaned up.  
 
1. Addition of 60 μl RNase-free H2O to the IVT reaction tube and mixed. 
2. Addition 350 μl IVT cRNA Binding Buffer and mixed.  
3. Addition 250 μl 100% ethanol to the mixture, and mixed by pipetting.  
4. Applied the sample (about 700 μl) to the IVT cRNA Cleanup Spin Column  
5. Centrifuged at 13,000 rpm for 15 s 
6. Pipetted 500 μl of IVT cRNA Wash Buffer onto the spin column and 
centrifuged at 13,000 rpm for 15 s to wash the column membrane 
7. Discarded the flow-through 
8. Opened the column cap and centrifuged for 5 min at 13,000 rpm to dry the 
membrane 
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9. Transferred the column into a new 1.5 ml Collection tube 
10. Addition11 μl Elution buffer to the centre of the membrane and allow the 
buffer to soak the membrane for 1 min 
11. Centrifuged the column at 13,000 rpm for 1min 
12. Re-added 10 μl Elution buffer to the centre of the membrane and 
centrifuged at 13,000 rpm for 1min 
13. The “cleaned-up” cRNA was be kept at -20°C until use after the 
quantification step ( see below) 
2.14.2.6 Quantification and fragmentation of cRNA  
Before hybridize the cRNA to the GeneChip microarray, the cRNA must be 
quantified in order to use the same amount cRNA as the start material in hybridization. 
Quantification of cRNA 
According to the GeneChip analysis technique manual, because total RNA was 
used as starting material in this experiment, (Gene expression profiling in MCF-12A 
cells after knock-down the HS3ST3A1 by siRNA), so the final cRNA yield was 
adjusted to excluded the carryover amount of the unlabelled total RNA.  
Adjustment formula was as following by using an estimation of 100% carryover. 
Adjusted cRNA yield = cRNAtotal - (starting total RNA) x (y)  
where:  cRNAtotal = amount of cRNA measured after IVT (µg)  
starting total RNA = starting amount of total RNA (µg) 
 y = fraction of double stranded cDNA reaction used in IVT  
In this experiment, 2.5 µg total RNA was the starting amount and 100% of the 
double stranded cDNA product was added to the IVT.  
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So adjusted cRNA yield = measurement amount of the total cRNA- (2.5 µg total 
RNA) x (100% fraction)  
The quantity, quality, and purity of the RNA and cRNA were checked first by 
using an Eppendorf spectrophotometer (Biophotometer, Eppendorf, Hamburg, 
Germany) and a 1-cm pass-length cuvette. The absorbance was measured at the 
wavelength of 260 nm and 280 nm and the A260:A280 ratios were calculated. Then the 
quantity, quality, and purity of the RNA and cRNA were assessed by detecting 28S/18S 
ribosomal RNA peak using the RNA 6000 Nano LabChip® kit on the Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) according to the 
manufacturer's instructions as described in the RNA 6000 Nano Assay reagent kit guide 
(Agilent Part number: G2941-90126). Briefly, the chip was primed with gel–dye mix 
made of 1 μl of RNA 6000 Nano dye and 65 μl of filtered gel and the conditioning was 
done using 9 μl of RNA 6000 Nano gel-dye solution. Five μl of RNA 6000 Nano 
Marker was added to each of the sample wells and the well for the RNA ladder. One μl 
of heat denatured RNA ladder (diluted 150-fold) was added to the RNA ladder well and 
1 μl of sample was added to each of the sample wells. The chip was vortexed in the IKA 
vortex station at 2400 rpm for 1 min and was then inserted into the Agilent 2100 
BioAnalyzer. Only samples that reached the anticipated purity and integrity parameters 
(RIN >= 9.5; A260:A280>= 1.9) were introduced within the microarray pipeline 
process.  
 The RIN (RNA Integrity Number) is an algorithm developed by Agilent (Agilent 
Technologies, Palo Alto, CA, USA). The algorithm assigns integrity values to RNA by 
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selecting and calculating several features of the RNA integrity. This is a 
user-independent and automated process that makes the RNA integrity measurements 
standardized across all the samples. The Agilent 2100 Bioanalyzer can be used to 
measure the quantity, integrity and purity of small amount of RNA. A valuable 
advantage of the Agilent 2100 Bioanalyzer is that it combines and automates rapid 
sample handling, sensitive separation and accurate analysis through the micro-channels 
in a Lab-on-a-Chip at the same time.  
2.14.2.7 Fragmentation of cRNA  
Twenty ug of the labeled cRNA was fragmented. 
Addition of :  
• 20 μg  adjusted cRNA 
• 8  μl   5 x Fragmentation buffer 
• ~12 μl  Rnase-free H2O to top up to 40μl final reaction volume 
1. Incubated at 94°C for 35 min. 
2. Put on ice and 1 μl of the fragmented cRNA was used for analysis on the 
Bioanalyzer 2100. The standard fragmentation procedure produced a distribution 
of RNA fragment sizes from approximately 35 to 200 bases 
2.14.2.8 Hybridization to Affymetrix GeneChip U133 plus 2.0 
The final hybridization mixture was prepared as following:  
Addition of  
• 15 μg  Fragmented cRNA ( about 3/4 reaction volume of the above fragmented 
cRNA) 
•  5 μl   Control oligonucleotide B2 
• 15 μl   20x Eukaryotic Hybridization Controls (bioB, bioC, bioD, Cre) 
•  3 μl   Herring Sperm DNA (10 mg/ml) 
•  3 μl   BSA (50 mg/ml) 
• ~84 μl  Nuclease free water 
• 150 μl  2x Hybridization Buffer              Total volume: 300 μl 
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1. Denaturation of the hybridization cocktail at 99 °C for 5 min 
2. Transferred the hybridization cocktail to a 45°C heat block for 5 minutes. 
3. Hybridization cocktail(s) was spun at maximum speed in a microcentrifuge for 5 
min to remove any insoluble material from the hybridization cocktail 
4. Addition of the cocktail to the Affymetrix Test 3 array to check the quality of the 
hybridization cocktail according to manufacturer’s criteria and if the Test chip 
gave a satisfactory hybridization results, the “real” hybridization was run. 
The criteria of a satisfactory hybridization included: 
z 3´/5´ratios of housekeeping genes, β-actin and GAPDH were ≤ 3 and very 
close to 1.0 
z Singnal background was below 100  
z Relative ratios of scaling factors among all the chips were ≤ 3 
z Spike-in controls of bioC, BioD and cre must be present 
z Spike-in control of bioB must be present in at least 50% of arrays 
5. The cocktail was then added to Affymetrix GeneChip U133 plus 2.0 and allowed 
to hybridize for 16 hrs at 45°C with rotation at 60 rpm in the Hybridization Oven 
640 (Affymetrix Inc., Santa Clara, CA, USA) 
2.14.2.9 Washing and staining procedure  
After 16 hrs hybridization, the hybridization cocktail was removed from the 
GeneChip U133 plus 2.0 array and stored at -80°C. The Chips were filled completely 
with Non-Stringent Wash Buffer to remove any remaining air bubbles. Then the U133 
plus 2.0 arrays were washed and stained with streptavidin-phycoerythrin conjugate 
(Molecular Probes, Eugene, OR, USA). The washing and staining procedure were 
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performed in the Fluidics Station 400 (Affymetrix) by using the appropriate fluidics 
protocols, following the manufacturer´s instructions. 
During the washing and staining processes, the GeneChip was stained with a 
streptavidin-phycoerythrin (SAPE) that binds to biotin which was conjugated to cRNA 
on the Chips. This streptavidin-biotin interaction was a signal amplification step that 
resembles the mechanism of the ABC kit as in Section 2.4 Immunohistochemistry. On 
the day of washing and staining, prepare the following SAPE stain solution and 
antibody solution as in Table 2.3 and Table 2.4. The Affymetrix Fluidics Station was 
set up to perform the protocol as in Table 2.5. 
Table 2.3 SAPE stain solution 
Components Volume Final Concentration 
2x MES Stain Buffer 600.0 µl 1x 
50 mg/mL acetylated BSA  48.0 µl 2 mg/ml 
1 mg/mL Streptavidin-Phycoerythrin
(SAPE) 
 12.0 µl 10 µg/ml 
Water 540.0 µl  
Total  1200 µl    
Table 2.4 Antibody Solution 
Components Volume Final Concentration 
2x MES Stain Buffer  300.0 µl 1x 
50 mg/mL acetylated BSA   24.0 µl   2 mg/ml 
10 mg/mL Normal Goat IgG    6.0 µl 0.1 mg/ml 
 0.5 mg/mL biotinylated antibody   3.6 µl  3 µg/ml 
Water  266.4 µl    
Total    600 µl    
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 Table 2.5 Washing protocol 
Post Hybridization Wash 1  10 cycles of 2 mixes/cycle  
Wash Buffer A at 25°C  
Post Hybridization Wash 2  4 cycles of 15 mixes/cycle  
Wash Buffer B at 50°C  
Stain  Stain probe array for 30 minutes  
SAPE Solution at 24°C  
Final Wash  10 cycles of 4 mixes/cycle  
Wash Buffer A at 25°C  
2.14.2.10 Image scanning 
After washing and staining, the GeneChips were again filled completely with 
Non-Stringent Wash Buffer to remove any remaining air bubbles. The microarrays 
were then scanned by Affymetrix GeneChip Scanner 3000 according the Affymetrix 
protocol. Scanned output image files ( .Dat file) were analyzed with Affymetrix 
Microarray Suit V5.0 (MAS5) to create .CEL Files and .CHIP Files. 
2.14.3 Gene expression data analysis 
The scanned images was read and pre-processed by Affymetrix Microarray Suite 
5.0 (Affymetrix, Santa Clara, CA, USA). All microarrays were pre-processed and 
scaled to a standard target intensity of 500 by using the MAS 5.0 software. Then 
the .CEL files were processed and normalized using different analysis softwares 
For every probeset, background subtraction, normalization and expression 
summaries were calculated by three commonly used methods. First the MAS5 method 
was used to obtain probeset summaries. The MAS 5.0 algorithm uses a scale 
normalization technique taking into account perfect match (PM) and mismatch (MM) 
probe pairs to correct for non-specific hybridization A detailed description of this 
algorithm has been widely published (Affymetrix, 2001; Affymetrix Inc, 2002). Next, 
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dCHIP software (Li and Wong, 2001a; Li and Wong, 2001b) was used. This software 
incorporates the model-based expression indexes (MBEI) which by using of a 
multiplicative model to take account for probe affinity effects in calculating probeset 
expression. Finally, the robust multiarray average (RMA) method (Irizarry  et al., 
2003a; Irizarry  et al., 2003b) was used; this method first uses a model-based 
background noise correction which ignores MM values and then performs a quantile 
normalization, and finally runs an iterative median polish to remove probe affinity 
effects when calculating probe set expression.  
2.14.3.1 MAS5 analysis:  
For single array analysis, MAS 5.0 first calculates the value for each probe pair 
by subtracting the MM (non-specific) signal from the PM (total) signal, then 
MAS5.calculates statistical significance for the average difference between probe pairs 
and generates the detection calls Absent (A), Marginal (M), or Present (P) for each 
probe set which indicates whether a gene transcript is reliably detected or not. A value 
of  p > 0.06 indicates that the gene is not detected at a level significantly different from 
background and is thus designated as Absent; a  p value between 0.06 and 0.04 results 
in a Marginal call; and a p < 0.04 indicates Present.  The average of the differences 
represents the final "signal" and is reflective of the level of expression of the gene. 
During this single array analysis, each array was checked by looking into the 
hybridization control spikes which were used to address the array hybridization 
sensitivity and efficiency. Quality control for spike controls BioB and BioC were 
present in all 6 arrays. Internal controls GAPDH and β-actin were inspected by 
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calculating the 3’/5’ ratio. In all our experiment, these ratios in all 6 samples were near 
1 (not more than 3 according to Affymetrix protocol). 
The comparison analysis:   MAS 5.0 estimates the magnitude and direction of 
changes (Signal Log Ratio) of a gene transcript in two conditions by comparing each 
other (for example, experiment versus control). In our present study, comparison files 
were generated from .CEL files by MAS5 for each array of the two group samples, 
using control array as a baseline and the siRNA group array as an experiment, thus 
generating 9 comparisons.  The scale used for Signal Log Ratio) was base 2, making it 
easy to calculate fold change as a Change of 1 in Signal Log Ratio indicates 2 fold 
change of the expression level.  
The Change algorithm generated “Change p- value” and an associated a change 
call of Increase (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), 
or Decrease (D). Change p-values range in scale from 0.0 to 1.0 with those close to 0.0, 
indicating likelihood for an increase in gene transcript expression.  This strategy 
removes differences (variability) due to different probe binding efficient and cancels 
out much of the proportional relationship between random error and signal intensity, it 
is therefore a more accurate estimate of differential expression than comparisons made 
from single-array analyses where the probe pairs are first averaged so that only a single 
pair of values is used for comparison. Finally the MAS 5.0 program creates the user's 
file (so-called .CHP file), which can be two forms: single array file or comparison file.  
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Filter criteria for gene selection in MAS5 
The following criteria were used for determining the selection for those 
differentially expressed genes in MAS5.  
First filter: Detection calls, P call was at least 50% present in 6 arrays 
Second filter: Change algorithm calls, the same Change directions were at least 5 
out of the 9 comparisons, for example 5 Is out 9 comparisons, or 4 
Ds plus 1 MD out of 9 comparisons. 
Third filter:  Fold Change, the absolute fold-change value was at least 2 fold 
between the average of the control group and the siRNA groups.   
2.14.3.2 GeneSpring analysis 
The data set was then loaded into a data mining program, GeneSpring 7.0 (Silicon 
Genetics, Redwood City, CA, USA). Expression values for each gene were calculated 
using the Affymetrix Microarray suite (MAS5.0) software as above. In each array, the 
expression files were normalized to the median (50th percentile) intensity of the same 
array. The expression value were normalized across the arrays by scaling the average of 
the intensities of all the probesits to a constant target intensity and compare the 
expression change in DATA Mining Tool 3.0 ( Affymetrix, Santa Clara, CA, USA). 
The resultant file containing signals, p-values, and detection calls were imported to 
GeneSpring V7.0 (Silicon Genetics, Redwood City, CA) software for subsequent 
analysis. Differentially expressed genes were analyzed by One-Way ANOVA with P 
level of 0.05 taken as statistically significant. Agglomerative average-linkage 
hierarchical clustering of the 6 arrays of two experimental groups was obtained for 
Materials and Methods 
 85
selected genes with GeneSpring (Chu et al., 2001) software using standard correlation 
as similarity matrix. 
Filter criteria for gene selection in GeneSpring 
The following criteria were used for determining the selection for those 
differentially expressed genes analyzed by GeneSpring.  
First filter: Detection calls, P call was at least 50% present in 6 arrays and if the 
Present calls were just 50%, then they must be in all of the 3 control groups or in all of 
the siRNA experimental groups. Second filter: Fold Change, the absolute fold-change 
value was at least 2 fold between the average of the control group and the siRNA 
groups. Third filter: Statistically significance, analyzed by One-Way ANOVA with P 
level of 0.05 taken as statistically significant. 
2.14.3.3 dChip analysis 
DNA-Chip Analyzer 2007 (dChip; http://www.dchip.org/ ) software was used to 
normalize the raw microarray intensity by read in the .CELfiles and then calculate the 
model-based expression indexes (MBEI) using the PM-MM-only model with outlier 
detection. dCHIP software (Li and Wong, 2001a; Li and Wong, 2001b) incorporates 
the model-based expression indexes (MBEI) that applies an invariant probe set 
normalization method to summarize gene-level intensity. The “invariant probe set” 
chooses a subset of PM-only probes with small within-subset rank difference in the two 
microarrays to serve as the basis for fitting a normalization curve with one array as a 
reference array and keeps the expression ratio values between two datasets under 
consideration unchanged by forcing the selected non-differentially expressed genes to 
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have equal values. The outlier detection algorithm of the dChip software allowed 
further quality assessment of microarray data by cross-referencing one array with other 
arrays through a modeling approach to identify problematic arrays (Li and Wong, 
2001a). 
Filter criteria for gene selection in dChip 
The following criteria were used for determining the selection for those 
differentially expressed genes analyzed by dChip. 
First filter: Detection calls, P call was at least 50% present in 6 arrays and if the 
Present calls were just 50%, then they must be in all of the 3 control 
groups or in all of the siRNA experimental groups. For example, 
control 1, P, control 2, P, control 3, P and siRNA1, A, siRNA2, A, 
siRNA3, A. or control 1, A, control 2, A, control 3, A and siRNA1, P, 
siRNA2, P, siRNA3, P. 
Second filter: Fold Change, the absolute fold-change value was at least 2 fold 
between the average of the control group and the siRNA groups. 
2.14.3.4 Robust Multi-array Analysis (RMA) analysis 
Robust multi-array analysis, RMA (Irizarry et al., 2003b) software was used to 
normalize the raw microarray intensity by read in the .CEL files. RMA performs the 
following operations: first, probe-specific background correction was used to remove 
nonspecific binding using PM distribution rather than PM-MM method to summarize 
probe intensities into a gene expression value; Secondly, RMA estimates a common 
mean non-specific hybridization background (for an entire chip) from PM using a 
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convolution model and subtracts this background from PM to generate the PMrma; 
Thirdly, probe-level multichip quantile normalization was applied to unify PM 
distributions across all microarrays; Finally the robust probe-set summary of the 
log-normalized probe-level data by median polishing was performed to determine 
genes with a greater than 2-fold difference. 
Filter criteria for gene selection in RMA was those genes with a greater than 
2-fold difference after the normalization and summaries. 
2.14.4 Functional categorization of target genes 
Gene functions were curated based on Gene Ontology available in PubMed 
(http://www.ncbi.mlm.nih.gov/) and the Affymetrix NetAffx database (Cheng  et al., 
2004). Based on the above mentioned gene selection criteria, differentially expressed 
genes were extracted and categorized according to their biological function.  
2.14.5 Pathway analysis 
The differentially expressed genes were imported into PathwayStudio 4.0 
PathwayStudio® 4.0 (Nikitin et al., 2003) Ariadne Genomics, Inc pathway analysis 
software to find possible pathways that account for the phenotype changes in 
MCF-12A after silencing the HS3ST3A1 expression. 
2.15 Statistical analysis 
The GraphPad Prism statistical package version 4.03 (GraphPad Prism, San 
Diego, CA, USA) was used for statistical analysis. Student’s t-test or ANOVA 
followed by post-hoc Tukey or Bonferroni test was performed to compare the means 
















CHAPTER  3   Studies on the effects of undersulphation of 
HS and differentially sulphated HS on breast carcinoma cellular 
behaviours 
Substantial evidence demonstrated that HSPG is involved in many biological 
processes of the malignant cells including cell proliferation, adhesion, migration and 
invasion (Esko and Selleck, 2002; Whitelock and Iozzo, 2005; Sasisekharan et al., 2006). These 
biological effects are influenced by the sulphate group of the heparan sulphate (HS) 
chains. Sulphate groups modulate the ability of heparan sulphate to bind and interact 
with different growth and signaling factors. Researchers have shown that the MCF-7 
and MDA-MB-231 breast cancer cells produce high levels of sulphated proteoglycans. 
MCF-7 cells are known to release HSPG as the main proteoglycan component into the 
culture medium (Delehedde et al., 1997). The aim of this study was to investigate the 
effects of undersulphation of HS and differentially sulphated HS on breast carcinoma 
cellular behaviours. 
3.1 Sodium chlorate inhibited sulphation of HS in MCF-7 breast cancer cells 
To determine the effect of disrupting sulphation of glycosaminoglycans by 
sodium chlorate on MCF-7 cells, MCF-7 breast cancer cells were cultured in the 
presence of 30 mM sodium chlorate. Sodium chlorate is a widely used and 
well-known competitive inhibitor of glycosaminoglycan sulphation. It acts as a 
sulphate analogue in the cellular synthesis of the sulphate donor 3'-phosphoadenosine 
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5'-phosphosulphate, which is required for glycosaminoglycan sulphation (Humphries 
and Silbert, 1988; Keller et al., 1989; Delehedde et al., 1996; Yip et al., 2002).  
Many studies involving breast cancer cell cultures and other biological systems 
have shown that sodium chlorate disrupted sulphation of glycosaminoglycans while 
having no significant effects on glycosaminoglycan chain or protein synthesis when 
chlorate was used at concentrations of up to 30 mM (Greve et al., 1988; Humphries 
and Silbert, 1988; Keller et al., 1989; Delehedde et al., 1996). Thus it is a useful tool 
to investigate the role of sulphate moieties in HSPG. 
To define the distribution of HSPG on MCF-7 cell surface after sodium chlorate 
treatment, HSPG specific monoclonal antibody 10E4 was used. 10E4 anti-HSPG 
monoclonal antibody recognizes N-sulphated glucosamine-containing domains in the 
HSPGs. The binding specificity was demonstrated by David et al. (1992). 
Immunostaining results showed that prominent staining of HSPG on the MCF-7 cells 
was observed in the control cells (Fig. 3.1, a). In contrast, markedly diminished 
staining of HSPG on the cells was observed in the sodium chlorate treated MCF-7 
cells (Fig. 3.1, c), which indicated that 30 mM sodium chlorate could successfully 
inhibit the sulphation of HSPG in MCF-7 cells.  
To further verify the de-sulphation of glycosaminoglycans by sodium chlorate on 
the MCF-7 proteoglycans, sulphation of total glycosaminoglycans and heparan 
sulphate were measured using the Blyscan glycosaminoglycan assay (Biocolor Ltd, 
Belfast, Ireland). Blyscan glycosaminoglycan assay is based on the specific binding of 
the cationic dye, 1, 9-dimethylmethylene blue (Farndale et al., 1986). Sulphated 
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glycosaminoglycans (GAG) were purified from cell monolayers and culture medium 
with or without sodium chlorate treatment. Fig.3.2A shows that compared with the 
total sulphation of GAG measured in control cells, sodium chlorate significantly 
inhibited sulphation of total GAG as the GAG/protein ratio was reduced to 60.8%. 
The sulphation inhibition in heparan sulphate was also confirmed because the 
GAG/protein ratio was reduced to 54.5% as shown in Fig. 3.2B. These data therefore 
collectively confirmed that sulphation of heparan sulphate in MCF-7 cells was 









Fig. 3.1. Sodium chlorate disrupted GAG sulphation in MCF-7 cell surface HSPG. 
MCF-7 cells were cultured for 24 hrs before the 30 mM sodium chlorate added for 
treatment for 48 hrs. Cells were fixed using Sainte-Marie's fixative and blocked by 
5% FBS in PBS for 1 hr at room temperature. The cells were then incubated for 
anti-HSPG antibody 10E4 mAb (1:100 dilution in PBS containing 2% FBS) 
(Seikagaku Corp, Japan). Cells were then washed 3 times with PBS, incubated with 
Alexa Fluor 488 labeled goat anti-mouse IgM antibody (1:400 dilution) (Molecular 
Probes, Eugene, OR) for 1 hr at room temperature, washed with PBS and mounted 
with Vectashield mounting medium. The cells were viewed by fluorescence confocal 
microscope. a: control, b: transmitted light image of control, c: sodium chlorate 
treated MCF-7 cells, d: transmitted light image of sodium chlorate treated MCF-7 

























Fig. 3.2. Measurement of sulphation in GAGs and heparan sulphate in MCF-7 
cells. A. MCF-7 cells were cultured with or without 30 mM sodium chlorate for 48 hrs. 
The culture medium were collected. The cell were collected by directly scratch with a 
cell scraper. The total GAG were extracted and measured with Blyscan kit as 
described in Materials and Methods. Data were expressed as mean ± SD. n = 3, ** p 
< 0.01. Student’s t-test. B. MCF-7 cells were cultured with or without 30 mM sodium 
chlorate for 48 hrs. The culture medium were collected. Cells were collected by 
directly scratch with a cell scraper. The total GAG were extracted and treated with 
nitrious acid to remove the heparan sulphation. The total and remaining GAG 
sulphation was measured with Blyscan kit as described in Materials and Methods. 
Heparan sulphation was calculated by substracting the remaining sulphation from the 
total sulphation. Data were expressed as mean ± SD. n = 3, ** p < 0.01. Student’s 
t-test. 
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3.2 Sulphate group in heparan sulphate was involved in regulating breast cancer 
cell proliferation  
To examine whether sulphation of heparan sulphate is involved in regulating the 
proliferation of breast cancer cells, the effect of undersulphation of GAG on MCF-7 
and MDA-MB-231 cell growth was first studied. 
MCF-7 and MDA-MB-231 cells were cultured in medium with or without 30 
mM sodium chlorate for 7 days. Cell growth curve results showed that sodium 
chlorate significantly inhibited MCF-7 cell proliferation over a seven-day treatment 
period as revealed by crystal violet assay (Fig. 3.3A). Similar inhibition results were 
obtained from MDA-MB-231 cells cultured with 30 mM sodium chlorate (Fig. 3.3B). 
These results show that presence of sulphation group in the glycosaminoglycan of 





















Fig. 3.3. Growth inhibition of breast cancer cells through undersulphation of HS. 
4 x 103 MCF-7 cells (A) and 2 x 103 MDA-MB-231 cells (B) were seeded in 96-well 
plates, and treated with PBS (control) or 30 mM sodium chlorate (to inhibit 
glycosaminoglycan sulphation) for 7 days (A) or 5 days (B). The cell number was 
determined by crystal violet assay. Data were expressed as mean ± SD. n = 8, **p < 
0.01. 











































To examine if differentially sulphated heparan sulphate species would rescue the 
inhibitory effect of sodium chlorate on breast cancer cell proliferation, two types of 
exogenous heparan sulpates were used, heparan sulphate from porcine intestinal 
mucosal (HS-PM) and from bovine kidney (HS-BK). MCF-7 and MDA-MB-231 cells 
were cultured in medium with 100 ng/ml HS-BK or HS-PM in the presence or 
absence of 30 mM sodium chlorate for 72 hrs. 
As shown in Fig. 3.4 and Fig. 3.5, HS-PM, but not HS-BK significantly reduced 
the growth inhibitory action of sodium chlorate on the growth of breast cancer MCF-7 
cells. A small rescue effect was seen in MDA-MB-231 cells cultured in medium 
containing 100 ng/ml HS-PM and 30 mM sodium chlorate (Fig. 3.6), but no such 
effect was found with HS-BK (Fig. 3.7). These data further verified that sulphation 
group in heparan sulphate glycosaminoglycan was indeed involved in the cell 












Fig. 3.4. HS-PM blocked the inhibitory effects of sodium chlorate on MCF-7 
breast cancer cell proliferation. MCF-7 cells were cultured in medium containing 
100 ng/ml HS-PM as described in Materials and Methods. Cell proliferation was 
assessed by crystal violet assay at 72 hrs. Data were expressed as percentage of 
control. Data represent means ± SE of 8 determinations from 3 separate experiments. 
One-way ANOVA, ** p < 0.01, Tukey post hoc analysis, sodium chlorate group vs. 















Fig.3.5. HS-BK did not block the inhibitory effects of sodium chlorate on MCF-7 
breast cancer cell proliferation. MCF-7 cells were cultured in medium containing 
100ng/ml HS-BK as described in Materials and Methods. Cell proliferation was 
assessed by crystal violet assay at 72 hrs. Data were expressed as percentage of the 
control. Data represent means ± SE of 8 determinations from 3 separate experiments. 
One-way ANOVA, ** p < 0.01, Tukey post hoc analysis, sodium chlorate group vs. 
sodium chlorate plus HS-BK group, p > 0.05.   






























































Fig. 3.6. HS-PM blocked the inhibitory effects of sodium chlorate on 
MDA-MB-231 breast cancer cell proliferation. MDA-MB-231 cells were cultured 
in medium containing 100 ng/ml HS-PM as described in Materials and Methods. Cell 
proliferation was assessed by crystal violet assay at 72 hrs. Data were expressed as 
percentage of control. Data represent means ± SE of 8 determinations from 3 separate 
experiments. One-way ANOVA, p = 0.0329, Tukey post hoc analysis, control group vs. 
sodium chlorate group, *p < 0.05, control group vs. sodium chlorate plus HS-PM 













Fig. 3.7. HS-BK did not block the inhibitory effects of sodium chlorate on 
MDA-MB-231 breast cancer cell proliferation. MDA-MB-231 cells were cultured 
in medium containing 100 ng/ml HS-BK as described in Materials and Methods. Cell 
proliferation was assessed by crystal violet assay at 72 hrs. Data were expressed as 
percentage of the control. Data represent means ± SE of 8 determinations from 
3 separate experiments. One-way ANOVA, p = 0.0057, Tukey post hoc analysis, 
control group vs. sodium chlorate group, *p < 0.05, control group vs. sodium chlorate 
plus HS-PM group, ** p < 0.01, sodium chlorate group vs. sodium chlorate plus 
HS-BK group, p > 0.05.  



























































3.3 Effect of undersulphation of heparan sulphate on cell cycle changes in 
MCF-7 and MDA-MB-231 breast cancer cells. 
Cell cycles progression reflects cell proliferation. To test if undersulphation of 
heparan sulphate by sodium chlorate influence cell cycle, MCF-7 cells were treated 
with 30 mM sodium chlorate for 12 hrs, 24 hrs and 36 hrs. After 24 hrs, the S-phase 
fraction of cells treated with sodium chlorate was ~18.0% whereas the S-phase of 
control cells was ~22.7%. This indicated that cells in S phase after 24 hrs treatment 
were reduced by 22.0%. This was accompanied by an increase in cells of similar 
magnitude in the G0-G1 phase of the cell cycle (Fig. 3.8 and Table 3.1). The cell cycle 
analysis results suggested that sodium chlorate inhibited the G0/S phase transition at 
24 hrs treatment as the cells in G2-M phase were almost the same between the control 
and sodium chlorate-treated cells. An important note was that there was no sub-G1 
peak before the G1 peak either in the control or the sodium chlorate treated cells 
which suggested there were no obvious apoptosis (Fig. 3.8). These results are 
consistent with previous report that 30 mM sodium chlorate was sufficient to suppress 
heparan sulphation without inducing cytotoxic effect. This inhibition in G1 /S 
transition was also seen in MDA-MB-231 cells treated with 30 mM sodium chlorate 

























Fig. 3.8.  Effect of undersulphation of GAGs on cell cycle changes in MCF-7 
breast cancer cells. MCF-7 cells were seeded at a density of 1.5 x 105 cells per well 
in 6-well plates, and treated with PBS (control) or 30 mM sodium chlorate for 12, 24 
or 36 hrs. MCF-7 cells were processed as described in Material and Methods and 
analyzed by flow cytometry. Fig. shows a representative histogram of the cell cycle 






Table 3.1. Flowcytometer analysis of cell cycle in MCF-7 breast cancer cells. Data 
were expressed as mean ± SE. n = 3. Student’s t-test, *p < 0.05, **p < 0.01.  
 
    G1 S phase G2 
control 66.43± 0.06 23.01 ± 0.35 10.56 ± 0.40 
chlorate 
12 hrs 
69.45 ± 0.18* 19.32 ± 0.32* 11.24 ± 0.46 
control 66.79 ± 0.39 22.72 ± 0.50 10.49 ± 0.11 
chlorate 
24 hrs 
72.81 ± 0.11** 17.96 ± 0.29** 9.23 ± 0.22 
control 66.25 ± 0.03 23.24 ± 0.44 10.50 ± 0.42 
chlorate 
36 hrs 



















Fig. 3.9. Effect of undersulphation of GAGs on cell cycle changes in 
MDA-MB-231 breast cancer cells. MDA-MB-231 cells were seeded at a density of 
1.5 x 105 cells per well in 6-well plates, and treated with PBS (control) or 30 mM 
sodium chlorate for 12, 24 and 36 hrs. MDA-MB-231 cells were processed as 
described in Material and Methods and analyzed by flow cytometry. Fig. shows 
representative histograms of the cell cycle analyzed by ModFit software.  
 
 
Table 3.2 Flowcytometer analysis of cell cycle in MDA-MB-231 breast cancer 
cells. Data were expressed as mean ± SE. n = 3. Student’s t-test, *p < 0.05, **p < 
0.01.  
 
    G1 S phase G2 
control 59.73 ± 1.07 27.80 ± 1.30 12.47 ± 0.19 
chlorate 
12 hrs 
62.13 ± 1.56 25.41 ± 1.47 12.46 ± 0.19 
control 52.41 ± 0.82 32.10 ± 0.97  15.50 ± 0.99 
chlorate 
24 hrs 
62.43 ± 0.80** 26.52 ± 1.70** 11.05 ± 0.93 
control 60.43 ± 1.27 28.56 ± 0.33 11.01 ± 0.94 
chlorate 
36 hrs 
62.58 ± 0.85* 22.82 ± 1.37** 14.60 ± 0.56 
Channels (FL2-A)
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3.4 Sodium chlorate did not induce apoptotic nuclear morphology in MCF-7 and 
MDA-MB-231 breast cancer cells. 
To further exclude the possibility that the inhibitory effect on proliferation by 30 
mM sodium chlorate was due to its toxicity, apoptotic cell death was estimated by 
analyzing its effect on nuclear morphology of the cells using DAPI staining. The 
apoptotic cells were recognized on the basis of nuclear condensation and DNA 
fragmentation of DAPI stained cells under confocal microscope. It was found that 
after 48 hrs treatment with 30 mM sodium chlorate, there were no obvious apoptotic 
cells in MCF-7 and MDA-MB-231 cells under fluorescence microscope as no cells 
exhibited characteristics of apoptotic nuclear morphological changes, including 
chromatin condensation, segmentation of nuclear chromatin of irregular size (Fig. 
3.10).  
In MDA-MB-231 cells, Caspase-3 activity was examined after 24 and 48 hrs 
treatment with 30 mM sodium chlorate. MDA-MB-231 cells were treated with 
sodium chlorate (30 mM) in the presence or absence of caspase-3 inhibitor 
z-VAD-fmk (50 µmol/L) for 24 and 48 hrs. Cells were then harvested and the total 
protein was collected. The activation of caspase-3 in the cytosolic fraction was 
detected by the CaspACE™ Colorimetric Assay System (Promega, Cat.# G7220, 
G7351). Results showed the caspase-3 activity was not changed between the sodium 
chlorate treated cells with the caspase-3 inhibitor treated cells (Fig. 3.11). These 
results together with those in the cell cycle analysis strong suggested that the 
anti-proliferative effect of 30 mM sodium chlorate was not due to its cell toxicity.  
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These findings collectively showed that 30 mM sodium chlorate effectively 
induced undersulphation of HSPG in breast cancer which inhibited the proliferation of 
















Fig.3.10. Sodium chlorate did not induce apoptosis in MCF-7 and MDA-MB-231 
breast cancer cells. Cells were seeded on the coverslip for 24 hrs and cultured with 
PBS (control) or 30 mM sodium chlorate for 48 hrs. The cells were then stained with 
DAPI before were fixed and mounted with Vectashield mounting medium. The cells 












Fig. 3.11. Sodium chlorate did not induce Caspase-3 activity in MDA-MB-231 
breast cancer cells. MDA-MB-231 cells were treated with sodium chlorate (30 mM) 
in the presence or absence of caspase-3 inhibitor z-VAD-fmk (50 µM) for 48 hrs. 
Cells were then harvested and the total protein was collected. The activation of 
caspase-3 in the cytosolic fraction was detected by the CaspACE™ Colorimetric 






















3.5 Sulphate group in heparan sulphate was involved in regulating breast cancer 
cell adhesion 
Research has been exploring the role of cell surface expressed HSPG in cell 
adhesion to ECM components such as fibronectin, collagen I, collagen IV, laminin 
and selectin.  
To determine if sulphate group of heparan sulphate affects breast cancer cell 
adhesion, MCF-7 and MDA-MB-231 cells were cultured in medium in the presence 
of 30 mM sodium chlorate for 48 hrs before re-seeding them onto fibronectin and 
collagen I-coated surface. Fig. 3.12A shows that undersulphation of GAGs of MCF-7 
cells by incubation the cells with 30 mM sodium chlorate for 48 hrs resulted in 
significantly increased adherence to fibronectin by approximately 18% and to 
collagen I by approximately 37% (p = 0.0331 and p = 0.0114, Student’s t-test, control 
vs chlorate). A similar increase was also seen when MDA-MB-231 human breast 
cancer cells were cultured in medium containing 30 mM chlorate. There were an 
~25% increase in adhesion to fibronectin and an ~37% increase in adhesion to 
collagen I ( p< 0.001 and p<0.001, Student’s t-test, control vs chlorate) (Fig. 3.12B). 
These results suggested competitive inhibition of glycosaminoglycan sulphation in 



















Fig. 3.12. Sodium chlorate increased MCF-7 and MDA-MB-231 cell adhesion. 
Cells were pre-treated with PBS (control) or 30 mM sodium chlorate for 48 hrs. Cells 
were trypsinized and resuspended in DMEM with 0.1% BSA containing either 30 mM 
sodium chlorate or equal volume PBS. 1 x 105 cells in 100 μl volume were seeded in 
each well of 96-well fibronectin or collagen I coated-plate for 30 min. The attached 
cell number was determined by the crystal violet assay. Data were calculated as 
percentage of control and expressed as mean ± SE. n = 8, Student’s t-test, **p < 0.01.  
A: MCF-7 cells, B: MDA-MB-231 cells. 
























































3.6 Comparative effects of differentially sulphated heparan sulphate species on 
cancer cell adhesion.  
Sodium chlorate inhibits sulphation of all glycosaminoglycans and does not act 
specifically on heparan sulphate. Thus, to determine if the sodium chlorate-induced 
increase in cancer cell adhesion was due to a reduction in sulphation of heparan 
sulphate molecules, bovine kidney-derived heparan sulphate (HS-BK) was added to 
MCF-7 cells grown in chlorate-containing medium. As shown in Fig. 3.13A and B, 
supplementation of the culture medium with adequately sulphated HS-BK abolished 
the effect of chlorate on MCF-7 cell adhesion to fibronectin completely and 
drastically blocked the increment of adhesion to collagen I (Fig. 3.13B) suggesting 
that the sulphation status of heparan sulphate is important in regulating cancer cell 
adhesion.  
To investigate this further, repeated experiment was performed by adding porcine 
intestine mucosa derived heparan sulphate (HS-PM) to the chlorate-containing culture 
medium instead of the bovine kidney-derived species. Addition of HS-PM resulted in 
only a partial, instead of complete, block of the sodium chlorate-induced increase in 
cell adhesion to fibronectin (Fig. 3.14A). However it showed a complete blockage of 
the adhesion enhancement to collagen I induced by sodium chlorate (Fig. 3.14B). As 
heparan sulphate from porcine intestines mucosa possesses a higher degree of 
sulphation compared to that obtained from bovine kidney (Tsuda et al., 1996; Toida et 
al., 1997), it might be that HS-PM and HS-BK are differentially effective in blocking 



















Fig. 3.13. HS-BK blocked the enhancing effects of sodium chlorate on MCF-7 
breast cancer cell adhesion. MCF-7 cells were cultured in medium containing 100 
ng/ml of HS-BK with or without sodium chlorate as described in Materials and 
Methods. The cells were trypsinized and resuspended in DMEM with 0.1% BSA 
containing the same concentration of HS-BK and /or 30 mM sodium chlorate or equal 
volume PBS. 1x 105 cells in 100 μl volume were seeded in each well of 96-well 
Fibronectin (A) or Collagen I (B) coated-plate for 30 min. The attached cell number 
was determined by the crystal violet assay. Data were calculated as percentage of 
control and expressed as mean ± SE. n = 8, One-way ANOVA, p < 0.001, Tukey post 
hoc analysis, sodium chlorate group vs. sodium chlorate plus HS-BK group,, ** p < 
0.01. 










































































Fig. 3.14. HS-PM blocked the enhancing effects of sodium chlorate on MCF-7 
breast cancer cell adhesion. MCF-7 cells were cultured in medium containing 100 
ng/ml of HS-PM with or without sodium chlorate as described in Materials and 
Methods. The cells were trypsinized and resuspended in DMEM with 0.1% BSA 
containing the same concentration of HS-PM and /or 30 mM sodium chlorate or equal 
volume PBS. 1x 105 cells in 100 μl volume were seeded in each well of 96-well 
Fibronectin (A) or Collagen I (B) coated-plate for 30 min. The attached cell number 
was determined by the crystal violet assay. Data were calculated as percentage of 
control and expressed as mean ± SE. n = 8, One-way ANOVA, p < 0.001, Tukey post 
hoc analysis, sodium chlorate group vs. sodium chlorate plus HS-PM group, *p < 0.05, 
** p < 0.01. 
 
















































Indeed, as shown in Fig. 3.15A and B , Fig. 3.16A and B, different effects were 
also seen between these two kinds of heparan sulphate in the blockage of the adhesion 
enhancement to fibronectin and collagen I induced by sodium chlorate in 
MDA-MB-231 breast cancer cells. Addition of HS-BK completely blocked the 
adhesion increase of MDA-MB-231 cell to both fibronectin (Fig. 3.15A) and collagen 
I (Fig. 3.15B) while HS-PM did not block the increasing effect of MDA-MB-231 cell 
either to fibronectin (Fig. 3.16A) and collagen I (Fig. 3.16B). 
Taken together, these results suggested the sulphation of endogenous HSPG as 
well as the difference in sulphation of exogenous heparan sulphation must be of 
importance in the mediating the interactions between MCF-7 and MDA-MB-231 

















Fig. 3.15. HS-BK blocked the enhancing effects of sodium chlorate on 
MDA-MB-231 breast cancer cell adhesion. MDA-MB-231 cells were cultured in 
medium containing 100 ng/ml of HS-BK with or without sodium chlorate as 
described in Materials and Methods. The cells were trypsinized and resuspended in 
DMEM with 0.1% BSA containing the same concentration of HS-BK and /or 30 mM 
sodium chlorate or equal volume PBS. 1x 105 cells in 100 μl volume were seeded in 
each well of 96-well fibronectin (A) and collagen I (B) coated-plate for 30 min. The 
attached cell number was determined by the crystal violet assay. Data were calculated 
as percentage of control and expressed as mean ± SE. n = 8. In Fig. 3.15A, One-way 
ANOVA, p < 0.01, Tukey post hoc analysis, control group vs. sodium chlorate group, 
**p < 0.01, control group vs. sodium chlorate plus HS-PM group, p > 0.05, sodium 
chlorate group vs. sodium chlorate plus HS-BK group, ** p < 0.01.  In Fig. 3.15B, 
One-way ANOVA, p < 0.0001, Tukey post hoc analysis, control group vs. sodium 
chlorate group, **p < 0.001, control group vs. sodium chlorate plus HS-PM group, p 
> 0.05, sodium chlorate group vs. sodium chlorate plus HS-BK group, ** p < 0.001. 
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Fig. 3.16. HS-PM did not block the enhancing effects of sodium chlorate on 
MDA-MB-231 breast cancer cell adhesion. MDA-MB-231 cells were cultured in 
medium containing 100 ng/ml of HS-BM with or without sodium chlorate as 
described in Materials and Methods. The cells were trypsinized and resuspended in 
DMEM with 0.1% BSA containing the same concentration of HS-PM and /or 30 mM 
sodium chlorate or equal volume PBS. 1x 105 cells in 100 μl volume were seeded in 
each well of 96-well to fibronectin (A) and collagen I (B) coated-plate for 30 min. 
The attached cell number was determined by the crystal violet assay. Data were 
calculated as percentage of control and expressed as mean ± SE. n = 8. In Fig. 3.16A, 
One-way ANOVA, p = 0.0006, Tukey post hoc analysis, control group vs. sodium 
chlorate group, **p < 0.001, control group vs. sodium chlorate plus HS-PM group, 
**p < 0.01, sodium chlorate group vs. sodium chlorate plus HS-PM group,  p > 0.05. 
In Fig. 3.16B, One-way ANOVA, p = 0.0069, Tukey post hoc analysis, control group 
vs. sodium chlorate group, **p < 0.05, control group vs. sodium chlorate plus HS-PM 
group, *p < 0.05, sodium chlorate group vs. sodium chlorate plus HS-PM group,  p > 
0.05.         






























































3.7 Cell adhesion increase induced by sodium chlorate was associated with FAK 
and paxillin recruitment 
Focal adhesion kinase (FAK) and paxillin, both members of the focal adhesion, 
are key regulatory components in controlling cell adhesion and cell movement (Turner, 
1998; Cary and Guan, 1999; Turner, 2000; Hanks et al., 2003; Schaller, 2004). To 
explore if augment of adhesion caused by sodium chlorate would change the 
expression levels of focal adhesion molecules like FAK and paxillin, focal adhesion 
formation in the MCF-7 cells treated with or without 30 mM sodium chlorate was 
studied by fluorescence immunostaining. MCF-7 cells were cultured on coverslip in 
the medium containing 30 mM sodium chlorate for 48 hrs and stained with anti-FAK 
and anti-paxillin antibody. Confocal microscopy observation showed that after 
treatment with sodium chlorate for 48 hrs, focal adhesion formation was increased as 
demonstrated by the recruitment of the FAK or paxillin (red) to the end of F-actin 
(green). While in the control cells, FAK (Fig. 3.17A, red) or paxillin (Fig. 3.17B, red) 
exhibited a low degree of colocalization at the end of F-actin (green), as revealed by 
the few yellow spots representing focal adhesion complex (Fig. 3.17 inserts and 
arrows). 
To further verify the changes in the focal adhesion molecules in the adhesion 
increase induced by sodium chlorate, MCF-7 cells were treated with or without 30 
mM sodium chlorate and re-seeded them into fibronectin-coated dishes or coverslips 
for 2 hrs. The total mRNA and protein were collected. 
Results 
 112










Fig. 3.17. Effect of sodium chlorate on the distribution of FAK, Paxillin and 
F-actin in MCF-7 cells. MCF-7 cells were processed as described in Material and 
Methods. Stress fiber F-actin was probed with fluorescein isothiocyanate 
(FITC)-conjugated phalloidin (green), FAK and Paxillin were detected with anti-FAK 
polyclonal antibody or anti-paxillin monoclonal antibody, followed by 
Alexa-568-labeled second Antibody (red). The arrows indicate the areas of F-actin 
and FAK (Fig. 3.17A) or F-actin and Paxillin (Fig. 3.17B) colocalization in the focal 
adhesion formation sites (yellow). Insertion is the high magnification of the focal 
adhesion complex in the sodium chlorate-treated cells. Scale bar = 20 µm 
 
Previously β1-integrin (ITGB1) has been shown to influence the activity of FAK 
and paxillin, with resultant effects on breast cancer cell adhesion and spreading (Lin 
et al., 2000). Using real-time RT-PCR, reduction in glycosaminoglycan sulphation 
was shown to significantly increase the expression of FAK and Paxillin by 1.9- and 
1.7-fold respectively (Fig. 3.18A). The expression of β1-integrin (ITGB1) was also 
upregulated, although this did not reach statistical significance. The changes in gene 
transcript levels were accompanied by similar upregulation in protein levels, as 
determined by Western blotting (Fig. 3.18B and C). Expressions of ITGB1, FAK and 
PXN proteins in sodium chlorate-treated cells were increased by 1.3-, 3.1- and 1.6- 
fold respectively. Using fluorescence immunocytochemistry, cells in the treatment 
group were found to possess a more obvious increase in focal adhesion formation 
together with stronger staining intensities for PXN and FAK proteins compared 




































Fig. 3.18. Effects of reduced glycosaminoglycan sulphation on ITGB1, FAK and 
paxillin expression in MCF-7 cells. MCF-7 cells were cultured for 48 h in medium 
supplemented with PBS (control group) or 30 mM chlorate and re-seeded on 
fibronectin-coated coverslips for 2 hrs. Total mRNA and protein was collected. 
mRNA was used for real time PCR analysis and total protein was analyzed by 
Western blot (A) Gene transcript levels of ITGB1, FAK and PXN were measured 
using real-time RT-PCR. Chlorate treatment significantly upregulated the expression 
of FAK (p = 0.0375) and PXN (p = 0.0440). (B) Representative Western blot of three 
independent experiments. (C) Analysis by densitometry measurements showed 
increased levels of ITGB1 (p = 0.0016), FAK (p = 0.0002) and PXN (p = 0.0003). 



































































































Fig. 3.19. Sodium chlorate enhanced MCF-7 cell focal adhesion formation on 
fibronectin. Coverslips were coated with 20 μg/ml fibronectin at 4°C overnight and 
blocked with 1% BSA at room temperature for 1 hr. MCF-7 cells were treated with 30 
mM sodium chlorate for 48 hrs and re-plated onto the fibronectin-coated coverslip for 
2 hrs.. FAK (A ) or Paxillin (B) were detected with anti-FAK polyclonal antibody or 
anti-paxillin monoclonal antibody, followed by Alexa-568-labeled second Ab (red), 
F-actin was probed with FITC-phalloidin (green). Panels are representative of 
triplicate experiments. The arrows indicate the areas of F-actin and FAK or F-actin 












3.8 Contrasting effects of different heparan sulphate species on migration of 
breast cancer cell. 
To determine if the increment in cell adhesion due to reduced glycosaminoglycan 
sulphation would affect cancer cell migration, wound scratch assay was used to 
evaluate migration capacity in vitro. MCF-7 cells (Fig. 3.20A) and MDA-MB-231 
cells (Fig. 3.21A) were cultured in the presence of sodium chlorate with medium 
containing only 2% FBS, and measured the distance migrated by the cells across a 
wound gap. Two percent FBS was much lower than normal culture condition (7.5% 
FBS) so that the cell proliferation was remarkably inhibited and the proliferation rate 
would not be a cofounder in the migration assay. Results showed that inhibition of 
glycosaminoglycan sulphation resulted in a significant decrease in cell migration of 
MCF-7 cells (Fig. 3.20A and B, Two-way ANOVA, p < 0.01) and  MDA-MB-231 
cells (Fig. 3.21A and B) (Two-way ANOVA, p< 0.01) 
This sodium chlorate-induced reduction in cell migration could be completely 
abolished by supplementation of the culture medium with porcine intestine 
mucosa-derived heparan sulphate (HS-PM, Fig. 3.22A ). However, in contrast to what 
was observed in the cell adhesion experiments (Fig. 3.13), addition of bovine 
kidney-derived heparan sulphate (HS-BK) to the sodium chlorate-containing culture 
medium led to a significant further decrease in cell migration instead of blocking the 
effect of chlorate (Fig. 3.22B). This suggests that differentially sulphated heparan 




















Fig. 3.20. Sodium chlorate inhibited MCF-7 cells migration. MCF-7 cells were 
seeded in 6-well plate and grew with or without 30 mM sodium chlorate till confluent. 
The cell monolayer was scratched with a 200 μl pipette tip (T= 4hr as baseline) and 
the culture continued with or without sodium chlorate (A). The distances of the 
wound gap were measured using the image analysis software at 5 randomly-selected 
sites. The migrated distance was calculated as the distance at the baseline time point 
minus the distance at the indicated time point (B). Distance data were expressed as 
mean ± SE. n = 5, ** p < 0.01.                    
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Fig. 3.21. Sodium chlorate inhibited MDA-MB-231 cells migration. 
MDA-MB-231cells were seeded in 6-well plate and grew with or without sodium 
chlorate till confluent. The cell monolayer was scratched with a 200 μl pipette tip (T = 
4hr as baseline) and the culture continued with or without sodium chlorate.  (A) The 
distances of the wound gap were measured using the image analysis software at 5 
randomly-selected sites. (B) The migrated distance was calculated as the distance at 
the baseline time point minus the distance at the indicated time point. Distance data 
















































Fig. 3.22. HS-PM, but not HS-BK rescued the inhibitory effect of sodium chlorate 
on the MCF-7 cells migration. MCF-7cells were seeded in 6-well plate and grew 
with or without HS-PM (A) or HS-BK (B) in the presence or absence of sodium 
chlorate till confluent. The cell monolayer was scratched with a 200 μl pipette tip (T = 
4 hr as baseline) and the culture continued with or without HS-BK or HS-PM in the 
presence or absence of sodium chlorate. The distances of the wound gap were 
measured using the image analysis software at 5 randomly-selected sites. The 
migrated distance was calculated as the distance at the baseline time point minus the 
distance at the indicated time point. Distance data were expressed as mean ± SE. n = 5,  
Chlorate vs Chlorate+ HS-PM, * p < 0.05, Chlorate vs Chlorate+ HS-BK, p > 0.05 




















































3.9 Undersulphation of GAGs inhibited invasion of breast cancer cell in vitro. 
Cancer cell penetrating through the ECM and basement membrane is an 
indispensable step for tumour cells to invade and metastasize. To examine the 
significance of undersulphation of GAGs in affecting the MCF-7 and MDA-MB-231 
breast cancer cell invasion in vitro, Matrigel invasion chamber was used. 
MDA-MB-231cells exhibited relative high capabilities to penetrate through 
Matrigel-coated filters whereas after the sodium chlorate treatment, the invasion 
capacity was reduce 39% compared with the control MDA-MB-231cells (Fig. 3.23A 
and B). A similar decrease (~43%) in cell invasion was also found in the MCF-7 cells 
cultured in the presence of sodium chlorate (Fig. 3.24A and B). These studies 
indicated that under sulphation in HSPG decreased the capacity of breast cancer cells 



















Fig. 3.23. Sodium chlorate inhibited MDA-MB-231 cell invasion through 
Matrigel in vitro. Matrigel Invasin chambers (24-well, 8 μm pore size) were used for 
invasion assay. A: MDA-MB-231 cells pretreated with sodium chlorate (30 mM) or 
PBS (control) for 48 hrs were harvested and seeded at a density of 5.0×104 cells per 
well. Cells were allowed to invade for 24 hrs. The number of cells that had invaded 
through the insert membrane pores was manually counted per high power field (100× 
magnification) using a microscope. Cell number at the bottom of the chamber was 
normalized against the control which was set at 100%. B: Images show representative 
fields of crystal violet stained MDA-MB-231 cells on the bottom of a Matrigel 
invasion chamber as captured from a Nikon microscope at 100× magnifications. Scale 





























































Fig. 3.24 Sodium chlorate inhibited MCF-7 cell invasion through Matrigel in vitro. 
Matrigel Invasin chamber (24-well, 8 μm pore size) was used for invasion assay. (A) 
MCF-7 cells pretreated with sodium chlorate (30 mM) or PBS (control) for 48 hrs 
were harvested and seeded at a density of 1.0×105 cells per well. Cells were allowed 
to invade for 24 hrs. The number of cells that had invaded through the insert 
membrane pores was manually counted per high power field (100× magnification) 
using a microscope. Cell number at the bottom of the chamber was normalized against 
the control which was set at 100%. (B) Images show representative fields of crystal 
violet stained MCF-7 cells on the bottom of a Matrigel invasion chamber as captured 

































The main findings in the current study were 1) undersulphation in endogenous 
heparan sulphate in the breast cancer cells altered the biological processes in cancer 
progression such as proliferation, adhesion, migration and invasion; 2) differentially 
sulphated heparan sulphate derived from different species had different function in 
these processes.  
HSPG and breast cancer growth 
Research findings have demonstrated that HSPG is involved in many biological 
behaviors of malignant cells including cell proliferation, adhesion, migration and 
invasion. These biological effects are influenced by the highly sulphated groups of 
heparan sulphate (HS) chains.  
Recently, expression of heparan sulphate glycosaminoglycan chain was shown to 
be correlated with tumour grade and cell proliferation in phyllodes tumours, one type 
of breast cancers (Koo et al., 2006). This year in our paper (Guo et al., 2007), Koo CY 
examined the expression of the 10E4 epitope of HSPG in both epithelial and stromal 
compartments of 32 samples of breast invasive ductal carcinoma and paired 
non-cancerous mammary tissues from corresponding patients. The study revealed that 
expression of the sulphated 10E4 epitope was up-regulated in both the epithelial and 
stromal compartments of breast cancers compared with normal mammary tissues. 
More importantly, the average immunoreactivity score of 10E4 in the cancer samples 
was 2.8 times higher than that of normal breast tissues, suggesting that heparan 
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sulphate would be a useful biomarker for breast invasive ductal carcinoma.  
One of the major features of metastatic cells is the re-organization of specific 
cytoskeleton components (e.g. F-actin, proteoglycans) and activation of specific 
degrading enzymes (e.g. heparanase, MMPs) which degrade the proteoglycan 
surrounding the cells and allow cell to penetrate the extracellular matrix (Bogenrieder 
and Herlyn, 2003; Elkin et al., 2003; Edovitsky et al., 2004; Reiland et al., 2004; Boyd 
and Nakajima, 2004; Gingis-Velitski et al., 2004b; Yip et al., 2006; Gotte and Yip, 
2006). Indeed, studies on heparanase, an endoglucuronidase that hydrolyses heparan 
sulphate, suggest that degradation of heparan sulphate leads to enhanced breast cancer 
growth and invasion (Vlodavsky et al., 1999). Cohen et al. (2006) also reported that 
using MCF-7 cells transfected with heparanase cDNA that were injected into the 
mammary pad of nude mice, they found enhanced tumour growth and invasion 
compared with tumours produced by mock-transfected cells. Up-regulated expression 
of heparanase, with a consequential reduction in heparan sulphate level, has been 
reported in breast cancers. Maxhimer et al. (2002) demonstrated that 
immunohistochemical staining of heparanase expression in breast cancer was 
positively associated with a larger tumour size and the presence of tumour metastases, 
together with a lack of heparan sulphate deposition. One recent study revealed that 
heparanase was more frequently expressed in invasive breast cancers than in in situ 
ductal carcinomas of the breast (Imada et al., 2006). These studies suggest that heparan 
sulphate glycosaminoglycan chains are involved in breast carcinogenesis. 
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However, recent studies have shown that not all heparan sulphate chains are bad, 
and that the sulphation status of different heparan sulphate species is an important 
determinant of the biological effects of molecules on cancer cells so that tumour cell 
surface heparan sulphate can be either promoters or inhibitors of tumour growth and 
metastasis. Liu et al. (2002) reported that heparan sulphate fragments released by Hep I 
treatment from the surface of the tumour cell were able to promote primary tumour 
growth. In contrast heparan sulphate fragments released by Hep III inhibited both 
primary tumour growth and tumour metastasis. The latter inhibition in tumour growth 
was related to the inhibition in proliferation and induction of apoptosis. Further studies 
confirmed that the Hep III treatment derived HS fragments had more of tri- and 
di-sulphated disaccharides, whereas the Hep I-treated HS fragments had more mono- 
and un-sulphated disaccharides 
This has been highlighted in the past few years in reports on the Sulf-1 gene, 
which codes for the enzyme sulphatase-1 that removes 6-O-sulphate groups from 
heparan sulphate (Dhoot et al., 2001; Ohto et al., 2002; Morimoto-Tomita et al., 2002). 
Loss of 6-O-sulphate groups by Sulf-1 was shown to be a negative regulator of FGF 
signaling and FGF-FGFR binding. Disrupting FGF2-FGFR1-heparan sulphate ternary 
complex formation (Wang et al., 2004) inhibited both tumour growth and tumour 
angiogenesis in xenografts in mice of Sulf-1 over-expressing MDA-MB-468 breast 
cancer cells (Narita et al., 2006). Previously results showed that sodium chlorate 
preferentially reduce 6-O-sulphation of heparan sulphate (Safaiyan et al., 1998; 
Safaiyan et al., 1999).  
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Experiments with sodium chlorate, which competitively inhibits 
glycosaminoglycan sulphation and thus mimics overexpression of sulphatase-1 in the 
loss of 6-O-sulphate groups, showed a reduction in cell proliferation. This phenomenon 
could be blocked by addition of adequately sulphated heparan sulphate to the culture 
medium, with porcine intestine mucosa-derived heparan sulphate (HS-PM, Fig. 3.4). 
Porcine intestine mucosa-derived heparan sulphate has a high degree of sulphation 
compared with bovine kidney HS, especially GlcN 6-O-sulphate and IdoA 
2-O-sulphate groups (Coltrini et al., 1994; Maccarana et al., 1996; Bianchini et al., 
1997; Warda et al., 2003). In a previous work, Delehedde et al. (1996) reported that 
sodium chlorate treatment reduced sulphation of proteoglycans in MCF-7 cells which 
totally inhibited FGF-2-mediated proliferation. Many studies have confirmed that 
FGF-2 binds FGFR1 though HS which must contain N-sulphated glucosamine (GlcNS) 
residues and at least one 2-O-sulphated IdoA as well as to a sequence rich in GlcNS, 
6-O-sulphated glucosamine residues (Maccarana et al., 1993; Ishihara et al., 1995; Wu 
et al., 2003; Ibrahimi et al., 2004). Altering 2-O sulphation or 6-O sulphation 
diminishes FGF-2 binding and signaling (Guimond et al., 1993; Zhang et al., 2001).  
Thus these results suggested that the partial rescue action in the proliferation by 
exogenous HS-PM supplementation, but not HS-BK, may act via selectively 
transferring sulphate group from the exogenous HS-PM to the endogenous HS or 
HS-PM has a higher capacity of protection FGF-2 from proteolytic cleavage, thus 




HSPG and adhesion, migration and invasion in breast cancer cells 
Interestingly, heparan sulphate regulation of breast cancer cell migration appears 
to be affected not only by the number of sulphate groups present but also by the position 
of the sulphate groups. Thus, inhibition of heparan sulphation, as well as the presence 
of highly sulphated bovine kidney derived heparan sulphate, both led to a significant 
reduction in cell migration (Fig. 3.22). In contrast, optimally sulphated porcine 
intestine mucosa-derived heparan sulphate was able to block the effect of sodium 
chlorate treatment (Fig.3.22).  
Heparan sulphate has been shown to be a key player in a number of signaling 
pathways in cell migration. It has been reported to modulate transendothelial migration 
of monocytes by regulating G-protein-dependent signaling (Floris et al., 2003). Study 
also revealed addition of the 65-kDa latent heparanase to endothelial cells stimulated 
phosphatidylinositol 3-kinase- (PI3K) dependent endothelial cell migration and 
invasion (Gingis-Velitski et al., 2004a). HT1080 fibrosarcoma cells that overexpressed 
the heparan sulphate proteoglycan syndecan-2 showed activation of the small GTPase 
Rac and increased cell migration (Park et al., 2005). Furthermore, in addition to acting 
as a co-receptor in FGF signalling, heparan sulphate may act as a direct receptor in the 
FGF-2 activation of ERK1/2, which is required for bronchial epithelial and corneal 
epithelial cell migration (Chua et al., 2004). Kaneider et a.l (2004) found that cleavage 
of heparan sulphate from proteoglycans on the leukocyte surface completely inhibited 
chemotactic migration. Chemotactic migration was also abolished by pretreating the 
cells with heparinase, sodium chlorate, or anti-syndecan-4 antibodies. This study 
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clearly indicated that heparan sulphate, especially syndecan-4 and the sulphation of HS 
were involved in cell migration. 
One of the important roles of HSPG is interaction with ECM molecules such as 
fibronectin, collagen and laminin, thus modulating cell adhesion and migration (Lark et 
al., 1985a; Saunders and Bernfield, 1988; Lundmark et al., 2001; Mendes de Aguiar et 
al., 2002). HSPG have been associated with newly formed adhesion of adherent cell. 
Together with integrin it is also involved in cell motility by promoting cell adhesion and 
spreading at the leading edge of a moving cell (Lark et al., 1985b).  
The primary receptor for adhesion to fibronectin commonly involves the RGD 
motif through integrins (Pytela et al., 1985). Integrin-mediated cell adhesion leads to 
recruitment of the cytoplasmic protein tyrosine kinase FAK to focal adhesion sites, and 
the phosphorylation of both FAK and paxillin (LaFlamme and Auer, 1996; 
Mostafavi-Pour et al., 2003). FAK is a prominent constituent of these focal adhesions 
complexes (Cary and Guan, 1999; Hanks et al., 2003; Mitra et al., 2005). Paxillin is a 
cytoskeletal focal adhesion docking protein that localizes at adhesion sites by binding 
to the carboxyl terminus of FAK (Anfosso et al., 1998; Turner, 1998; Turner, 2000). 
But this integrin mediated interaction is only sufficient for cell attachment and 
spreading.  
Additional signaling through the cell surface proteoglycan syndecan-4 is required 
for focal adhesion formation and rearrangement of the actin cytoskeleton into bundled 
stress fibers (Woods et al., 1998; Longley et al., 1999; Woods and Couchman, 2001). 
Syndecan-4 is a ubiquitous vertebrate transmembrane heparan sulphate proteoglycan 
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(HSPG), which localizes to focal adhesion complex and acts as a co-receptor with 
α5β1-integrin (Woods, 2001; Mostafavi-Pour et al., 2003). Syndecan-4 interacts with 
the Hep II domain of fibronectin through its heparan sulphate chains (Woods et al., 
2000) and with PKC-alpha through its cytoplasmic domain (Murakami et al., 2002; 
Lim et al., 2003; Keum et al., 2004). Expression of syndecan-4 in Chinese hamster 
ovary (CHO) cells resulted in increased numbers of focal adhesion complexes (Longley 
et al., 1999). On the other hand, CHO cell mutants deficient in glycosaminoglycans 
showed reduced focal adhesion formation when cultured on a fibronectin substrate 
(LeBaron et al., 1988). 
In the present study, reduction in heparan sulphation in MCF-7 breast cancer cells 
was shown to increase cancer cell adhesion and upregulate FAK and paxillin at both 
gene transcript and protein levels, and the increment in adhesion could be completely 
blocked by exogenous heparan sulphate HS-BK and partially blocked by HS-PM. 
The results in the present study that undersulphation in endogenous heparan 
sulphate increased the adhesion of breast cancer cells and retarded their migration as 
well as the differentially regulatory function of exogenous heparan sulphate derived 
from different species in these processes are in agreement with the recently proposed 
concept of a ‘heparanome’, in which differentially sulphated sugar sequences regulate 
the biological activities of different heparan sulphate species (Turnbull et al., 2001; 
Lamanna et al., 2007). Heparan sulphate has been shown to affect cancer cellular 
behaviour through several mechanisms (Bernfield et al., 1999; Timar et al., 2002; Liu 
et al., 2002). It is able to bind to and interact with a multitude of growth factors and 
Results 
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signaling proteins, resulting in stimulation of growth and metastasis of cancer cells 
(Turnbull et al., 2001; Mulloy and Rider, 2006; Kreuger et al., 2006). Heparan sulphate 
in the extracellular matrix also acts as a reservoir for aggregation of growth and 
angiogenic factors. Furthermore, binding of heparan sulphate to these molecules could 
protect them from degradation and thus prolong their effects on cancer cells. On the 
other hand, degradation of heparan sulphate may release fragments that antagonize 
these growth factors and signaling molecules, leading to the inhibition of tumour 
growth and metastasis (Timar et al., 2002). Thus by modulating the composition or 
“sulphation signature” of heparan sulphate at cell surface and in the ECM, cell provide 
itself a systemic mechanism for fine control of the final function of heparan sulphate 
proteoglycan, determining whether it is a promoter or an inhibitor of tumour growth 
and metastasis. 
In conclusion, in the present study, it has been demonstrated heparan sulphate is 
involved in regulating cancer cell proliferation, adhesion, focal adhesion complex 
formation, migration and invasion through different sulphation patterns on its sugar 
residues. Uncontrolled proliferation, loosening adhesive contacts with the extracellular 
matrix, increasing migration and invasiveness are characteristics of breast cancer 
growth and metastasis, contributing significantly to patient morbidity and mortality. 
The challenge to targeting heparan sulphate in breast cancer treatment therefore depend 
on selective inhibition of tumour promoting mediators, or identification and blockage 
of causative factors contributing to their unfavourable phenotypic alteration. A better 
understanding of the effects of differentially sulphated heparan sulphate species on 
Results 
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cancer cell behaviors is important for the development of these molecules into 















CHAPTER 4  Studies on phenotypic alterations in MCF-12A 
cells after silencing 3-O-HS sulphotransferase 3A1 (HS3ST3A1) 
gene 
 
Many research findings have verified that heparan sulphate (HS) functions are 
dependent on specific sulphation motifs. 3-O sulphation of glucosamine residues of 
HS-GAG chain is a rare but important modification of HS synthesis. The success in 
cloning and characterization of HS 3-O-sulphation enzymes increased the 
understanding for the mechanisms of generating HS with defined motif and the 
sequence-specific function. One good example, 3-O-sulphotransferase (3-O-ST, now 
known as 3-O-ST-1, HS3ST1) converts non-anticoagulant heparan sulphate into 
anticoagulant heparan sulphate, which is widely used in clinic and well known as 
heparin (Dementiev et al., 2004; Petitou and van Boeckel, 2004). HS3ST3 has been 
cloned and partially characterized (Shukla et al., 1999; Shworak et al., 1999; Liu et al., 
1999b). Biochemical studies have revealed the enzymatic function of HS3ST3s based 
on their respective substrate preferences and the resultant HS structures, but their 
biological functions in mammalian cells are still at large. 
4.1 Quantitative real-time PCR analysis of HS3ST3A1 and HS3ST3B1 mRNA 
expression levels in breast epithelial and breast cancer cell lines. 
In this study the expression of HS3ST3A1 in breast epithelial MCF-12A cells and 
breast cancer cell lines was first investigated by quantitative real-time PCR. As shown 
in Table 4.1, compared with that in MCF-12A, the expression level was 
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down-regulated about 230-fold in MCF-7 cells, 33-fold in ZR-75-1 cells and was 
undetectable in MDA-MB-231 cells and T47D cells. These results suggest that 
HS3ST3A1 may play an important role in breast tumourigenesis and progression. 
 
  MCF-12A MCF-7 MDA-MB-231 T47D ZR-75-1 
HS3ST3A1 1.00 ± 0.84 ↓230.72 ± 1.72 undetectable undetectable ↓32.90 ± 1.75 
HS3ST3B1 1.00 ± 0.73 ↓6.96 ± 1.22 2.91 ± 1.05 ↓3.70 ± 1.12 ↓3.56 ± 1.15 
 
Table 4.1. Quantitative real-time PCR analysis of the mRNA expression of 
HS3ST3A1 and HS3ST3B1 in normal breast cell line MCF-12A and four breast 
cancer cell lines. The expression levels are shown normalized to the expression of the 
reference gene β-actin. Data are expressed as average fold change of at least 3 
experiments, mean±SD. Fold change was calculated as 2−(ΔΔCt) . “↓” symbols 
down-regulation. 
 
4.2 In situ hybridization analysis of HS3ST3A1 expression in breast cancers. 
(Courtesy of Koo Chuayyeng) 
To further assess the expression of HS3ST3A1 in normal breast tissues and breast 
cancers, in situ hybridization was performed on corresponding breast normal and 
cancer tissues from 22 patients. Strong expression of HS3ST3A1 was detected in the 
epithelial cells of ducts in normal tissues but not in the tumour cells of the cancers in 
all of the 22 patients examined as shown in Fig. 4.1. The epithelial cells of the ducts 
in the normal tissues (Fig.4.1, A) were intensely stained as compared to the tumour 
cells (Fig.4.1, B and C). Low signal identity was observed in Fig. 4.1d as this section 
was hybridized with the sense probe. To evaluate HS3ST3A1 expression 
semi-quantitatively, average IPS (Koo et al., 2006) was calculated from the epithelial 
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cells of ducts in the normal tissues and the tumour cells. There was a significant 
difference in the average IPS between the normal breast tissues and breast cancers 
(Fig 4.2., p < 0.001), which was consistent with the results obtained from the breast 















Fig. 4.1. In situ hybridization analysis of HS3ST3A mRNA expression in normal 
breast tissue and breast cancers. A: normal tissue, B: infiltrating ductal carcinoma, C: 
invasive ductal carcinoma, D: negative control (sense probe). 
A 50 μm B 50 μm 









Fig. 4.2. Average IPS score of in situ hybridization analysis of HS3ST3A mRNA 









(IPS > 40) 
Significanc
e (P value) 
    
6 4 1 Tumour size ≤ 40mm 
Tumour size > 40mm 5 7  
    
ER - 5 0 0.0315* 
ER + 6 11  
    
PR - 9 0 0.0002* 
PR + 2 11  
    
cerB 2 - 3 3 1 
cerB 2 + 8 8  
    
Lymph Node Stage 1-2 6 7 1 
Lymph Node Stage  3 5 4  
    
 
Table 4.2. Correlations between HS3ST3A1 expression and various 











4.3 Optimization of the transfection parameters for knocking down of 
HS3ST3A1 mRNA expression by siRNA. 
Based on the above results, silencing HS3ST3A1 expression in MCF-12A cells 
using chemically synthesized siRNA was performed. In order to obtain good silencing 
effect, optimization experiments were first conducted by using Cyanine 
(Cy3)-conjugated scrambled siRNA that has no targeting gene. The optimization for 
transfection efficiency include transfection reagent amount, cell density and 
incubation time. As shown in Fig. 4.3, the transfection efficiency was about 97.1% at 
24 hrs and the transfection parameters were: final siRNA concentration, 30 nM; 
transfection time, 8 hrs and cell density, 3.5 x105 cells per well in 6-well plate 
(approximately 50% cell confluent at the time of transfection). There was no 
significant morphology change between cells in the control siRNA transfected group 
and the HS3S3A1 siRNA transfected cells at 48 hrs or 72 hrs as shown in Fig. 4.4. 
These results indicate that the transfection efficiency is quite satisfactory. Using these 
parameters, the positive control of GAPDH siRNA (Ambion, Inc. Cat No. AM4605) 
achieved a 97.6% knockdown effect with least cell death (Fig. 4.5).   
4.4 Knockdown of HS3ST3A1 mRNA expression by siRNA was gene-specific and 
dose-dependent. 
Next, 3 different siRNAs corresponding to 3 different regions of HS3ST3A1 
mRNA were used to screen if any of them could knockdown HS3ST3A1 expression 
under the same parameters. Fig. 4.6 shows that the #2 (siRNA ID: 113287 in Ambion 
siRNA database, Amibon, Inc.) sequence of the siRNA achieved the most significant 
knockdown effect (suppression ~91.58%). Repeated experiments results showed that 
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Fig. 4.3. Determination of transfection efficiency by Cy3-labelled control siRNA 
in the MCF-12A cells. MCF-12A human breast epithelial cells were transfected with 
Cy3-lablled non-targeting (control) siRNA using optimal conditions suggested by the 
manufacturers' protocols (Ambion, InC.) The optimized parameters in the transfection: 
3.5 x 105 cell per well with 8 µl siPORT Amine and 30 nM siRNA. (A) Cy3-labeled 
siRNAs in transfected cells (Positive transfected cells) were visualized using a Nikon 
inverted fluorescence microscope. Experiments were repeated three times in 
duplicates and representative images are presented. (B) The data represent the mean ± 
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Fig. 4.4. Cell morphology after transfection. Under optimized transfection 
conditions siPORT Amine transfection reagent did not adversely affect MCF-12A cell 
morphology at 48 hrs (a, b) and 72 hrs (c, d). a and b: control non-targeting siRNA. d, 


















Fig. 4.5. Silencing effect of positive siRNA targeting GAPDH mRNA in MCF-12A 
cells. Under optimized parameters, GAPDH mRNA expression was silenced more 
than 95% compare that in the non-targeting siRNA transfected group. The optimized 
parameters in the transfection: 3.5 x 105 cell per well in 6-well plate with 8 µl siPORT 


















































ATG  799 
5’ UTR 3’ UTR
Stop 2019 siRNA 3: 2360-2380 
GC%: 33.3% 
siRNA 1: 2325-2345 
GC%: 38.1% 
siRNA 2: 897-917 
GC%: 42.9% 
NM_006042.1 
HS3ST3A1 mRNA     NM_006042.1 
 
siRNA 1     Ambion ID 17338   
Sense:     5’-GGUUAAACAUCUCUCUCUCtt--3’ 
Antisense:  5’-GAGAGAGAGAUGUUUAACCtc-3’ 
GC% : 38.1% 
 
siRNA 2    Ambion ID 113287   we used this siRNA 
Sense:     5’-CGUCCCUUUACGUCUUCUAtt-3’ 
Antisense:  5’-UAGAAGACGUAAAGGGACGtg-3’ 
GC% :42.9% 
 
siRNA 3    Ambion ID  17338   
Sense:     5’-GGCCCUGAUAAAAUUGAUAtt-3’ 
























Fig. 4.6. Knockdown effect of three different siRNA sequences targeting 
HS3ST3A1 mRNA in MCF-12A cells.   
(A) Design and synthesis of siRNAs against HS3ST3A1. Schematic representation of 
the primary structure of human HS3ST3A1 mRNA (gi: NM_006042.1) and three 
target sites of siRNAs. The exact position of each target site was shown in the 
diagram and GC% was calculated 
(B) Sequences of siRNA duplexes. 3 different siRNAs were designed against 
HS3ST3A1 mRNA by Ambion, Inc.  
(C) #2 siRNA achieved the most significant silencing effect. Note: From here onwards, 
#2 HS3ST3A1 siRNA was used in the following experiments          







































As chemically synthesized siRNA degrades within a few days, silencing effects at 
different time points after transfection thus were examined. Fig. 4.7 shows that the 
knockdown effect lasted at least 96 hrs in this study. The most significant knockdown 
effect was achieved at 48 hrs with more than 86% silencing (Fig. 4.7A). Though with 
time lapse, the silencing effect was reduced, there was still 77.62% reduction at 72 hrs 
and 61.31% reduction at 96 hrs (Fig. 4.7A). This knockdown effect was specific to 
HS3ST3A1 as shown in Fig. 4.7A and B. There was only limited suppression on the 
HS3ST3B1 mRNA expression, the closest isoform of HS3ST3A1. As shown in Fig. 
4.7B, under the transfection conditions, HS3ST3B1 mRNA was knocked down only 
3.71% at 48 hrs, 18.62% at 72 hrs and 27.03% at 96 hrs, respectively. These results 
indicate the knockdown effect could last at least 96 hrs and was gene-specific. So #2 
siRNA was chosen in the later experiments and termed as HS3ST3A1 siRNA. The 
single sharp peak in melting curve and single band in the agarose gel electrophoresis 
analysis as shown in Fig. 4.8 suggested specific gene amplification of HS3ST3A1 and 
HS3ST3B1 mRNA both in control and siRNA silenced cells. 
As too much siRNA has been reported to have non-specific silencing effect and 
cytotoxicity (Sandy et al., 2005), dose-dependent effect on the silencing efficiency 
were analyzed. Two smaller final concentration of siRNA (7.5 nM and 15 nM ) were 
used to compare the results from 30 nM final concentration of siRNA. Fig. 4.9A 
shows that 30 nM final concentration was an ideal concentration as it achieved the 
greatest silencing effect while the other two concentrations could not achieve more 
than 80% reduction at 48 hrs. In all of the three concentrations, no significant 
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silencing effect was seen on HS3ST3B1 expression (Fig. 4.9B). Eighty percent 

















Fig. 4.7. Time-dependent knockdown effect of HS3ST3A1 siRNA on the mRNA 
expression of HS3ST3A1 and HS3ST3B1 in MCF-12A cells. HS3ST3A1 siRNA 
showed significant inhibitory effect on HS3ST3A1 mRNA expression in MCF-12A 
cells at 48, 72, and 96 hrs (A), while no such significant reduction was seen in the 
HS3ST3B1 mRNA expression (B). mRNA expression level was determined by 
quantitative real-time PCR using β-actin as the reference gene for normalization. 
Histograms represent the relative expression level in the cells. Data are 3 separate 

























































































Fig. 4.8. Real-time PCR melting curve and agarose gel electrophoresis analysis of 
HS3ST3A1 and HS3ST3B1 amplification. The melting curves are displayed as first 
negative derivative of the fluorescence versus the temperature. Thus, a single peak 
can be seen at the melting temperature. The results here show the specific 
amplification of HS3ST3A1 (A) and HS3ST3B1 (B) mRNA at 48, 72 and 96 hrs both 
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Fig. 4.9. Silencing effect of concentration titration of HS3ST3A1 siRNA on the 
mRNA expression of HS3STA1 and HS3ST3B1 in MCF-12A cells. Real-time PCR 
analysis showed the optimized concentration of 30 nM siRNA achieved the maximal 
reduction of expression of HS3ST3A1 mRNA (A), but no significant suppression on 
the expression of HS3ST3B1 mRNA (B). mRNA expression level was determined by 
quantitative real-time PCR using β-actin as the reference gene for normalization. 
Histograms representing the relative expression level in the cells. Data are 3 separate 















































































4.5 Silencing the expression of HS3ST3A1 impaired the synthesis of HSPG in 
MCF-12A cells.  
To study if the HSPG synthesis was impaired after successfully silencing 
HS3ST3A1 mRNA expression, immunohistochemical staining of HSPG in MCF12A 
cells was performed. HS3ST3A1 enzyme transfers 3-O-sulphation group to HSPG 
chain. Immunohistochemical staining showed that after silencing of HS3ST3A1 
mRNA, HSPG intensity was significantly reduced compared with that in the control 
group (Fig. 4.10). This immunohistochemical staining results clearly indicated that 
silencing of HS3ST3A1 mRNA suppressed the enzymatic activity of HS3ST3A1 
enzyme which resulted in the impaired synthesis of HSPG in MCF-12A cells.  
4.6 Reduction of HS3ST3A1 expression by siRNA in the MCF-12A cells inhibited 
cell proliferation. 
The effects after silencing HS3ST3A1 mRNA on the phenotype alterations in 
MCF-12A cells were further studied. Cell proliferation change was first investigated 
because HSPG is known to be involved in the regulation of cellular proliferation.  
Cell proliferation was measured by direct cell counting. MCF-12A cells were 
transfected in triplicate with the siRNA targeting HS3ST3A1 mRNA or the control 
scrambled siRNA. Cells were trypsinized and counted three days after transfection. 
Fig. 4.11 shows the effect of silencing HS3ST3A1 mRNA expression on MCF-12A 
cell proliferation. Reduction of HS3ST3A1 mRNA expression by siRNA inhibited 
MCF-12A cell growth by 21.64% (Student’s t-test, **p = 0.0043) compared with cells 




















Fig. 4.10. Immunohistochemical localization of heparan sulphate proteoglycan in 
MCF-12A cells after silencing HS3ST3A1. Cells were stained by using 10E4 mAb 
(anti-heparan sulphate antibody) with ABC method 72 hrs post siRNA transfection.. 
The cell surface is characteristically stained with the antibody. The staining is 
significantly weaker or almost negative in the HS3ST3A1 siRNA transfected cells.  
A: Non-targeting siRNA control      B: HS3ST3A1 siRNA knockdown    C: 
Immunohistochemical negative control (without 10E4 antibody)     













Fig. 4.11. Reduction of HS3ST3A1 expression inhibited MCF-12A cell 
proliferation. Direct counting cells 72 hrs post silencing HS3ST3A1 in MCF-12 
cells revealed that cell proliferation was inhibited by 21.64%.  Cells were 
trypsinized and counted at 72 hrs after transfection using a hemacytometer. 
Experiments were performed in triplicate and in three independent experiments. 
Results are expressed as mean ± SD. Student’s t-test, **p = 0.0043 
4.7 Reduction of HS3ST3A1 expression by siRNA in the MCF-12A cells inhibited 
cell cycle S/G2 transition.  
Cell cycle progress reflects cell proliferation. To confirm the proliferation 
inhibition in MCF-12A cells and to study which phase of the cell cycle was affected 
by the suppression of HS3ST3A1 mRNA expression, cell cycle distribution was 
examined in MCF-12A cells transfected with siRNA targeting HS3ST3A1 and 
scrambled siRNA (control ) (Fig. 4.12 and Table 4.2). 
After 72 hrs post transfection, the S-phase fraction of the control cells was 
28.01% whereas in the siRNA transfected cells S-phase was 38.21%. These mean the 
cells in S phase increased by 36.42% (Student’s t-test, **p < 0.001). This was 
























down 35.13% in G2-M phase (Student’s t-test, **p < 0.001, Table 4.2). These results 
suggest that the impaired cell proliferation by reduced HSPG synthesis may be due to 







Fig. 4.12 Representative histograms of MCF-12A cell cycle analyzed by ModFit 




Table 4.3 Reduction of HS3ST3A1 expression inhibited MCF-12A cell cycle 
progression.  MCF-12A cells were transfected with the siRNA targeting HS3ST3A1 
gene or the control scrambled siRNA. Compared with control, siRNA transfected 
group increased the percentage at S phase and correspondingly decreased the 
percentage of cells at G2/M phase. MCF-12A cells were trypsinized 72 hrs after 
transfection and stained with propidium iodide in Vindelov’s cocktail for 1 hr at 4°C 
in the dark. The stained cells were analyzed using FACS caliber flow cytometer 
(Becton Dickinson) with excitation wave-length of 488 nm to determine the 
percentage of cells in G1/S and G2/M. The resulting histograms were analyzed by 
program MODFIT (Becton Dickinson) for cell distribution in cell cycle phases. Data 
were expressed as mean ± SEM. N = 6.  Student’s t-test, ** p < 0.01        
 G1 S phase G2 
control 54.31 ± 0.83 28.01 ± 1.50 17.68 ± 1.29 
siRNA 50.39 ± 1.93 38.21 ± 2.14** 11.47 ± 1.14** 
Channels (FL2-A)

































A: Control B: siRNA 
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4.8 Knockdown of HS3ST3A1 expression in MCF-12A cells inhibited cell 
adhesion to fibronectin and collagen I 
Sulphation pattern of proteoglycans is widely known to be involved in cell 
adhesion to fibronectin, collagen, lamin and vitronectin in the extracellular matrix. To 
investigate the effect of suppression of HS3ST3A1 expression on MCF-12A cell 
adhesion to fibronectin and collagen I, MCF-12A cells were transfected with the 
siRNA targeting HS3ST3A1 gene or the control scrambled siRNA for 72 hrs and the 
cells were re-seeded into fibronectin- and collagen I-coated wells of 96-well plates. 
The cells were allowed to attach for 30 mins. It was found that the adhesion ability of 
the siRNA-knockdown cells was significantly impaired on both substrates. Fig. 4.13 
shows that MCF-12A cell adhesion to fibronectin and collagen I was reduced by 
21.76% (Student’s t-test, **p < 0.01) and by 16.21% (Student’s t-test, **p < 0.01), 
respectively.  These results demonstrate that the impairment of HSPG synthesis after 
silencing of HS3STA1 inhibits the adhesion of MCF-12A cells to extracellular matrix 
substrates. 
4.9 Suppression of HS3ST3A1 expression in MCF-12A cells promoted cell 
migration in vitro. 
Acquisition of migration and invasion capacity into the ECM and basement 
membrane are characteristics of the normal cell developing into malignant cell. To 
study whether suppression of HS3ST3A1 expression in MCF-12A cells would 
influence the migration ability of MCF-12A cells, transwell migration assay were 
performed. Experimental results revealed that suppressing HS3ST3A1 expression in 
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MCF-12A cells rendered the cells migrate faster by ~76.5% compared with the 
control cells (Student’s t-test, ** p < 0.01, Fig. 14A and B).  
4.10 Suppression of HS3ST3A1 expression increased MCF-12A cell invasive 
capacity through Matrigel in vitro. 
The capability of silencing HS3ST3A1 expression to stimulate MCF-12A cell 
migration predicts its role in promoting cell invasion, so invasive capacity of 
MCF-12A cells after reduction the HS3ST3A1 expression was studied. The results 
showed that silencing HS3ST3A1 expression also markedly enhanced MCF-12A cell 















Fig. 4.13. Suppression of HS3ST3A1 expression decreased MCF-12A cell 
adhesion to fibronectin and collagen I.  72 hrs post-transfection of the control 
scrambled-siRNA and siRNA targeting HS3ST3A1, MCF-12A cells were trypsinized, 
harvested and resuspended in DMEM/F12 medium containing 0.1%BSA. 8 x 104 
cells/well were re-seeded in DMEM/ F12 medium containing 0.1%BSA in 96-well 
plates coated with fibronectin and collagen I and allowed to attach for 30min. MTS 
methods (CellTiter 96® AQueous One Solution Cell Proliferation Assay, MTS, 
Promega) were used to determine the attached cell number. Data are representative of 














































Fig. 4.14 Suppression of HS3ST3A1 expression in MCF-12A cells promoted cell 
migration in vitro. 72 hrs post-transfection, MCF-12A cells were trypsinized and 
resuspended in DMEM/F12 medium. 5 × 104 cells/well were re-seeded in DMEM/ 
F12 medium containing 0.1% BSA (Sigma-Aldrich) without FBS in the upper 
chamber and 15% FBS in DMEM/ F12 medium in the lower chamber was used as 
chemoattractant. Cells were allowed to migrate 16 hrs. Migrated cells were stained 
with crystal violet and counted under a microscope. at 100 x magnification (Nikon). 
Experiments were repeated 3 times each run 2 replicates. (A) Data represent the cell 
number of five randomly selected microscopic fields from a single chamber. Data are 
mean ± SE, N = 5, Student’s t-test, **p < 0.01. (B) Images show representative fields 
of crystal violet stained MCF-12A cells on the bottom of a transwell insert as captured 
from a Nikon microscope at 100× magnifications. Cell number at the bottom of the 










































Fig. 4.15. Suppression of HS3ST3A1 expression increased MCF-12A cell invasion 
in vitro. 72 hrs post-transfection, MCF-12A cells were trypsinized and re-suspended 
in DMEM/F12 medium. 1×105 cells/well were re-seeded in DMEM/ F12 medium 
containing 0.1% BSA (Sigma-Aldrich) without FBS in the upper chamber and 15% 
FBS in DMEM/ F12 medium in the lower chamber was used as chemoattractant. 
Cells were allowed to invade 24 hrs. Invaded cells were stained with crystal violet and 
counted under a microscope at 100 x magnification (Nikon). Experiments were 
repeated 3 times each run 2 replicates. (A) Data represent the cell number of five 
randomly selected microscopic fields from a single chamber. Cell number at the 
bottom of the chamber was subtracted from the control which was considered as 
background. Data are mean ± SE, N = 6, Student’s t-test, **p < 0.01. (B) Images show 
representative fields of crystal violet stained MCF-12A cells on the bottom of an 
invasion chamber as captured from a Nikon microscope at 100× magnifications. Scale 

























The present study has shown that expression of HS3ST3A1 was significantly 
down-regulated in breast cancer cell lines as well as in cancer tissues compared with 
their benign counterparts. Knockdown of the expression of HS3ST3A1 by siRNA 
inhibited MCF-12A cell growth in culture, reduced its adhesion while increased its 
migration and invasive capacity in vitro, suggesting the possible functions of 
HS3ST3A1 in breast growth and tumourigenesis.  
Heparan sulphate proteoglycans (HSPGs) are widely distributed on cell surfaces 
and in extracellular matrix. HSPGs regulate many biological processes by interacting 
with a variety of proteins including cytokines, extracellular matrix proteins, enzymes, 
protease inhibitors, growth factors and other molecules (Bernfield et al., 1999; Lander 
and Selleck, 2000; Iozzo, 2001; Esko and Selleck, 2002; Nakato and Kimata, 2002). 
The positioning of the negatively charged sulphate groups on the disaccharide units 
covalently attached to the core protein are important for the specificity of the 
interactions (Esko and Selleck, 2002; Kusche-Gullberg and Kjellen, 2003). The 
3-O-sulphate groups on glucosamine units is supposed to be involved in important 
biological functions as 3-O sulphation occurs late in the HSPG biosynthesis and in 
unusual structures (Shworak et al., 1999a). Indeed, one of the most studied enzyme 
3-O-sulphotransferase (3-O-ST, now known as 3-O-ST-1, HS3ST1) converts 
non-anticoagulant heparan sulphate into the anticoagulant heparan sulphate, which is 
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widely used in clinic and well known as heparin (Petitou and van Boeckel, 2004; 
Dementiev et al., 2004). 
HS3ST3 are type II integral membrane glycoproteins of 406 amino acid residues. 
HS3ST3 has two isoforms, HS3ST3A1 and HS3STB1 which are widely expressed in 
human tissues with multiple transcripts (Shukla et al., 1999; Shworak et al., 1999; Liu 
et al., 1999b). The entire sulphotransferase domain sequence of the HS3ST3B1 is 
99.2% identical to the same region of HS3ST3A1, which strongly suggests that these 
two isoforms may have similar function in the sulphation of HSPG (Liu et al., 1999b). 
Recently years, many studies have explored the possible biological functions of 
the members of 3-O-sulphotransferase (HS3ST) family in cancers. Miyanoto et al. 
(2003) first reported low expression of HS3ST2 in breast cancers. They observed the 
average expression level of HS3ST2 in 37 breast cancers was significantly lower (p < 
0.005) than that in the non-cancerous samples, although the expression in the 
non-cancerous tissues was also variable. They also pointed out that the low expression 
of HS3ST2 in breast cancer may be due to hypermethylation of the 5’-region of the 
mRNA of HS3ST2 as they detected 75 of 85 primary breast cancers (88%) contain 
hypermethylation in the 5’-region of the mRNA. The authors also found that 
hypermethylation of this gene also existed in a majority of colon (80%), lung (70%), 
and pancreas (100%) cancers.  
Promoter methylation often results in low expression or silencing of the gene, 
which is widely believed to be indicative of the specific role of the gene in the 
tumourigenesis (Siegfried and Cedar, 1997; Jones, 1999; Momparler and Bovenzi, 
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2000; Toyota and Issa, 2000; Wajed et al., 2001). The findings of promoter methylation 
of HS3ST2 and low expression in cancers have raised much interest. Takahashi et al. 
(2004) found promoter hypermethylation of HS3ST2 in gallbladder carcinoma. 
Actually, they found HS3ST2 was the most frequently (72%) methylated gene in 
gallbladder carcinoma compared with other genes. Such a 
promoter-methylation-induced low expression of HS3ST2 was also found more 
recently in non-small cell lung cancers (Shivapurkar et al., 2007). The low expression 
of HS3ST2 gene thus indicates that altered modification of HSPGs by this gene could be 
involved in cancer development and progression in a broad range of cancers.  
Promoter methylation of other 3-OST isoforms has also been studied. Dick et 
al.(2004) reported their findings of the expression of 3-OST isoforms in 69 breast 
cancers. The authors found that methylation was frequent in the promoters of HS3ST2 
(51%, 40/69), HS3ST3B (41%, 28/69), and HS3ST4, (45%, 32/69), but rare in HS3ST1 
(1%, 1/69). However, they did not detect promoter methylation in HS3ST3A. High 
levels of methylation and thus a possible low expression of specific 3-O-ST isoforms 
suggests that HSPGs modified by these enzymes may play an important role in breast 
carcinogenesis and development.  
Though promoter methylation of HS3ST3A has not been detected in breast cancer 
(Dick et al., 2004), the possibility of low expression level of HS3ST3A compared with 
that in normal breast epithelial cells is not excluded. Thus a study on the expression 
level of HS3ST3A in breast cancer cells and normal breast epithelial cells is needed. 
Such an investigation may give more information on the function of HS3ST3A in breast 
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cancer. Thus expression profile of HS3ST3 in a normal breast epithelial cell line and 
four breast cancer cell lines available in our lab were examined. Real-time PCR data 
showed that expression of one of the isoforms of HS3ST3, HS3ST3A1, was 
unanimously reduced, especially in the highly invasive cell line MDA-MB-231 cells 
compared with that in the normal breast cell line MCF-12A cells. The other isoform 
HS3ST3B1 was also down regulated in the MCF-7, T47D and ZR-75-1 cell lines and 
only slightly up regulated in MDA-MB-231 cells. The expression profile of HS3ST3A1 
in breast cancer cell lines promoted consideration of HS3ST3A1 expression in breast 
cancer patients. Thus the mRNA expression of this gene in a panel of 22 corresponding 
breast normal and cancer tissues was studied by using in situ hybridization. The 
expression results in the clinical samples were consistent with those in the cell lines.  
Till today, most of the functional studies on the HS3ST3A1 have been limited to 
biochemical studies, e.g. the substrate specificity. The specific binding sites for 
glycoprotein gD interaction for herpes simplex virus type 1 (HSV-1) still remain the 
only known example demonstrating the potential relationship between the formation of 
a biologically significant motif of HS and expression of HS3STA1 isoform (Liu et al., 
1999a; Liu et al., 1999b; Tiwari et al., 2007). Although some of the biological functions 
of HS3STs in cancers, especially in breast cancer, were also studied and their 
significance in breast cancer development and progression was also suggested as 
mentioned above, the causal relationship between the expression of HS3ST3A1 isoform 
and breast tumourigenesis is still not clear.  
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To answer whether this gene exerts its function in the transformation of normal 
breast cells into cancer cells, siRNA technology was used to knockdown the expression 
of HS3ST3A1 in the normal breast epithelial MCF-12A cells to explore the phenotype 
changes in the cells because the expression of this gene in all of the cancer cell lines was 
remarkably down-regulated. 
Proliferation, adhesion, migration and invasion are key features in tumour cell 
growth and metastases. It is widely believed that the expression of HS with defined 
structural properties is essential for those processes. Thus the phenotypic alterations in 
proliferation, adhesion, migration and invasion after down-regulation of HS3ST3A1 
expression were examined in vitro. The findings in this study demonstrated that after 
knockdown expression of HS3ST3A1, MCF-12A cells acquired the properties of 
malignant cells which include less adhesive to the ECM substrate fibronectin and 
collagen I as well as enhanced migration and invasion in vitro.  
Previously Mei et al. (2003) reported that repeated treatments of non-cancerous 
human breast epithelial cells MCF-10A (a similar cell line to MCF-12A cells) with a 
low dose of a tobacco-specific carcinogen induced malignant transformation of these 
cells. The transformed cells acquired cancerous properties including increased cell 
motility and invasion in Matri gel in vitro and increased tumourigenicity in vivo. It has 
been demonstrated that increasing invasiveness of cells indicated an increased 
metastatic potential. Suppression of cell-substrate adhesion has been proposed to 
correlate with increased motility of cancerous cells (Berx et al., 1995; Sun and 
Rotenberg, 1999b; Critchley, 2000). 
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However, in this study, proliferation was retarded in the HS3ST3A1 silenced cells. 
It has been reported that overexpression of PKCα in MCF-10A cells results in a 
significant suppression of cell proliferation but endowed MCF-10A cells with 
properties consistent with the metastatic phenotype (Sun and Rotenberg, 1999). Similar 
results were found in oncogenic Ha-Ras overexpression transformed MCF-10A cells 
which showed a reduce cell proliferation in monolayer cell culture with two times of 
doubling time compared with that of the control (Zantek et al., 2001), although the 
transformed cells had malignant phenotypes. In contrast, ectopic expression of 
oncogenic Ha-Ras in MCF-10A cells induces increased cell proliferation (Basolo et al., 
1991; Ochieng et al., 1991). However, overexpression of oncogenic R-Ras2 in 
MCF-10A cells did not cause any detectable changes in the rate of cell proliferation 
(Clark et al., 1996). These results taken together indicate that malignantly transformed 
MCF-10A cells by oncogenic proteins are not necessarily accompanied by increased 
rate of cell proliferation. Such notion may also be applied in the MCF-12A cells. 
To further determine the mechanism by which reduction of HS3ST3A1 inhibits 
breast cell growth but promotes its metastasis potential in vitro, a systematic analysis of 
the gene expression profile could be valuable and informative.  
As HS3ST3 plays a role in the notch-signaling pathway in Drosophila (Kamimura 
et al., 2004) and notch-signaling pathway is a well known regulatory network in breast 
development and tumourigenesis (Nam et al., 2002; Callahan and Egan, 2004; Shi and 
Harris, 2006), the study on gene expression profile after silencing HS3ST3A1 in breast 
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epithelial cells could also reveal whether any pathways are dysregulated by suppression 
of HS3ST3A1 in breast carcinogenesis.  
In summary, the present study has shown for the first time in mammalian cells 
that knockdown of the expression of HS3ST3A1 inhibited breast epithelial cell growth, 
reduces its adhesion while increases migration and invasive capacity in vitro, 
suggesting the possibility that HS3ST3A1 function in malignant transformation of 






















CHAPTER 5 Gene expression profiling by Affymetrix 
GeneChips in MCF-12A cells after silencing HS3ST3A1 mRNA 
Microarray technology has the ability to simultaneously evaluate gene expression 
across tens of thousands of genes and thus has revolutionized the fields of molecular 
biology. To further explore the possible mechanisms for the phenotype changes 
induced by the transfection of HS3ST3A1 siRNA, Affymetrix GeneChip analysis was 
applied in MCF-12A cells following silencing HS3ST3A1. 
5.1. Assessment of yield, quality and integrity of total RNA obtained from 
MCF-12A cells. 
The success of microarray analysis in determining differential gene expression of 
thousands of genes is dependent upon the quality and integrity of the starting RNA 
because the quality of the initial RNA sample is the first step to ensure successful 
cDNA and cRNA synthesis before microarray hybridization. The quantity and quality 
of total RNA were first analyzed spectrophotometrically. All the samples had ratio of 
absorbance at 260/280 more than 1.80. RNA was then further assessed for quality and 
integrity using Agilent's 2100 Bioanalyzer. Total RNA from cultured MCF-12A cells 
were analyzed using RNA 6000 LabChip kit. The Agilent 2100 bioanalyzer provides 
two visual representations of each sample, an electropherogram (Fig. 5.1A) and a 
gel-like image (Fig. 5.1B).  
The Agilent Bioanalyzer is one of the most effective tools for characterizing 
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RNA integrity by capillary microelectrophoresis, in which RNA degradation is 
indicated by an altered 28S/18S ribosomal RNA (rRNA) signal ratio. Using an 
Agilent Bioanalyzer, typical indications of high quality, intact total RNA samples are 
electropherograms showing distinct 18S and 28S rRNA subunit spikes, with a ratio of 
28S/18S >1.80 with flat baselines. 
The Agilent Bioanalyzer also adopts RIN software algorithm RNA Integrity 
Number, which allows for the quality classification of total RNA, based on a 
numbering system from 1 to 10, with 1 being the most degraded profile and 10 being 
the most intact. Analysis results of the total RNA showed all the sample RNA had 
sharp peaks at 18S and 28S with the 28S/18S ratio around 2.0 (1.8~2.3), and RNA 
number 10 (Fig. 5.1A and B). This ratio, along with the contours of the 
electropherogram and the RIN value led to the conclusion that the RNA samples were 






























Fig. 5.1.  Analysis of total RNA of MCF-12A cells after silencing HS3ST3A1 
expression by using RNA 6000 LabChip kit. The Agilent 2100 bioanalyzer provides 
two visual representations of each sample, an electropherogram (A) and a gel-like 
image (B). Prominent bands can be seen as sharp peaks at 18S and 28S indicating 
highly intact RNA. MCF-12A cells were transfected with the siRNA targeting 
HS3ST3A1 gene or the control scrambled siRNA for 48 hrs and the total RNA was 
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5.2. Assessment of yield and quality / integrity of total cRNA and fragemented 
cRNA 
The preparation of the target cRNA is a multi-step procedure that requires total 
RNA isolation, first strand cDNA synthesis with an oligo(dT) T7 primerr, 
second-strand cDNA synthesis, and a final step of in vitro transcription using T7 RNA 
polymerase and biotinylated ribonucleotides. The cRNA was further fragmented into 
25~200bp oligonucleotides. These enzymatic reactions are sensitive to the quality of 
the starting RNA, the intermediate cDNA template, the occurrence of endogenous 
priming. The quality of the unfragmented cRNA and the fragmented cRNA were 
analyzed by using the Agilent Bioanalyzer.  
Bioanalyzer analysis showed the unfragemented cRNA was quite satisfactory 
(Fig.5.2A and B) with the median size around 1500bp.The size of the resultant 
fragemented cRNA was about 25~200bp indicating good quality for microarray 





























Fig. 5.2. Analysis of unfragemented cRNA quality and size distribution. 1 µl 
unfragemented cRNA were analyzed using the RNA 6000 LabChip kit by Agilent 
2100 Bioanalyzer. Samples run in duplicates (A). Lowest frame of the panel shows 
the classic output of RNA 6000 ladder (the RNA 6000 Ladder, Cat# 7152; Ambion) 
with six RNA peaks (50 (internal marker), 200, 500, 1,000, 2,000, 4,000, and 6,000 bp 
from left to right). The resulting electropherogram shows the classic output of high 
quality unfragmented cRNA samples with median size around 1500 bp. The median 
size was determined by selecting the point (nt) at which separating 50% of the area in 
the electropherogram against the ladder. Data is displayed as electropherograms (A) 

































Fig.5.3. Analysis of fragemented cRNA quality and size. 1µl fragemented cRNA 
were analyzed using the RNA 6000 LabChip kit by Agilent 2100 Bioanalyzer.  
Lowest frame of the panel A shows the classic output of RNA 6000 ladder (the RNA 
6000 Ladder, Cat# 7152; Ambion) with six RNA peaks (50 (internal marker), 200, 
500, 1,000, 2,000, 4,000, and 6,000 bp from left to right). The resulting 
electropherogram shows the classic output of high quality fragmented cRNA samples 
with size about 25~200 bp. Data is displayed as electropherograms and gel-like 
image.  
control3 
control1 control2 control3 
siRNA1 siRNA2 siRNA3 
control1 control2 





   Test array hybridization: Fragmented cRNA was hybridized to Affymetrix Test 
chips (Affymetrix, Santa Clara, CA, USA) to verify the quality and IVT labeling 
efficiency of cRNA. On these chips, a number of house keeping genes (e.g. β-actin 
and GAPDH) are controlled with a set of 3 probes directed toward the 5-prime, 
middle, and 3-prime region of the transcript. For good quality cRNA, the signal ratio 
between the 3'- and 5'- of these genes should not exceed 3. The 3'/5' ratio was less than 
2 in this project as shown in Table 5.1. These results showed that the cRNA quality 
was quite satisfactory. 
Table 5.1 cRNA quality verification on Test Chips 
3'/5'ratio 
  control1 control2 control3 siRNA1 siRNA2 siRNA3 
β-actin 1.46  1.63  1.80  1.60  1.47  1.75  
GAPDH 1.11  1.27  1.00  1.16  1.31  1.16  
5.3 Analysis of microarray data 
To check the quality of the data from the hybridizations, the hybridization data 
acquired from the Affymetrix MAS 5.0  (GCOS) were first analyzed by using two 
-dimensional scatterplot. A scatter-plot summary of the 6 microarray expression data 
(54,676 probeset) including all genes represented on the HU133 Plus 2.0 GeneChip is 
shown in Fig. 5.4. The consistent location of average expression values of the control 
groups and the siRNA groups along the first diagonal (the line for x = y in Fig. 5.4) 
indicates that there was no systematic bias between control and siRNA experimental 
groups. As expected, a higher variance is seen at lower expression levels, most of 
them Absent-Absent call, than at higher ones, which were Present- Present call (The 
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absolute analysis generated by GCOS revealed Present calls were between 37.03% 
~38.99% on all of the 6 arrays). Fig. 5.4 also indicates that, although the expression 
levels of most genes do not differ between the control and siRNA groups, a substantial 
number of genes are differentially expressed between the two groups.  
The data from the arrays were then extracted/normalized using four different 
analytical softwares (MAS5, dCHIP, RMA and Genespring). The differentially 
expressed probe sets (genes) list was generated by the selection criteria in each 
software as in Chapter 2 Materials and Methods. Only those genes that pass the 
selection criteria in each software were selected. The overlapped gene list was 
selected by comparing the 4 gene lists produced from the analysis softwares. Venn 
diagrams were generated to visualize gene probes that were commonly selected by 
these four analysis software packages. Fig. 5.5 shows the experimental design and 
Venn diagram of differentially expressed genes among the four different software 
packages. It can be found from Fig. 5.5, MAS5 analysis showed 592 probes, dChip 
analysis showed 877 probes, RMA analysis showed 1216 probes and GeneSpring 
analysis showed 648 probes. The overlapped (common expressed) probe sets among 
the 4 software analysis was 213 probes, with 70 probes up-regulated and 143 probes 
















Fig. 5.4. Representative two-dimensional scatter-plot of microarray 
hybrization data. Linear scatter plot of normalized average gene expression 
intensity measured from the three control hybridizations and the average gene 
expression intensity from the three siRNA transfection hybridizations. Control 
values (x-axis) were plotted against the siRNA values (y-axis). Genes with 
similar average expression levels appear along the first diagonal (the line y=x); 
genes with expression levels that are different in the two groups appear above and 
below this line, respectively. The parallel green lines mark the limits for two-fold, 























Fig. 5.5. Experimental design and comparison of the overlapped probesets 
among four analysis softwares. RNA samples from three controls and three siRNA 
silenced MCF-12A cell cultures were analyzed on Affymetrix GeneChip HU133 plus 
2.0. The data from the arrays were then extracted/normalized using four different 
analytical softwares (MAS5, dCHIP, RMA and Genespring). The total number of 
differentially expressed genes revealed by each software is indicated. The overlapped 
genes list was selected by comparing the 4 gene lists produced in each software 
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5.4 Validation of microarray expression data by real-time PCR 
The reliability of microarray expression data was independently verified by the 
use of real-time PCR of the mRNAs used in the microarray experiments. Quantitative 
real-time RT-PCR were done for 80 genes (Table 5.4), among them, 57 genes (Table 
5.5) was selected from the common expressed gene list (213 probe sets, 186 genes, 
see Table 5.2 and 5.3), and 23 genes (Table 5.6) were randomly selected. 55 of the 57 
genes (96.5%) that were selected from the common expressed gene list were 
confirmed to be the same regulated direction after silencing HS3ST3A1 in MCF-12A 
cells. Among the 23 randomly selected genes, 21 genes (91.3%) were validated to be 
the same regulated direction. The four genes that showed opposition regulation 
direction between the real-time PCR and the microarray data were HIST1H1C, 
HIST1H4H, HIST1H2AE, and HIST2H2BE. All of them were Histone isoforms. To 
make a statistical inference about the validation rate by real-time PCR for genes of 
2-fold or expression change obtained by microarray analysis, a confidence interval 
was calculated according to the following formula: where Sp = √pq/n, p = percentage 
of genes validated, q = 1– p, µ0.05 = 1.96, n = total population size (number of 2-fold 
change genes identified in microarray analysis). The present microarray analysis 
revealed a total of 186 genes (213 probe sets) with expression changes >2-fold. 
RT-PCR analysis confirmed the microarray results in 76 of the 80 genes analyzed 
(95%). The confidence interval for all the 186 genes to be verifiable was 0.919 ≤ p ≤ 
0.981. Hence, statistically there was 95% confident that 91.9–98.1% of the genes with 
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2-fold change or above can be validated by real-time RT-PCR. Overall, quantitative 
real-time PCR showed quite similar regulation trends compared with the data 
recorded by the Affymetrix U133 plus 2.0 Genechip Arrays. Most importantly, 
microarray data showed that HS3ST3A1 itself was down-regulated (MAS5 -3.98, 
dChip -3.25, Genespring -4.12, and RMA -6.19) which is another evidence to show 
the reliability of microarray results. When the calculation of fold differences by the 
two methods in the samples are compared, most of the cases are reminiscent but not 
equal (Leo et al., 2005). Because of a much more precise detection of real-time PCR, 
it is considered that the real-time PCR results are much reliable. Fig. 5.6 presents the 
fold changes in the expression of nine example genes after comparative analyses 








Fig. 5.6. Validation of mRNA expression of selected 14 gene examples by 
quantitative real-time PCR for microarray data. MCF-12A cells were transfected 
with control siRNA or HS3ST3A1 siRNA for 48 hrs. RNA was re-isolated from 3 
replicate experiments. mRNAs expression level was determined by semi-quantitative 
real-time PCR by using β-actin as the reference gene for normalization. Histograms 
represent the relative expression level in the cells. Data are 3 separate experiments 
mean ± SD. Note: Overall the validation data showed the same trend observed in the 









































Function Gene Symbol Gene Name Entrez ID
Apoptosis
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A U83981
TNFRSF25 tumor necrosis factor receptor superfamily, member 25 AF026071
Cell cycle
CYLD cylindromatosis (turban tumor syndrome) BE046443
HDAC9 histone deacetylase 9 NM_014707
MDM2 Mdm2, transformed 3T3 cell double minute 2 NM_002392
SESN2 sestrin 2 AL136551
ARHGAP27 Rho GTPase activating protein 27 AI769587
C20orf161 chromosome 20 open reading frame 161 CA447177
DGKQ diacylglycerol kinase, theta 110kDa N45308
DUSP2 dual specificity phosphatase 2 NM_004418
FLJ20186 hypothetical protein FLJ20186 BE676248
FSD1L fibronectin type III and SPRY domain containing 1-like AI970348
GEM GTP binding protein overexpressed in skeletal muscle NM_005261
GPSM1 G-protein signalling modulator 1 (AGS3-like, C. elegans) AI242661
HSPG2 heparan sulfate proteoglycan 2 (perlecan) M85289
IL6R interleukin 6 receptor NM_000565
LAMB3 laminin, beta 3 L25541
PILRB paired immunoglobin-like type 2 receptor beta NM_013440
PVT1 Pvt1 oncogene homolog, MYC activator (mouse) BG200951
Transcription
ATF3 activating transcription factor 3 AB066566
ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) BC017314
EZH1 enhancer of zeste homolog 1 (Drosophila) AB002386
HABP4 hyaluronan binding protein 4 AK025144
HIC2 hypermethylated in cancer 2 AL043112
JMJD2B jumonji domain containing 2B AW237172
KLF6 Kruppel-like factor 6 AB017493
ZNF282 zinc finger protein 282 AW130128
Metabolism
DNAJB2 DnaJ (Hsp40) homolog, subfamily B, member 2 NM_006736
PTPN21 protein tyrosine phosphatase, non-receptor type 21 X79510
STK40 serine/threonine kinase 40 BC005169
USP35 ubiquitin specific peptidase 35 AB037793
YOD1 YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) AF090896
Table 5.2    63 genes significantly up-regulated by HS3ST3A1 silencing in MCF-12A cells




Function Gene Symbol Gene Name Entrez ID
Table 5.2    63 genes significantly up-regulated by HS3ST3A1 silencing in MCF-12A cells
(threshold 2 fold change) with functional categories.
PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic subunit AL552001
C20orf194 chromosome 20 open reading frame 194 AI498144
HIST1H1C histone 1, H1c BC002649
HIST1H2AC histone 1, H2ac AL353759
HIST1H2BC histone 1, H2bc NM_003526
HIST1H4H histone 1, H4h NM_003543
POLG polymerase (DNA directed), gamma NM_002693
PSPC1 paraspeckle component 1 NM_018282
PTBP2 polypyrimidine tract binding protein 2 NM_021190
SFRS7 splicing factor, arginine/serine-rich 7, 35kDa AA524053
STX1A syntaxin 1A (brain) NM_004603
ZXDC ZXD family zinc finger C NM_025112
Others
    Stress
OR5AU1 ribonuclease, RNase A family, 7 AK023343
RNASE7 ribonuclease, RNase A family, 7 AJ131212
SQSTM1 sequestosome 1 N30649
ZDHHC11 zinc finger, DHHC-type containing 11 AF267859
   Unknow
C1orf54 chromosome 1 open reading frame 54 NM_024579
C6orf141 chromosome 6 open reading frame 141 NM_153344
C8orf58 chromosome 8 open reading frame 58 AL519427
C14orf78 chromosome 14 open reading frame 78 AI935123
DKFZp451A211 DKFZp451A211 protein BC036906
FAM46B family with sequence similarity 46, member B AA531023
FAM54B family with sequence similarity 54, member B AL512766
FLJ10404 hypothetical protein FLJ10404 NM_019057
GRSF1 Transcribed locus AI075999
JOSD3 Josephin domain containing 3 AF275800
LOC388796 hypothetical LOC388796 AA827892
LOC440248 hect domain and RLD 2 pseudogene 2 AB002391
SETD4 SET domain containing 4 NM_017438
SH3TC1 SH3 domain and tetratricopeptide repeats 1 NM_018986
TMEM40 transmembrane protein 40 NM_018306




Function Gene Symbol Gene Name Entrez ID
Apoptosis
BCL2L12 BCL2-like 12 (proline rich) AF289220
SNCA synuclein, alpha (non A4 component of amyloid precursor) BG260394
Cell growth
EMP2 epithelial membrane protein 2 AV686514
TMEM97 transmembrane protein 97 BF038366
VANGL1 vang-like 1 (van gogh, Drosophila) NM_024062
Cell cycle
BARD1 BRCA1 associated RING domain 1 NM_000465
BRCA1 breast cancer 1, early onset NM_007295
BRRN1 barren homolog 1 (Drosophila) D38553
CCNE2 cyclin E2 NM_004702
CDC2 cell division cycle 2, G1 to S and G2 to M NM_001786
CDC6 CDC6 cell division cycle 6 homolog (S. cerevisiae) U77949
CDCA3 cell division cycle associated 3 NM_031299
DCC1 defective in sister chromatid cohesion homolog 1 NM_024094
E2F5 E2F transcription factor 5, p130-binding U15642
MCM10 MCM10 minichromosome maintenance deficient 10 (S. cerevisiae) NM_018518
MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) AY028916
NBL1 neuroblastoma, suppression of tumorigenicity 1 NM_005380
PLK4 polo-like kinase 4 (Drosophila) NM_014264
PRC1 protein regulator of cytokinesis 1 NM_003981
SPBC24 spindle pole body component 24 homolog (S. cerevisiae) AI469788
WEE1 WEE1 homolog (S. pombe) X62048
ARHGAP18 Rho GTPase activating protein 18 BE644830
ASAM adipocyte-specific adhesion molecule BF056275
CLDND1 claudin domain containing 1 BC013610
DST dystonin AL096710
EVA1 epithelial V-like antigen 1 BF437750
F11R F11 receptor AF191495
FZD2 frizzled homolog 2 (Drosophila) L37882
IFNAR1 interferon (alpha, beta and omega) receptor 1 AA811138
IGSF3 immunoglobulin superfamily, member 3 AB007935
IL1B interleukin 1, beta NM_000576
KLHL5 kelch-like 5 (Drosophila) AK002174
NMU neuromedin U NM_006681
OIP5 Opa interacting protein 5 BE045993
RAB22A RAB22A, member RAS oncogene family N95443
RAB38 RAB38, member RAS oncogene family NM_022337
RAB7L1 RAB7, member RAS oncogene family-like 1 BC002585
SNTB2 CDNA clone IMAGE:5263917 AI695684
SSX2IP synovial sarcoma, X breakpoint 2 interacting protein R52678
Table 5.3    123 genes significantly down-regulated by HS3ST3A1 silencing in MCF-12A cells
(threshold 2 fold change) with functional categories.
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Function Gene Symbol Gene Name Entrez ID
Table 5.3    123 genes significantly down-regulated by HS3ST3A1 silencing in MCF-12A cells
(threshold 2 fold change) with functional categories.
ETV1 ets variant gene 1 BE881590
GPR177 G protein-coupled receptor 177 AA775681
LHX6 LIM homeobox 6 NM_014368
MYST2 MYST histone acetyltransferase 2 NM_007067
PIR pirin (iron-binding nuclear protein) NM_003662
SIX4 sine oculis homeobox homolog 4 (Drosophila) AI554514
SURB7 SRB7 suppressor of RNA polymerase B homolog (yeast) AI688580
TMPO thymopoietin AW272611
TWIST2 twist homolog 2 (Drosophila) AI086614
WDHD1 WD repeat and HMG-box DNA binding protein 1 AW772140
Metabolism
ABHD7 abhydrolase domain containing 7 AI807532
ASPH aspartate beta-hydroxylase AF306765
LACTB2 lactamase, beta 2 BC000878
RNF20 ring finger protein 20 AK022532
B4GALT6 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 6 BG503479
EXTL2 exostoses (multiple)-like 2 AF000416
FUT1 fucosyltransferase 1 (galactoside 2-alpha-L-fucosyltransferase, H blood group) AI417362
GNS glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) AW167793
HS3ST3A1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 NM_006042
SLC35D1 solute carrier family 35 (UDP-glucuronic acid/UDP-N-acetylgalactosamine dual transporter),member D1 AI769637
ACSL3 acyl-CoA synthetase long-chain family member 3 NM_004457
CPOX coproporphyrinogen oxidase NM_000097
MLSTD2 male sterility domain containing 2 N63551
PIGK phosphatidylinositol glycan, class K AI275605
PTGS1 prostaglandin-endoperoxide synthase 1 NM_000962
SGPL1 sphingosine-1-phosphate lyase 1 AB033078
ALG9 asparagine-linked glycosylation 9 homolog NM_024740
ASF1B ASF1 anti-silencing function 1 homolog B (S. cerevisiae) NM_018154
ATAD2 ATPase family, AAA domain containing 2 AI139629
CTDSPL CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like NM_005808
DHFR dihydrofolate reductase AI144299
FIGNL1 fidgetin-like 1 NM_022116
FLJ20273 RNA-binding protein NM_019027
GINS1 GINS complex subunit 1 (Psf1 homolog) NM_021067
GINS2 GINS complex subunit 2 (Psf2 homolog) BC003186
HELLS helicase, lymphoid-specific NM_018063
POLE2 polymerase (DNA directed), epsilon 2 (p59 subunit) NM_002692
RBM18 RNA binding motif protein 18 AA167623
SLC29A1 solute carrier family 29 (nucleoside transporters), member 1 AF079117
SNRPD1 small nuclear ribonucleoprotein D1 polypeptide 16kDa NM_006938
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Table 5.3    123 genes significantly down-regulated by HS3ST3A1 silencing in MCF-12A cells
(threshold 2 fold change) with functional categories.
Transport
ATP10D ATPase, Class V, type 10D AI478147
ATP11C ATPase, Class VI, type 11C BF475862
DBNDD2 dysbindin (dystrobrevin binding protein 1) domain containing 2 NM_018478
KCNK1 potassium channel, subfamily K, member 1 NM_002245
PDCL phosducin-like AF031463
SLC16A14 solute carrier family 16 (monocarboxylic acid transporters), member 14 R15072
SLC16A7 solute carrier family 16 (monocarboxylic acid transporters), member 7 NM_004731
SLC35A4 solute carrier family 35, member A4 BE618656
XK X-linked Kx blood group (McLeod syndrome) NM_021083
Others
Stress
BLM Bloom syndrome NM_000057
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 NM_000295
SQSTM1 sequestosome 1 N30649
CALU calumenin NM_001219
KLHL23 kelch-like 23 (Drosophila) BE326381
TPD52 tumor protein D52 AI632972
VSNL1 visinin-like 1 NM_003385
ZDHHC23 zinc finger, DHHC-type containing 23 AW003367
ANKRD32 ankyrin repeat domain 32 AL136560
ANTXR1 anthrax toxin receptor 1 AF279145
KIAA1794 KIAA1794 BG403615
MOBK1B MOB1, Mps One Binder kinase activator-like 1B (yeast) AK023321
SLITRK5 SLIT and NTRK-like family, member 5 AW449813
  Unknow
C11orf75 chromosome 11 open reading frame 75 NM_020179
C16orf75 hypothetical protein MGC24665 AW138157
C9orf40 chromosome 9 open reading frame 40 NM_017998
CCDC99 coiled-coil domain containing 99 AF269167
CPNE8 copine VIII AI765180
DKFZP761M1511 hypothetical protein DKFZP761M1511 AK026748
DPY19L1 dpy-19-like 1 (C. elegans) AB020684
FAM111A family with sequence similarity 111, member A NM_022074
FAM122B similar to hypothetical protein MGC17347 AI348001
FAM54A family with sequence similarity 54, member A AL138828
FAM72A family with sequence similarity 72, member A AL135396
FSIP1 fibrous sheath interacting protein 1 NM_152597
KIAA0152 KIAA0152 NM_014730
LOC201725 hypothetical protein LOC201725 BE620598
LOC54103 hypothetical protein LOC54103 AK026747
MTX3 metaxin 3 AI743044
RCCD1 RCC1 domain containing 1 AW007826
SPG20 spastic paraplegia 20, spartin (Troyer syndrome) AI651603
TMEM57 transmembrane protein 57 AI582192
TMEM64 transmembrane protein 64 BF732480
TMEM87A transmembrane protein 87A AL049944
   Protein binding
     Iron binding
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ACSL3 NM_004457 gactcttgggaacacgtgaag tttggtttctgacccaacatc 169
ANTXR1 NM_032208 tggaacagttggctcacaaat taagtgtctcctcctggcaga 160
ARHGAP27 NM_199282 caagttttccacccctgagta cttatgccaggtgctgatgat 166
ARL14 NM_025047 gctctgactgctgaggacatc cttgaagaacgccaaagtgtc 183
ASPH NM_004318 gatgctgatggtgatggagat tcgatattctggggttctgc 165
ATF3 NM_001674 agcccctgaagaagatgaaag tctgagccttcagttcagcat 152
B4GALT6 NM_004775 agctgccttatatgcgaggat aggaatgagaactgccacctt 158
C11orf75 NM_020179 acacaccctcctagcatcctc aaacaccacgatcaagagcac 173
C6orf141 NM_153344 ctcagggagctgcgaatc ctgccgttctgtcctcgt 165
CCNE2 NM_057735 caggtttggagtgggacagta cttcctccagcatagccaaat 168
CLDND1 NM_001040199 ggattgtggagacggtgtatc gagatcaatcccgctattgtg 168
CPEB2 NM_182485.1 tcgattgagctatccacatcc agcgttctattcgctctccat 173
CPOX NM_000097 ggcatcagctgtgtacttcaa ataacagagctcacgcccata 176
DBNDD2 NM_001048222 cgaggacattttacagccaga aagaacacatctgctgcatcc 171
DGKQ NM_001347 acctctgctccgacttcatct ggcagacagcacagaacttg 192
DKFZp451A211 NM_001003399 gacgcaggcaggtgaatc catgtctgaggctcttttgct 168
DKFZP761M1511 DR002751 taccttgtctccgtctctgga ggtagagagctgtctgcatcg 166
DST NM_183380 ggtacaaagatgaacgggaca gggcaaggtatctcctgaaag 164
DUSP10(MKP5) NM_144729 atcttgcccttcctgttcct ttctgcttgttgctgtcagtg 173
DUSP2(PAC-1) NM_004418 ccactgccgtgtacttcctg aggtagggcaagatctccaca 175
EMP2 NM_001424 cctggtgggtaggagatgagt tggagcacgaagatgaagaag 175
ETV1 NM_004956 gcagtcaagaacagcccttta ggtcaggtttcggtgtatgag 180
EVA1 NM_005797 tctccttggcatacagctcac ggacgaaaattccaggtcact 165
EXTL2 NM_001439 cgtctgtgtttcacccattg gggaaaggaggagaaagagaa 115
F11R NM_144503 aacagctatggggaggtcaag cccatctttgaaccaggtgta 162
FAM122B NM_145284 agtctgacatggctcaggaga tgtgacggctcataattgttg 180
GABARAPL1 NM_031412 ggaggaccatccctttgagta ctggccaacagtaaggtcaga 160
GADD45B NM_015675 gtacgagtcggccaagttgat cacgatgttgatgtcgttgtc 151
GBP3 NM_018284 tgaacaagctagctgggaaga tcattctggttgtcacccttc 172
GEM NM_005261 tggtcctctgactccacagac tgtatcttctcccagcacctc 168
GINS1 NM_021067 tcaacgaggatggactcagac gcagcgtcgatttcttaacag 155
GPSM1 NM_015597 cgaggacctgaagacactgag gagtgtgtttcccaggtttcc 172
HABP4 NM_014282 gggaataccgaccctatgaga ctctctggtcaaaagcgtcaa 189
HDAC9(HDAC7) NM_178423 ctctccaccccttagtggaac gcttctcctctctgccacttt 154
HIC2 NM_015094 ctgctgctcacatggtgtct gatgatgacgtcacacaggaa 161
HIST1H1C NM_005319 gccgtatcaaacttggtctca tggcttcttaggtttggttcc 161
HIST1H2AC NM_003512 cgtaaaggcaactacgcagag cagtttgttgagctcctcgtc 186
HIST1H2AE NM_021052 tcttagagctagctggcaacg tcttcttaggcagcaatacgg 174
HIST1H2BG NM_003518 catgcctgaaccagctaagtc gtatcggggtgaacctgtttt 159
HIST1H4H NM_003543 tttgggtaagggaggagctaa gaatcacgttctccaggaaca 173
HIST2H2BE NM_003528 gtgtgaaggtcatgggaaatg gcctaattgagaaccgactcc 150
HS3ST3A1 NM_006042 cagtgccctctccacctc gccaggcagtagaagacgtaa 108
Table 5.4    Primers for 80 genes selected for validation by real-time PCR
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HSPG2 NM_005529              gggcaccttgtcttcaggta gacttggatggaacctctgc 128
IFIT2 NM_001547 ctgcaaccatgagtgagaaca tcacgattctgaaactcagtcc 151
IL1B NM_000576 agctgatggccctaaacagat cagcatcttcctcagcttgtc 160
IL6R NM_000565 agctgggactgtgcacttg gccggactgttctgaaactt 168
IL8 NM_000584 ctgcgccaacacagaaatta gcttgaagtttcactggcatc 179
INHBA NM_002192 ggagaacgggtatgtggagat gtcactgccttccttggaaat 151
IRAK2 NM_001570 ggctgaggatgaacaggaag ggaggtgctgaagtcctttg 178
KLF6 NM_001300 tacaccaaaagctcccacttg tcagacctggaaaaacacctg 188
KLHL5 NM_001007075 cagcttcatccatccaactgt caatttcgctggctggtaat 154
KREMEN1 NM_001039570 gcctgggtgagcacaactat ggtgccagttagaggaggtg 176
LAMA5 NM_005560 cctggagtacaacgaggtcaa ctcttggaggaggcaaagaac 171
LAMB3 NM_000228 caagcctgagacctactgcac ctgcagagagacagggttcac 172
LOC153222 BC041709 tcggaacaaactctgatgagc ccctcattatccaggacatctg 179
MICAL2 NM_014632 ctggacctagaccctctggac gtcctcccccaactatgagac 172
MND1 NM_032117 catgcaagcctacagaaaagc caacttgcggatcacagtctt 157
NMU NM_006681 attctcagcctcaggcatcc ggatgcacaactgacgacac 172
OAS1 NM_016816 tgtgtgtgtccaaggtggtaa tctctctttgacaggcttcca 180
OIP5 NM_007280 cccttcctagttggcattga gcacaccattttgtcactgg 162
PILRB NM_013440 tgtatttctgccgagtcgag ttctgagtgccctttgcttt 176
PPP1R15A NM_014330 tgaggcagccggagatact gtagcctgatggggtgctt 192
PPP2R5B NM_006244 gaggatgagcccaatcttga cggggatcctcactatcaaa 167
PRKAB2 NM_005399 acaagatcatggtggggagta ggacccagagatgaagacctc 188
PTBP2 NM_021190 acggaatcgtcactgaagttg  agtacacgagaaggagcacca 178
RAB22A NM_020673 gtattgtgtggcggtttgtg agccgaccctcgatagtaca 179
RAB38 NM_022337 acgtgcaccagaacttctcc gcacccatagcttctcggta 172
RAB7L1 NM_003929 caggacagcttcagcaaaca gcagaggcatcccgataata 164
RASAL2 NM_004841 caatattttctggggcgaac tacaaattggcgaccagtca 166
RNASE7 NM_032572 tgcaaagacctcaacaccttc acctgcagttcggatacttcc 169
SERPINA1 NM_001002235 cgaagaggccaagaaacagat gaagtcctcttcctcggtgtc 175
SESN2 NM_031459 atgctgtgctttgtggaagac ctggaacttctcatccagcag 171
SFRS7 NM_001031684 aaggtcaaggtcagcatctcc tggtcgtgaaatagacctgga 160
SLC35D1 NM_015139 gcgtgctcaccaattacagat agtggaaacgtctttcgaggt 151
TMEM57 NM_018202 gcacacagaaaggggagtgt agccaaaccccaaagttacc 167
VANGL1 NM_138959  gcttctacagcctgggacac cattgttactggggccatct 174
VSNL1 NM_003385  tgagcatgaactcaagcagtg tgaactctcggaagtcaatgg 188
XK NM_021083 ccaggcagaaggcaaactaat caatggacaacagggatatgg 173
YOD1 NM_018566 atggggataccattctggaag agaggcaagagttgtctgctg 180
ZDHHC23 NM_173570 cgtggctacttgtttgtgtga gggatgatgctgatgttcact 171
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Gene Symbol Gene Name Microarray Real-time PCR
ACSL3 acyl-CoA synthetase long-chain family member 3 ↓ ↓
ANTXR1 anthrax toxin receptor 1 ↓ ↓
ASPH aspartate beta-hydroxylase ↓ ↓
B4GALT6 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 6 ↓ ↓
C11orf75 chromosome 11 open reading frame 75 ↓ ↓
CCNE2 cyclin E2 ↓ ↓
CPOX coproporphyrinogen oxidase ↓ ↓
DBNDD2 dysbindin (dystrobrevin binding protein 1) domain containing 2 ↓ ↓
DKFZP761M1511 hypothetical protein DKFZP761M1511 ↓ ↓
DST dystonin ↓ ↓
EMP2 epithelial membrane protein 2 ↓ ↓
ETV1 ets variant gene 1 ↓ ↓
EVA1 epithelial V-like antigen 1 ↓ ↓
EXTL2 exostoses (multiple)-like 2 ↓ ↓
F11R F11 receptor ↓ ↓
FAM122B similar to hypothetical protein MGC17347 ↓ ↓
GINS1 GINS complex subunit 1 (Psf1 homolog) ↓ ↓
HS3ST3A1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 ↓ ↓
IL1B interleukin 1, beta ↓ ↓
KLHL5 kelch-like 5 (Drosophila) ↓ ↓
MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) ↓ ↓
NMU neuromedin U ↓ ↓
OIP5 Opa interacting protein 5 ↓ ↓
RAB22A RAB22A, member RAS oncogene family ↓ ↓
RAB38 RAB38, member RAS oncogene family ↓ ↓
RAB7L1 RAB7, member RAS oncogene family-like 1 ↓ ↓
SERPINA1




solute carrier family 35 (UDP-glucuronic acid/UDP-N-
acetylgalactosamine dual transporter), member D1
↓ ↓
TMEM57 transmembrane protein 57 ↓ ↓
VANGL1 vang-like 1 (van gogh, Drosophila) ↓ ↓
VSNL1 visinin-like 1 ↓ ↓
XK X-linked Kx blood group (McLeod syndrome) ↓ ↓
ZDHHC23 zinc finger, DHHC-type containing 23 ↓ ↓
Down-regulated genes
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Gene Symbol Gene Name Microarray Real-time PCR
ARHGAP27 Rho GTPase activating protein 27 ↑ ↑
ATF3 activating transcription factor 3 ↑ ↑
DGKQ diacylglycerol kinase, theta 110kDa ↑ ↑
DUSP2 dual specificity phosphatase 2 ↑ ↑
GEM GTP binding protein overexpressed in skeletal muscle ↑ ↑
GPSM1 G-protein signalling modulator 1 (AGS3-like, C. elegans) ↑ ↑
HABP4 hyaluronan binding protein 4 ↑ ↑
HDAC9 histone deacetylase 9 ↑ ↑
HIC2 hypermethylated in cancer 2 ↑ ↑
HIST1H1C histone 1, H1c ↑ ↓
HIST1H2AC histone 1, H2ac ↑ ↑
HIST1H4H histone 1, H4h ↑ ↓
HSPG2 heparan sulfate proteoglycan 2 (perlecan) ↑ ↑
IL6R interleukin 6 receptor /// interleukin 6 receptor ↑ ↑
KLF6 Kruppel-like factor 6 ↑ ↑
LAMB3 laminin, beta 3 ↑ ↑
PILRB paired immunoglobin-like type 2 receptor beta ↑ ↑
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A ↑ ↑
PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic subunit ↑ ↑
PTBP2 polypyrimidine tract binding protein 2 ↑ ↑
RNASE7 ribonuclease, RNase A family, 7 ↑ ↑
SESN2 sestrin 2 ↑ ↑
SFRS7 splicing factor, arginine/serine-rich 7, 35kDa ↑ ↑
YOD1 YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) ↑ ↑
Up-regulated genes
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Gene Symbol Gene Name Microarray Real-time PCR
CLDND1 claudin domain containing 1 ↓ ↓
KREMEN1 kringle containing transmembrane protein 1 ↓ ↓
OAS1 oligoadenylate synthetase 1 ↓ ↓
ARL14 ADP-ribosylation factor-like 14 ↑ ↑
C6orf141 chromosome 6 open reading frame 141 ↑ ↑
CPEB2 cytoplasmic polyadenylation element binding protein 2 ↑ ↑
DKFZp451A211 DKFZp451A211 protein ↑ ↑
DUSP10 dual specificity phosphatase 10 ↑ ↑
GABARAPL1 GABA(A) receptor-associated protein like 1 ↑ ↑
GADD45B growth arrest and DNA-damage-inducible, beta ↑ ↑
GBP3 guanylate binding protein 3 ↑ ↑
HIST1H2AE histone 1, H2ae ↑ ↓
HIST1H2BG histone 1, H2bg ↑ ↓
HIST2H2BE histone 2, H2be ↑ ↑
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 ↑ ↑
IL8 interleukin 8 ↑ ↑
INHBA inhibin, beta A (activin A, activin AB alpha polypeptide) ↑ ↑
IRAK2 interleukin-1 receptor-associated kinase 2 ↑ ↑
LAMA5 laminin, alpha 5 ↑ ↑
LOC153222 adult retina protein ↑ ↑
MICAL2 microtubule associated monoxygenase, calponin and LIM domain containing 2 ↑ ↑
PPP2R5B protein phosphatase 2, regulatory subunit B (B56), beta isoform ↑ ↑
RASAL2 RAS protein activator like 2 ↑ ↑







Western blot analysis and immunohistochemical staining for F11R (also known 
as Junction Adhesion Molecule, JAM) were performed to test if down- regulation is 
also reflected at the protein level. Cell lysates were extracted at 72 hrs post 
transfection and the level of F11R protein expression were determined by 
non-reducing Western blotting (Fig. 5.7A). Densitometric analysis of the Western 
blotting showed that after 72 hrs of silencing HS3ST3A1 expression, protein level of 
F11R was 2.26-fold lower in the HS3ST3A1-sileced cells compared to that in the 
controls (Fig. 5.7B), which was consistent with the suppression at the mRNA level 
(-2.09 fold) (Figs. 5.6). The down-regulation in protein levels were also verified by 
immunocytochemical staining (Fig. 5.7C). After confirming of the microarray 
expression data, the gene expression pattern was further explored.  
5.5 Principal component analysis (PCA) of microarray expression data 
Principal Component Analysis (PCA) was applied to cluster the expression data 
in the control groups vs siRNA silencing groups. PCA is commonly used in 
microarray data analysis as a cluster analysis tool (Yeung and Ruzzo, 2001). PCA 
simplifies the dimensionality of the data set to a few principal components and thus 
identifies patterns in the microarray expression data. Using this analysis tool, 
microarray data in this study clearly showed that the 3 samples of the control groups 
(c1, c2 and c3) were separating distinctly from those of the siRNA groups (e1, e2 and 
e3) (Fig. 5.8). As shown in Fig. 5.8, silencing the expression of HS3ST3A1 in 
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Fig. 5.7. Validation for the expression of F11R protein. (A) Western blot 
analysis of F11R protein expression after 72 hrs post silencing HS3ST3A1 gene in 
MCF-12A cells. Western blot analysis under non-reducing conditions shows two 
major bands of F1R, migrating at 32 and 35 kDa, probably representing one of the 
glycosylated forms (Naik et al., 1995). Protein was extracted and processed as in 
Chapter 2 Materials and Methods. (B) Densitometry analysis of the Western band. 
Both 32 kDa and 35 kDa bands were quantified by densitometry and analyzed by 
QuantityOne software (Bio-rad). Data are expressed as F11R normalized to β-actin 
and represented the Mean ± SD. (Student t-test, **p<0.05, n = 3). (C) 
Immunocytochemical staining of F11R protein. MCF-12A cells were cultured on 
coverslips. 72 hrs post silencing HS3ST3A1 mRNA. MCF-12A cells were fixed, 
processed for detection of F11R expression with anti-F11R mAb 

























Fig. 5.8. Principal component analysis (PCA) of microarray data. Principle 
component analysis of gene expression was generated in a three dimensional platform 
and presented here as graph providing a global view on the difference and similarities 
among the control and siRNA groups. Note: The 3 arrays of the control group (c1, c2 




5.6 Hierarchical clustering of microarray expression data 
To further analyze the data for a clear visualization the expression pattern, 648 
differentially expressed probes that were generated in the analysis by GeneSpring 
v7.0 were sent into the software for hierarchical clustering. Fig. 5.9 depicts a 
dendrogram of the two-way hierarchical clustering (genes-horizontal, samples-vertical) 
of differentially expressed genes in the siRNA groups as compared with those in the 
control groups. Hierarchical cluster analysis by GeneSpring v7.0 demonstrated good 
concordance between the 3 biologic replicates (Fig. 5.9) as the control and siRNA 
samples clustered together perfectly. Two main vertical branches were also identified 
that clearly discriminated the control groups from the siRNA groups, reflecting the 
two groups of genes that are up- and down-regulated between the control and siRNA 
samples.  
5.7 Functional categorization of target genes 
Based mainly on the Gene Ontology (GO) Biological Function categories (Cheng 
et al., 2004; Harris et al., 2004), the list of differentially expressed genes (213 probe 
set, 186 genes) among the four analysis softwares could be divided into different 
functional categories. It was found that silencing HS3ST3A1 in MCF-12A cells altered 
a variety of genes which were identified in this study covering a diverse range of 
biological functions. These differentially expressed genes were grouped into 7 major 
functional categories as is shown in Table 5.2 and 5.3, which includes cell cycle, 





















Fig. 5.9. Hierarchical clustering of 
differentially expressed genes in 
the control groups as compared 
with those in the siRNA groups. 
Two-way hierarchical clustering 
(genes-horizontal, samples-vertical) 
was performed on the log2 
normalized data using GeneSpring 
v7.0. Each row denotes a single 
gene and each column represents an 
individual sample. The dendogram 
to the left presents the list of probe 
sets grouped by similarity using 
Pearson correlation. Yellow 
indicates no change from controls, 
red indicates probe sets with 
enhanced expression relative to 
controls, increasing in brightness 
with higher values, and blue 
indicates suppressed expression 
relative to controls, increasing in 
brightness with lower values. Note 
that the control and siRNA samples 
cluster together perfectly. Two main 
vertical branches were identified 
that clearly discriminated the control 




5.8 Possible pathway analysis 
The relationship between the genome-wide gene expression changes with the 
phenotype alterations in biological function assays which were demonstrated above 
was further explored. As genes function together in these biological processes such as 
cell proliferation, adhesion, migration and invasion, PathwayStudio 4.0 (Nikitin et al., 
2003) was used to generate possible pathways involved in the phenotype changes 
after silencing HS3ST3A1 genes expression. All the differentially genes were 
displayed and selected, and the "Build Pathway" command was used with the option 
of "Find only direct interactions between selected nodes" to create new pathways. The 
whole complicate gene interaction in pathways was too big to be included here. So the 
complicated interaction network was further narrowed down. Fig.5.10 provides 
schematic representation of the models generated through this analysis, focusing on 
cell cycle-related genes (Fig.5.10A) and the pathway associated with cell-ECM and 
cytoskeleton related genes (Fig.5.10B) in MCF-12A cell phenotype alterations. 
Combined together, the genomic gene expression profiling results provide strong 
evidence that the Affymetrix GeneChip microarray represents an ideal tool to analyze 
differentially expressed genes and identifies potentially important genes in the 




























Fig. 5.10 Interactive pathway analysis in PathwayStudio 4.0 from the list of differentially expressed genes. A: cell cycle associated genes 
differentially regulated by HS3ST3A1 silencing in MCF-12A cells. B: Cell-communication and cell cytoskeleton associated genes differentially 
regulated by HS3ST3A1 silencing in MCF-12A cells, focusing on the function of perlecan (HSPG2) and F11R. Only selected genes that could be 
linked from the selected genes to other genes, functions, or categories are included in the map. Cellular processes, such as “proliferation”, “cell 











































Genome-wide gene expression profiling with microarray technique allows 
simultaneously analysis of tens of thousands of genes that were differentially 
expressed under two conditions such as treatment and without treatment, or between 
control and knock down samples. In this study, three controls and three siRNA 
silenced MCF-12A cell culture RNA samples were hybridized and analyzed on 
Affymetrix HU133 plus 2.0 GeneChip. The gene expression was globally analyzed 
using different softwares for data normalization and subsequently identification and 
clustering of differentially expressed genes were performed. 
Analysis of microarray data is currently a dynamic field. Recent research trends 
have suggested the use of various normalization approaches to minimize experimental 
variation. Affymetrix MAS 5.0, Robust Multiarray Analysis(RMA，Irizarry et al., 
2003a; Irizarry et al., 2003b), DNA-Chip Analyzer (D-Chip, Li and Wong, 2001a; Li 
and Wong, 2001b) and Genespring as well as others are widely used. In the analysis 
of data from this study, D-Chip, RMA and GeneSpring v7.0 in addition to MAS 5.0 
were utilized to determine differentially expressed genes. Comparison of gene list 
from all of these methods revealed the overlapping genes among the four analysis 
tools, which were differentially expressed in response to HS3ST3A1 silencing. This 
gene list is more conservative and thus more reliable in the likehood that they are 
really differentially expressed genes. 
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In the present study, the main aim is focused on the identification of subgroups 
of genes that may account for the phenotype alterations in MCF-12A cells after 
silencing HS3ST3A1 gene by siRNA. Furthermore, possible pathways that might link 
those differentially expressed genes with concordant functions in the phenotype 
changes were also explored.  
Using different microarray analysis tools, a detailed comparison of the genomic 
expression profiles between the three controls and three knockdown samples were 
performed. It revealed 186 genes ( 2-fold as the threshold) were differentially 
expressed, among them 123 genes were down-regulated and 63 genes were 
up-regulated. The expression data from microarray were further validated by real-time 
PCR for 80 genes and the expression of one gene, F11R was confirmed by both 
immunohistochemistry and Western blot. 
Based mainly on the Gene Ontology Biological Function categories (Cheng et 
al., 2004), the list of differentially expressed genes (186 genes) could be divided into 
different functional categories. It was found that the silencing HS3ST3A1 in 
MCF-12A cells altered a variety of genes which were identified in this study covering 
a diverse range of biological functions (Table 5.2 and 5.3). 
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Identification of molecular pathways 
To reveal potential pathways affected by HS3ST3A1 silencing-induced alterations 
in gene expression, PathwayStudio 4.0 software (Nikitin et al., 2003) was used. 
PathwayStudio 4.0 software is incorporated with the “build pathway” function. Only 
genes that are recognized by the software and found to be part of a pathway are 
included. Genes that were significantly (2- fold threshold) were imported into the 
software. A simplified graphical summary of the pathway for genes associated with 
HS3ST3A1 silencing in MCF-12A cells is shown in Fig.5.10A and B.  
One of the pathways revealed by the PathwayStudio software was cell cycle 
related. There were a considerable number of genes that could be linked to cell cycle 
and proliferation regulation rather than apoptosis, including genes such as CDC2, 
CDC6, CDCA3, CCNE2, CCND3, BRCA1 and BARD1. The proliferation of breast 
cells and cancer cells is regulated by extracellular growth signals such as FGF-2 
(Delehedde et al., 1996). During this period, growth factors induced signals (either 
stimulatory or inhibitory) are transduced from the extracellular environment to cell 
cycle operating apparatus in cytoplasm and nucleus. This apparatus, composed of 
cyclins and their cyclin-dependent kinases, may respond by setting the cell into cell 
division program that carries the cells through G1, S, G2 and M phases or, alternatively, 
by causing exit from the active cell cycle into the quiescent G0 state. The majority of 
genes in this group are down-regulated in HS3ST3A1 silenced MCF-12A cells, 
indicating that a major negative influence on cell cycle transition.  
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Cyclin E  
Microarray results showed a down-regulation of Cyclin E2 in the 
HS3ST3A1-silenced MCF-12A cells. E-type cyclins (both cyclin E1 and cyclin E2) 
(Koff et al., 1991; Zariwala et al., 1998; Lauper et al., 1998; Gudas et al., 1999) are 
expressed during the late G1 phase of the cell cycle until the end of the S-phase. 
Cyclin E-CDK2 complex plays a critical role for mammalian cells progression of 
G1/S transition (Koff et al., 1992; Dulic et al., 1992). Many research demonstrated 
that Cyclin E protein overexpression was often found in human breast cancers. For 
example, Payton et al. (2002) reported the expression and associated catalytic activity 
for both cyclin E1 and cyclin E2 were elevated in primary breast tumours when 
compared to normal breast tissue with a significantly increased expression of Cyclin 
E2 compared with Cyclin E1 (Payton et al., 2002). Such evidence was also reported 
by Geng et al. (Geng et al., 2001). They also found cyclin E2 was overexpressed in 
approximately 24% human mammary carcinomas. 
It was clear now that overexpression of cyclin E protein was not only associated 
with tumour initiation, progression and proliferation, but also indicated a more 
malignant phenotype (Yasmeen et al., 2003a; Moroy and Geisen, 2004). Furthermore 
its overexpression also has been associated with a poor prognosis in primary breast 
cancer patients (Keyomarsi et al., 1994; Keyomarsi et al., 2002; Keyomarsi et al., 
2003; Yasmeen et al., 2003b). Indeed, cyclin E2 has the potential to be a breast cancer 
predictor in clinics. In microarray molecular prediction signature of breast cancer, 
Cyclin E2, but not Cyclin E1, overlapped between the 76-gene prediction signature 
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from Wang et al. (Wang et al., 2005) and the 70-gene prediction signature from van't 
Veer et al. (van't Veer et al., 2002) for metastasis-free survival of lymph 
node–negative breast cancer patients. This suggested that Cyclin E2 plays a critical 
role in breast cancer progression.  
CDC2 (cell division cycle 2, G1 to S and G2 to M), also known as cyclin-dependent 
kinase 1，CDK1.  
While cyclin E-CDK2 complex regulates the G1/S phase transition 
CDC2-Cyclin B complex control the G2/M transition (Zhan et al., 1999). Progression 
of the cell cycle from the G2 to the M phase is controlled by a protein kinase complex, 
called mitosis or maturation promoting factor (MPF) (Hoffmann et al., 1993). MPF 
consists of two major proteins, the catalytic subunit, p34cdc2 and cyclin B1. The 
G2/M DNA damage checkpoint serves to prevent the cell from entering mitosis 
(M-phase) if the genome is damaged. Thus the activity of the cdc2-cyclin B complex 
is pivotal in regulating this transition. During the G2-phase, cdc2 is maintained in an 
inactive state by the kinases Wee1 and Myt1. As cells approach M-phase, the 
phosphatase cdc25 is activated by phosphorylation which in turn activates cdc2, 
establishing a feedback amplification loop that efficiently drives the cell into mitosis. 
It is now know that p34cdc2 is necessary for the induction of mitosis because it 
participates in the condensation of chromosomes, the formation of the mitotic spindle, 
and the breakdown of the nuclear membrane (Wiesener et al., 1998). Microarray data 
in this study showed the CDC2 gene expression was down regulated, which was 




Of particular interest in this pathway is the down-regulation of BRCA1 and 
BRAD1, because of their relationship to the control of cell cycle and breast cancer 
development. BRCA1, a tumour suppressor gene on chromosome 17q21, was 
identified based on its linkage to hereditary breast and ovarian cancer syndromes 
(Easton et al., 1993; Miki et al., 1994) from which its name was derived, breast and 
ovarian cancer susceptibility gene-1.  
BRCA1 has been found to play a important role in cell cycle control. Loss of 
BRCA1 results in cell cycle checkpoint dysfunction, improper DNA damage repair, 
and genomic instability. Xu et al. (1999b) found in their BRCA1 mutant mice model, 
tumours displayed characteristic genomic aberrations and cell cycle defects that were 
very similar to those seen in BRCA1-deficient mammary gland tumours (Brodie et al., 
2001). More research has established that the control function of BRCA1 in cell cycle 
was attributed to its function of maintenance of genomic integrity via participation in 
homologous-recombination-mediated double-strand-break repair, and centrosome 
amplification control (reviewed in Deng and Wang, 2003; Venkitaraman, 2002)). 
BRCA1 was also one of the first genes to be associated with familial breast 
cancer susceptibility in humans. Carriers of mutations in BRCA1 account for a much 
higher risk of early onset familial breast cancer and/or breast/ovarian cancer than 
noncarriers (Easton et al., 1993; Miki et al., 1994; Ford et al., 1995). Targeted 
deletion of BRCA1 in mammary epithelium resulted in carcinomas and 
adenocarcinomas of varying histology (Bowen et al., 2005). Using conditional 
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knockout mice, Xu et al. (1999) have found mice with deletion of exon 11 of BRCA1 
displayed variable types of mammary carcinomas, commonly ductal and lobular 
carcinomas as well as more rare cases of squamous carcinomas, medullary 
carcinomas, and anaplastic carcinomas, all of which are found in human familial 
breast cancers. All these studies suggest mutant BRCA1 and thus low expression of 
BRCA1 plays a vital role in breast tumourigenesis. 
BARD1 
BRCA1-associated RING domain protein (BARD1) which binds to the BRCA1 
N-terminal RING domain (Wu et al., 1996) was down-regulated in the present study. 
Wu et al. (1996) found that most BRCA1 molecules form heterodimers with BARD1 
in vivo. Research evidence showed that BRCA1/BARD1 heterodimer complex plays a 
critical role in mitotic spindle assembly that likely contributes to its role in 
chromosome stability control (Joukov et al., 2006) and loss of this mitotic function 
might contribute to tumourigenesis (Clarke and Sanderson, 2006).  
The spindle assembly checkpoint modulates the timing of anaphase initiation in 
mitotic cells containing improperly aligned chromosomes and increases the 
probability of successful delivery of an euploid chromosome set to each daughter cell. 
Failure to properly form spindle poles can lead to chromosome segregation and 
postmitotic nuclear-assembly defects, abnormalities that are characteristics of both 




Using BRCA1/BARD1-siRNA-treated cells, researchers have found the 
chromosome segregation defects and micronucleus formation. Mutations in the 
BARD1 gene and thus possibly loss of its function in primary breast and ovarian 
cancers have also been reported (Thai et al., 1998; Ghimenti et al., 2002). Studies also 
found that reduced BRCA1 expression level was simultaneously existed with 
over-expressed MDM2, one of negative regulators of p53 (Sourvinos and Spandidos, 
1998). In this study, MDM2 was also up-regulated, suggesting it may function 
together with BRCA1 and BARD1. 
To summarize above, as HS and its sulphation pattern have different functions 
with the interaction of a myriad of growth factors, such functions are often with 
opposing effects, due to the binding to pro- or anti-mitogenic effect of these growth 
factors. From previous study, silencing HS3ST3A1 impaired the sulphation of HS (Fig. 
4.10), it is not surprising genes that are known to inhibit or promote tumour 
proliferation are both dysregulated. The net effect on cell growth undoubtedly 
depends on the intricate interplay between these genes. The data from microarray 
analysis showed down-regulation of most of the cell cycle related genes, which 
strongly suggested that silencing HS3ST3A1 in MCF-12A cell rendered a negative 
effect on the breast cell proliferation. At the same, the expression profile of this group 
genes from microarray analysis in present study and the results from all the researches 
cited above demonstrated that the phenotype changes after HS3ST3A1 silencing in 
MCF-12A cells could be reconciled. One possibility is that the down-regulation those 
genes such as Cyclin E2 and CDC2 resulted in cell cycle arrest and thus proliferation 
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inhibition. But at the same time, loss of function of those genes such as BRCA1 and 
BARD1 rendered the HS3ST3A1-silenced MCF12A cell tumourigenic phenotype with 
features of higher mobility and invasion as the primary function of BRCA1 and 
BARD1 genes might not be to regulate cell cycle and proliferation during the 
development of breast cancers. 
Another possible pathway revealed by Pathway studio 4.0 software is related to 
cell-ECM communication. HSPGs are widely expressed at cell surface or in the ECM 
of virtually every type of cells. It influences cell function by interaction with a variety 
of proteins in the ECM or directly influence cell shape remodeling during cell 
migration, adhesion or invasion.  
The microarray analysis showed that HSPG2 (Perlecan) was up-regulated with 
4 others genes that are involved in HS synthesis were down-regulated.  They are 
EXTL2, β4GALT6, HS3ST3A1 and SLC35D1.  HS3ST3A1 is the gene that was 
the target to be silenced. Also noted is that the remaining 4 genes in the “carbohydrate 
metabolism group” were all down-regulated, suggesting a possible dysregulation in 
heparan sulphate synthesis (Table 5.3).  
EXTL2 
From Chapter 1 Introduction, it is clear that chain polymerization for HS is 
initiated once an α-GlcNAc is transferred to the tetrasaccharide linkage (-glucuronic 
acid-galactose-galactose-xylose where Xyl is attached to a serine residue in the core 
protein) by the action of α-GlcNAc transferase I (GlcNAcT-I) (Fritz et al., 1994), 
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whereas β-GalNAc transferase triggers CS/DS synthesis (Rohrmann et al., 1985; 
Nadanaka et al., 1999).  
Elongation then proceeds by the action of glycosyltransferases (GlcNAc-TII and 
GlcA-TII), which add 1,4-GlcA and 1,4-GlcNAc units in alternating sequence to the 
nonreducing end of the growing polymer. The exostosin (EXT) family of genes 
encodes this α-glycosyltransferase involved in heparan sulphate biosynthesis. Five 
human members of this family have been cloned to date: EXT1(Ahn et al., 1995), 
EXT2 (Le Merrer et al., 1994), EXTL1 (Wise et al., 1997), EXTL2 (Wuyts et al., 
1997), and EXTL3 (Van et al., 1998). EXT1 and EXT2 have dual enzyme activities 
(Kim et al., 2003; Busse and Kusche-Gullberg, 2003), GlcA-TII and GlcNAc-TII. 
EXTL1 shows GlcNAc-TII activity (Kim et al., 2001) while EXTL2 and EXTL3 have 
GlcNAc-TI activity (Kitagawa et al., 1999; Kim et al., 2001). EXTL2 protein is an α 
-1,4-N-acetylhexoaminyltransferase I that transfers not only α-GalNAc but also 
GlcNAc to the common linkage-region, segregating HS from CS/DS biosynthesis 
(Kitagawa et al., 1999).  
The human hereditary multiple exostoses (EXT) family genes are tumour 
suppressors. The EXT is an autosomal dominant disorder characterized by 
cartilage-capped skeletal excrescences (benign tumours of bony outgrowths), which 
has been attributed to mutations in EXT1 and EXT2 (Schmale et al., 1994; Zak et al., 






In this possible pathway, HSPG2 (perlecan) has been put into the centre. In the 
presents study, HSPG2 was up-regulated. HSPG has three types. The third types are 
secreted into extracellular matrix. This includes collagen type XVIII, agrin, and 
perlecan. Human perlecan, encoded by a single-copy HSPG2 gene, consists of 94 
exons and spans more than 120 kb of genomic DNA (Iozzo and Murdoch, 1996) with 
a 14.35-kb mRNA (Murdoch et al., 1992; Kallunki and Tryggvason, 1992). The 
protein core of human perlecan is about 470 kDa. It can be attached with as many as 
four HS chains and numerous other O-linked oligosaccharides (Dolan et al., 1997; 
Friedrich et al., 1999). 
Perlecan is the most abundant ECM HSPG of epithelial cells and endothelial 
basement membranes (BM). As a major HSPG in BMs, perlecan plays active roles in 
cell proliferation, adhesion, differentiation, and growth factor binding (Knox and 
Whitelock, 2006). Expression of perlecan was increased in a number of tumour types, 
both in vivo and in vitro.  
It has been also shown to promote invasive behaviours (Iozzo et al., 1994). 
Nerlich et al. (1997 and1998) reported that high expression levels of perlecan mRNA 
were detected in both human breast tumour and stromal cells which was consistent 
with the findings that human breast cancer stroma has been detected with abundant 
deposits of perlecan proteins (Iozzo et al., 1994). Sabit et al. (2001) showed strong 
expression of perlecan core protein was detected in tumour stroma in human 
intrahepatic cholangiocarcinoma (ICC), and liver carcinoma metastatisized from the 
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colon, whereas only small amounts of perlecan were detected in normal livers. Similar 
findings were revealed in human metastatic melanomas. Perlecan mRNA level was 
markedly increased compared to normal tissue. Perlecan core protein was 
over-expressed in the ECM, which seemed to be related to the invasiveness of the 
melanoma cells (Cohen et al., 1994).  
The upregulation of perlecan was also observed in vitro. The tumourigenic 
mouse epidermal cell line RT101 synthesized more perlecan at both mRNA and 
protein levels than its normal counterpart (Tapanadechopone et al., 2001). Studies 
also found that down-regulation of perlecan expression inhibited tumour growth and 
angiogenesis in vivo (Sharma et al., 1998) and suppressed the proliferation of 
melanoma cells in vitro (Adatia et al., 1997). 
More evidence was accumulated in recent years. Ghiselli et al. (2001) 
demonstrated that by using targeted homologous recombination method, they found 
the perlecan-deficient human colon carcinoma cells grew much more slowly both in 
vitro and in vivo, did not respond to FGF7 and were less tumourigenic than control 
cells. Jiang et al. (2004).showed that antisense targeting of perlecan inhibited tumour 
cell growth in vitro and in vivo, while exogenous recombinant perlecan restored the 
growth of antisense perlecan-expressing cells of mouse RT101 epithelial tumours. 
Zhou et al. (2004) showed very similar findings in proteoglycan-mutated mice which 
exhibited significantly retarded FGF-2-induced tumour growth, and defective 
angiogenesis. Using a ribozyme approach to knockdown the expression of perlecan 
both at mRNA and protein levels in prostate cells, Savoe et al. (2005) showed that 
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knockdown perlecan reduced cell adhesion in vitro and tumour growth in vivo with 
smaller tumour size and less vasculariztion. 
Though a lot of experiments showed a positive effect of perlecan in 
tumourigenesis, growth, invasion and metastasis, there were also evidence showing 
the different effect of perlecan in tumours. Mathiak et al. (1997) reported that in 
human fibrosarcoma cells, antisense suppression of perlecan expression resulted in 
stimulation of tumour cell growth, both in vitro and in vivo, and increased invasion of 
ECM Later in human Kaposi's sarcoma cells, Marchisone et al. (2000) demonstrated 
that antisense reduction of perlecan reduced cell migration and proliferation in vitro 
but increased tumour growth in vivo   
To reconcile the discrepancy, Knox and collaborators (Knox and Whitelock, 
2006) suggested that the local context of the extracellular microenvironment defines 
the function and downstream effects of perlecan. Many researches have confirmed 
that perlecan exerted its function together with the binding of many growth factors 
such as FGF2, VEGF and FGF7. Perlecan may modulate the activities of those 
growth factors by either sequestering them in the BMs and ECM or presenting them 
to their cell surface receptors (Jiang and Couchman, 2003; Fjeldstad and Kolset, 
2005), such that in the positive relationship of perlecan with tumour growth, perlecan 
may favour the diffusion and presentation of growth factors, leading to enhanced 
tumour growth.  
This can also be the explanation in the present findings up-regulation of HSPG2 
and down-regulation of EXTL2 render the HS3ST3A1 silenced MCF-12A cell 
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malignant phenotype which showed increased migration and invasion while decreased 
cell adhesion in vitro. 
Although many genes found in the present study have not been directly linked 
each other in the PathwayStudio software, they may also function in the phenotype 
alterations in the MCF-12A cells after silencing HS3ST3A1. 
Results in Chapter 4 have shown that silencing HS3ST3A1 in MCF-12A cells 
made the cell less adhesive to substrate and enhanced migration. Altered-expression 
of genes encoding cell adhesion/cytoskeleton-associated molecules is thus a reflection 
of the phenotype alterations. It may be relevant that expressions of some epithelial 
adhesion molecules which are known to be associated with the breast cancer growth 
and proliferation and even invasion or metastasis are changed.  
One such gene is F11R. F11R which is also known as Junctional adhesion 
molecule-A (JAM-A), JAM, JAM-1, belongs to the immunoglobulin (Ig) superfamily 
of cell adhesion molecules and contains two Ig-like domains in its 236-amino-acid 
long extracellular region (Bazzoni, 2003). It was first identified in human platelets as 
a 32/36 kDa protein. Later it was also found widely expressed at cell–cell contacts in 
endothelial and epithelial cell monolayers and predominantly localized to the tight 
junctions of these cells (Martin-Padura et al., 1998; Liu et al., 2000). 
Its down-regulation at mRNA level in MCF-12A cells after silencing HS3ST3A1 
was confirmed by using real-time PCR (Fig. 5.6). Down-regulation at protein level 
was validated by Western blot and immunocytochemical staining (Fig.5.7). 
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Structurally F11R is a transmembrane protein, with the Ig-like extracellular 
domain, the transmembrane domain and a PDZ-domain-binding cytoplasmic domain. 
On the basis of this localization and structure of this protein, accumulating evidence 
showed that F11R in these cells was believed to be involved in the formation of tight 
junctions (TJs) and the regulation of their integrity (Liang et al., 2000; Bazzoni et al., 
2000; Bazzoni et al., 2000b; Liu et al., 2000; Ostermann et al., 2002)..  
Tight junctions is a cell-cell adhesion complex in epithelial and endothelial cell 
monolayers, forming continuous seals around cells and serving as a physical barrier to 
prevent solutes and water from passing freely through the paracellular space. TJ 
structure is composed of three regions: (1) the transmembrane region incorporates 
three families of proteins, occludins, JAMs (JAM-1, 2, 3) and claudins; (2) the 
peripheral region (comprising the zonula occludens (ZO- 1, 2, 3 and other MAGUK 
proteins such as MAGI-1); (3) associated proteins (such as AF-6, PAR3cingulin, 
afadin and α-catenin) (Ebnet et al., 2000; Bazzoni et al., 2000; Bazzoni et al., 2000b; 
Ebnet et al., 2003; Ebnet et al., 2004). F11R, through its PDZ-domain-binding 
cytoplasmic domain is involved in the recruitment of ZO-1, AF-6 and Par-3 which are 
also PDZ-domain-containing proteins.  
Growing evidence indicates that F11R proteins contribute to the regulation of TJ 
integrity. Researches have indicated that in mammalian cells, the recruitment of F11R 
to the cellular borders to form homodimer appears to be a vital step (Hamazaki et al., 
2002), as it allows Par3 to interact with the cytoplasmic domain of F11R. This 
binding triggers the junctional recruitment of the Par3/Par6/aPKC complex. The latter 
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step regulates late stages of tight junction assembly that allows the maturation of TJs 
(Matter and Balda, 2003; Ebnet et al., 2003).  
One of the crucial changes detected upon decrease of cell adhesion and 
enhanced migration is the loss or alteration of intercellular cell–cell contacts and 
junctions. It was therefore presumed that overexpression of F11R would enhance tight 
junction formation and inhibit cell migration by enhancing cell-cell contacts. 
Consistent with this notion, it has recently been shown that loss of F11R enhanced the 
spontaneous and random motility of F11R-null mouse endothelial cells (Bazzoni et al., 
2005). In turn, the enhanced motility of F11R defective cells was abolished after 
transfection of full-length F11R cDNA (Bazzoni et al., 2005). Moreover, if tested 
under the presence of shear stress, F11R absence increased protrusion extension in the 
direction of flow (Huang et al., 2006). Knockdown of endogenous F11R reduced 
adhesion to vitronectin (Naik et al., 2003b; Naik and Naik, 2006), suggesting that 
surface expression of F11R regulated the adhesive function. Previous studies have 
confirmed that F11R also plays a critical role in leukocyte adhesion and migration by 
heterophilic interactions with FA-L1integrins (Martin-Padura et al., 1998; Del 
Maschio et al., 1999; Ostermann et al., 2002; Cera et al., 2004; Corada et al., 2005).  
Research findings pointed out that when treating breast cancer MCF-7 and 
MDA-MB-231 cells with hepatocyte growth factor (HGF), F11R mRNA was reduced 
(Martin et al., 2004; Martin et al., 2004b). Previously Liu et al. (2000) demonstrated 
that F11R-specific monoclonal antibodies markedly inhibited the function of tight 
junctions As studies have been pointed out that HGF promotes both migration and 
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invasion of breast cancer cell lines (Jiang et al., 2001; Martin and Jiang, 2001; Jiang 
et al., 2003), these results suggested that the loss of function of F11R may enhance 
breast cancer migration and invasion. Indeed Martin et al. (2007) published a recent 
paper that revealed strengthening the function of TJs significantly reduced in vitro 
invasion of MDA-MB-231 cells through an endothelial cell barrier and reduced 
17-beta-estradiol induced breast cancer cell motility.  
Naik et al. (2003a) has also showed that F11R was important in the regulation 
of basic fibroblast growth factor (bFGF)-induced endothelial cell proliferation and 
angiogenesis. Inhibition of F11R signaling blocks bFGF-induced endothelial cell 
proliferation, tube formation and in vivo angiogenesis. 
Taken together, the functional assay results in Chapter 4 are consistent with the 
above F11R–related experimental data that the proliferation and adhesion were 
inhibited while the migration and invasion were enhanced.  
To summarize above, this study on the gene expression profile after silencing of 
HS3ST3A1 gene results in a pattern of transcriptional alterations that represent a 
unique molecular pathogenesis in the MCF-12A cells. Even this is not yet a full 
picture of the malignant transformation of breast epithelial cells, the evidence of its 
function on the phenotype changes and the gene expression signature are pretty 
informative that HS3ST3A1 gene is indeed involved in the malignant transformation 
of breast epithelial cells. The gene expression signature and the possible pathways are 
consistent with the observation of the phenotypic changes in the MCF-12 cells after 
silencing HS3ST3A1 gene. An extensive understanding of the molecular mechanisms 
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by HS3ST3A1 mediated through 3-O sulphation in heparan sulphate can not only 
provide an explanation for the phenotype changes but also suggest novel therapeutic 






















In the first part of this study, the functions of sulphation status of heparan 
sulphate in breast cancers were studied and the differentially regulatory effects of 
exogenous heparan sulphate from different species on the breast cancer behaviours 
were investigated. The main findings were that undersulpahtion of heparan sulphate 
induced by sodium chlorate, a competitive analogue of PAPS in heparan sulphate 
synthesis, significantly inhibited breast cancer cell growth, decreased breast cancer 
migration and invasion, possibly through increasing the cell adhesion to ECM 
components. These data verified that sulphation group in the glycosaminoglycan was 
involved in cell proliferation of breast cancer. The other main findings were that 
sulphated heparan sulphate from porcine intestine mucosa (HS-PM) rescued 
completely the inhibitory effect of sodium chlorate on MCF-7 cell growth. It also 
showed a rescuing effect, to a less extent on cell growth in MDA-MB-231 cells 
treated with sodium chlorate. But sulphated heparan sulphate from bovine kidney 
showed no rescuing effect on the growth impairment induced by sodium chlorate in 
both breast cancer cell lines. Such diametrically opposite effects were also 
demonstrated between these two heparan sulphate species on breast cancer cell 
migration. However, there was a different scenario regarding the function of these two 
exogenous heparan sulphate in breast cancer cell adhesion.  
The study results showed sulphated HS-BK completely abolished the enhancing 
effect of chlorate on MCF-7 cell adhesion to fibronectin and drastically blocked the 
increment of cell adhesion to collagen I. But HS-PM showed only a partial blockage 
of the enhancing effect induced by sodium chlorate on cell adhesion to fibronectin. 
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However, HS-PM also showed a complete blockage of enhancement induced by 
sodium chlorate in cell adhesion to collagen I. Such different blockage effects of these 
two heparan sulphate species were also found in MDA-MB-231 breast cancer cells. 
As heparan sulphate from porcine intestine mucosa possesses a higher degree of 
sulphation compared to that obtained from bovine kidney (Toida et al., 1997; Tsuda et 
al., 1996), conclusion was made that HS-PM and HS-BK may thus be differentially 
effective in blocking the effect of sodium chlorate on cell adhesion to fibronectin and 
collagen I.  
These results are reminiscent of the Janus-faced functions of heparan sulphate in 
cancer growth and progression. HSPG functions were not only depended on its 
sequence and sulphation pattern, but also relied on the growth factors, cytokines, 
signaling molecules and ECM proteins that were within the proximal 
microenvironment where heparan sulphate presents and performs its influence.  
In the second part of this study, the use of knockdown model to define the 
functional relationships between HS biosynthetic enzyme HS3ST3A1 and its 
biological impact was investigated in vitro and the gene interaction networks 
regulated by 3-O-sulphation of HS was examined by microarray analysis. The results 
shown in Chapter 4 were that the expression levels of HS3ST3A1 in four breast cancer 
cell lines were significantly down-regulated or were not detected compared with that 
in normal breast epithelial MCF-12A cells. In situ hybridization results also showed 
lower expression levels of HS3ST3A1 in breast cancer tissues. The results obtained in 
this study indicated the expression level of HS3STA1 may play a vital role in breast 
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tumourigenesis as many researches have revealed that abnormally high or low 
expression of one gene in normal and/or malignant cells suggests its important 
function in the transition of the cell phenotype.  
Using HS3ST3A1 siRNA, the expression of HS3ST3A1 was successfully reduced 
more than 80%. Thus in vitro functional assays were carried out. The results obtained 
from functional experiments showed that after silencing HS3ST3A1, MCF-12A cells 
were less adhesive to extracellular matrix surface and became more migratory in 
chemoattractant model and invasive in Matri-gel in vitro, two main behaviours of 
malignant cells. One of the reasons is that the poorer adhesiveness of the cell permits 
the cells to detach from the cell mass and to shed into their environment, which is the 
first step for a malignant tumour to metastasize. To metastasize, the cells must further 
acquire the migratory ability to penetrate epithelial layer of blood vessels and invade 
into the basal layer of the vessel. Another reason is that silencing the expression 
HS3ST3A1 modulates the synthesis of HSPG, which in turn modulates the growth 
factors sequestrated inside, and thus regulating cell signaling. These results also 
indicate that silencing the expression of HS3ST3A1 renders in breast epithelial cells a 
malignant phenotype.  
This study also found that MCF-12A cells became less proliferative and cell 
cycle progression was delayed at the S-G2 phase transition after the expression of 
HS3ST3A1 was silenced. These results in this study are unexpected because they are 
not consistent with the malignant cell behaviours. However, less proliferation is also 
often found in other malignant transformation models. For a cell to become more 
Conclusions 
 214
malignant, it must acquire the ability to grow faster than the normal cells in vivo and 
obtain the dominant status in the cell mass and form a tumour core. One possible 
explanation for the unexpected results is that HSPG has promoting or inhibitory 
function on cell growth depending on the sulphation domain of HSPG as well as on 
its interacting proteins, such as growth factors. Reduction in 3-O-sulphation domain 
along the HS chains by the siRNA of HS3ST3A1 possibly changes the interaction of 
HSPG with growth factors, such as FGF-7 (Ye et al., 2001). Other possible 
explanation is that cells cultured in 2-D culture in vitro are different from the 
behaviours in vivo.  
The possible mechanisms underlying the phenotype alterations after silencing 
HS3ST3A1 gene expression were studied by genomic gene expression profiling 
analysis. In Chapter 5, the differential expressed genes were revealed by Affymetrix 
microarray and a variety of genes that accounted for the alterations in the phenotype 
of MCF-12A cells after silencing HS3ST3A1 were identified. Two possible pathways 
were found, one was cell-cycle related, accounting for less proliferation, and another 
one was cell-extracellular matrix communication related, accounting for malignant 
transformation. Taken together the present microarray analysis of the alteration in 
gene expression reveals a broad panel of genes that help define the signaling 
pathways used by MCF-12A cell to response to the impaired 3-O sulphation of HS. 
The present findings are an excellent pilot work that has begun to delineate gene 
expression profiles in the transformation of breast epithelial cell to tumour cells after 
HS3ST3A1 silencing. The knockdown system also increased understanding of the 
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novel aspects of HS function in regulatory networks responsible for phenotype 
alterations. This study has shown for the first time the gene expression alteration at 
genomic level after silencing HS3ST3A1 expression in mammalian cells. The gene 
expression signature revealed by microarray analysis following HS3ST3A1 silencing 
provides a complex and interesting base for future studies. 
Future studies 
Base on the findings in the present study, not only the sulphation degree of 
heparan sulphate but also the sulphation position plays a role in different function 
exerted by heparan sulphate in breast cancer behaviours. As commercially available 
exogenous heparan sulphate are quite heterogeneous in their sulphation degree, other 
studies using heparan sulphate with defined length or even short oligosaccharides 
with consistent sulphation pattern should reveal more defined function of sulphation. 
Experiment using specific enzymatic modified heparan sulphate should give valuable 
information of the biological function of a particular sulphation position on heparan 
sulphate. 
The results of the function of HS3ST3A1 gene in this study have important 
implications for further studies on the involvement of 3-O sulphation of HS as 
modulators of human breast cancer growth and tumour development. The knockdown 
effect in MCF-12A cells should be examined using vector-based siRNA and the 
transfected MCF-12A cells should be further developed into stable siRNA expression 
cell line. Stable transfected breast epithelial MCF-12A cell lines may represent a 
useful tool in in vivo studies, which could achieve reproducibility and to avoid the 
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variability of epithelial cell characteristics usually observed in cell cultures conditions. 
The proliferation and invasion assays should be studied in vivo by transplanting this 
stable cell line into SCID or nude mouse. Stable transfected breast epithelial 
MCF-12A cell lines should be useful in angiogenesis research in vivo as angiogenesis 
is an important step in tumour progression which requires the tumour size of about 1 
mm3.  
The regulatory networks revealed in this study should be further investigated by 
over-expressing down-regulated gene(s) or knocking down up-regulated gene(s) in the 
stably cell line. By such a method, specific pathways in the downstream of silencing 
HS3ST3A1 can be elucidated. The ligands of 3-O sulphated HS should be identified to 
examine the functions of this class of enzyme in the breast tumourigenesis. Ligand 
binding study should reveal new insights into the function of HS3ST3A1 gene in the 
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Abstract. Heparan sulphate is a sulphated glycosamino-
glycan and is able to bind to and regulate the activity of
many growth and signalling factors. We have previously
shown that its expression is correlated with tumour grade and
cell proliferation in breast phyllodes tumours. In this study,
we examined the use of heparan sulphate as a biomarker of
invasive ductal carcinoma and the effects of differentially
sulphated heparan species on breast cancer cell behaviour.
Immunohistochemistry using the 10E4 monoclonal anti-
body was carried out on 32 paraffin-embedded breast cancer
specimens and paired non-cancerous breast tissues to compare
the expression patterns of heparan sulphate. Upregulated
expression of the sulphated 10E4 epitope in heparan sulphate
was detected in both epithelial and stromal compartments of
breast cancer compared with normal mammary tissues, with
a 2.8X increase in immunoreactivity score. To determine the
effects of differentially sulphated heparan sulphate molecules
on breast cancer behaviour, cultured breast carcinoma cells
were treated with chlorate, a competitive inhibitor of glyco-
saminoglycan sulphation, and two different heparan sulphate
species. Inhibition of glycosaminoglycan sulphation resulted
in a significant increase in cancer cell adhesion and a reduction
in cell migration, together with upregulated expression of
focal adhesion kinase and paxillin. Both porcine intestine-
and bovine kidney-derived heparan sulphate species could
block the change in cell adhesion. However, the former
heparan sulphate species completely abolished, while the
latter exacerbated, the chlorate-induced decrease in cell
migration. The results show that heparan sulphate is a
useful biomarker of breast invasive ductal carcinoma.
Different sulphation patterns of heparan sulphate residues
have differential effects in regulating breast cancer cellular
behaviour, and this may be exploited to develop heparan
sulphate into a useful target for treatment of breast
carcinoma.
Introduction
Breast carcinoma is the most widespread form of malignancy
in women worldwide, and the commonest cause of cancer-
related deaths (1,2). Besides clinical and histopathological
staging and hormonal receptor status, cancer cell adhesion
and migration are important parameters that affect patient
prognosis (3,4). Thus, understanding the molecular regulators
of cancer cellular behaviour and determination of their effects
on tumour cell adhesion and migration are essential to a
better comprehension of cancer biology, and is of fundamental
importance in the development of therapeutic targets.
Heparan sulphate is an unbranched, polyanionic glycosa-
minoglycan composed of alternating repeats of glucosamine
and glucuronic/iduronic acid residues (5,6). Heparan sulphate
chains are attached to core protein backbones to form heparan
sulphate proteoglycans, which can be found attached to
the cell surface or within the extracellular matrix (7). The
physiological function of heparan sulphate is highly depen-
dent on the presence of sulphate groups, which modulate the
ability of heparan sulphate to bind to and interact with
different growth and signalling factors (7-9). The importance
of differential sulphation of heparan sulphate has been
highlighted by recent studies on knockout mice, in which
loss of heparan 2-O-sulphation resulted in renal, ocular
and skeletal defects whereas absence of N-sulphation led to
pulmonary hypoplasia and respiratory distress in newborn
pups (10-12).
Studies on the core proteins of heparan sulphate proteo-
glycans using breast cancer tissue samples have shown that
these molecules may be important prognostic indicators.
Several authors have reported increased expression of the
core protein of syndecan-1, a transmembrane heparan
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sulphate proteoglycan, in women with aggressive forms of
breast cancer associated with a poorer prognosis (13-15).
Indeed, expression of syndecan-1 in breast ductal carcinoma
in situ was found to be associated with the presence of
angiogenic and lymphangiogenic factors, and correlated
with the response of primary breast cancer to neoadjuvant
chemotherapy (16,17). Upregulated expression of the core
protein of glypican-1, a glycosylphosphatidylinositol-linked
heparan sulphate proteoglycan, was also noted in human
breast cancer and influenced the response of cancer cells to
growth factors (18).
In contrast to the heparan sulphate proteoglycan core
proteins, relatively less is known about the potential use
of the heparan sulphate glycosaminoglycan chain as a bio-
marker of invasive ductal carcinoma in clinical samples, and
the effects of differentially sulphated heparan sulphate
species on breast cancer cellular behaviour. We have recently
shown that expression of the heparan sulphate glycosa-
minoglycan chain is correlated with tumour grade and cell
proliferation in phyllodes tumours (19). In the current study,
we present evidence that sulphated heparan is upregulated
in human breast invasive carcinoma tissues, and that the
level of sulphation influences tumour cellular behaviour.
We also show that differentially sulphated porcine intestine-
and bovine kidney-derived heparan sulphate species have
dissimilar effects on breast carcinoma cells.
Materials and methods
Clinical samples. A total of 32 archived, formalin-fixed
paraffin-embedded breast cancer specimens and paired non-
cancerous breast tissues from the corresponding patients
were obtained from the Department of Pathology, Singapore
General Hospital for this study. Ethics approval was obtained
from the Institutional Review Board, Singapore General
Hospital.
Immunohistochemistry. Immunohistochemical staining of
clinical samples using the 10E4 antibody was performed as
previously described (19). Briefly, 4-μm thick tissue sections
were deparaffinised and rehydrated. Antigen retrieval using
0.1 mg/ml testicular hyaluronidase (Sigma-Aldrich, St.
Louis, MO) in PBS was carried out at room temperature for
2 h prior to overnight incubation with the 10E4 primary
antibody (Seikagaku, Tokyo, Japan) at 4˚C. After washing,
colorimetric detection was achieved using the avidin-biotin-
complex technique and diaminobenzidine. The sections were
examined using an Olympus BX51 microscope and analysed
using the Image J v1.33 software (NIH, USA). An immuno-
reactivity score (IRS) was determined for each specimen,
calculated by multiplying the percentage of cells stained by
the staining intensity.
Cell culture. MCF-7 and MDA-MB-231 human breast cancer
cell lines were obtained from the American Tissue Culture
Collection (Manassas, VA). Cells were cultured in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 7.5%
foetal bovine serum (FBS), 2 mM glutamine and 40 mg/l
gentamycin in a humidified 5% CO2 incubator at 37˚C. Bovine
kidney- and porcine intestine-derived heparan sulphate
species, chlorate, and sulphate (all from Sigma-Aldrich)
were added in various combinations to the culture medium.
Quantification of sulphated glycosaminoglycans. Cultured
cells were collected with a cell scraper, and the glycosami-
noglycans extracted by ethanol precipitation as previously
described (20). Quantification of sulphated glycosami-
noglycans was carried out using the Blyscan assay (Biocolor,
Newtownabbey, Northern Ireland), a dye-binding assay that
measures sulphated glycosaminoglycans without interference
from non-sulphated glycosaminoglycans, according to the
manufacturer's protocol. Briefly, the extracted glycosami-
noglycans were allowed to bind to the Blyscan dye reagent to
form a precipitate, which was then pelleted by centrifugation
at 9,000 x g for 10 min. The precipitate was dissolved in the
dissociation reagent, and the absorbance at 656 nm measured
using a spectrophotometer.
Cell adhesion assay. Coating of 96-well culture plates with
20 μg/ml fibronectin (BD Biosciences, San Jose, CA) in
phosphate-buffered saline (PBS) was carried out overnight at
4˚C (21). The wells were washed with PBS and the unbound
sites blocked using 1% bovine serum albumin for 1 h at room
temperature. The wells were then washed with PBS and
dried.
Cells were pre-cultured for 48 h in serum-containing
DMEM supplemented with PBS (control group), 30 mM
chlorate or 30 mM chlorate plus 100 ng/ml heparan sulphate.
The cells were then collected and seeded at a density of
1x105 cells per well in the above fibronectin-coated culture
plates and allowed to attach for 30 min at 37˚C. The attached
cells were washed with PBS, fixed for 15 min in 4% para-
formaldehyde, and stained for 30 min using 0.25% crystal
violet in 20% methanol. After washing, the number of
attached cells was determined by releasing the crystal violet
with 1% sodium dodecyl sulphate and measuring the
absorbance at 595 nm.
Cell migration assay. Cancer cells were cultured in serum-
containing DMEM in 6-well plates until they reached 90%
confluence. A horizontal line was then scraped across the
bottom of each well using a sterile 100-μl plastic pipette
tip, after which the culture was continued and the culture
medium was supplemented with PBS (control group), 30 mM
chlorate or 30 mM chlorate plus 100 ng/ml heparan sulphate.
The average distance between the wound edges in each well
was determined by measurement at five randomly selected
sites along the length of the wound. The difference in the
wound gap distance at 0 and 18 h after scraping was
calculated to determine the distance migrated.
Cell proliferation assay. Cells were seeded in 96-well plates
at a density of 4x103 cells per well and cultured for 72 h in
serum-containing DMEM supplemented with PBS (control
group), 30 mM chlorate or 30 mM chlorate plus 100 ng/ml
heparan sulphate. At the end of the culture period, the cells
were washed with PBS, fixed in 4% paraformaldehyde
for 15 min, and stained using 0.25% crystal violet in 20%
methanol for 30 min. After washing, 1% sodium dodecyl
sulphate was added for 1 h to release the crystal violet, and
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the absorbance was then measured at 595 nm using a
microplate reader.
Fluorescence immunocytochemistry. Cover slips were coated
with fibronectin as described above. Cells were pre-cultured
for 48 h in serum-containing DMEM supplemented with
PBS (control group) or 30 mM chlorate. The cells were
then trypsinised and washed in PBS. They were seeded at a
density of 1x105 cells per coverslip and allowed to attach for
2 h to form adhesion. Unattached cells were then washed
off. Attached cells were fixed in 4% paraformaldehyde for
10 min and washed with PBS containing 0.2% Triton X-100.
After blocking, the cells were incubated with a 1:100 dilution
of either mouse anti-paxillin IgG1 antibody, clone 165
(BD Biosciences) or rabbit anti-FAK antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) at 4˚C overnight as
previously described (22,23). After washing, the signal
was detected using an Alexa Fluor 568 goat anti-mouse
secondary antibody (Invitrogen, Carlsbad, CA) or an Alexa
Fluor 568 goat anti-rabbit secondary antibody respectively.
To achieve double fluorescence labelling for F-actin, the
cells were then incubated with Alexa Fluor 488 phalloidin
(1:50 dilution) for 1 h at room temperature. The samples
were examined using a FluoView FV1000 laser scanning
confocal microscope (Olympus, Melville, NY).
For immunocytochemical detection of heparan sulphate,
cells were fixed using Sainte-Marie's fixative as this gives
better preservation of glycosaminoglycans (24). After
blocking, cells were incubated with the anti-heparan sulphate
antibody 10E4 at 1:100 dilution followed by an Alexa Fluor
488 goat anti-mouse IgM secondary antibody.
Real-time RT-PCR. Total RNA was extracted from cultured
cells using the RNeasy Mini Kit (Qiagen, Valencia, CA)
according to the manufacturer's protocol. After synthesis
of cDNA using Superscript III (Invitrogen) and random
hexamers, real-time PCR was carried out in a LightCycler
(Roche, Indianapolis, IN) with the intron-spanning primers
listed in Table I. After an initial activation step of 95˚C
for 15 min, 45 PCR cycles were performed as previously
described: denaturation step of 94˚C for 15 sec, annealing
step of 60˚C for 25 sec, and extension step of 72˚C for 18 sec
(25). Melting curve analysis was carried out to verify the
specificity of the amplification, and the size of the PCR
product was confirmed by electrophoresis on a 2% agarose
gel. The 2-ΔΔCt method was used to determine the relative
level of expression of gene transcripts after normalisation to
RPLP0 (also known as 36B4), an oestradiol-independent
mRNA control (26).
Western blot analysis. Cancer cells were grown in 100-mm
petri dishes for 48 h and then lysed with 200 μl cold lysis
buffer consisting of 50 mM HEPES, 150 mM sodium chloride,
1% Triton X-100, 5 μg/ml pepstatin A, 5 μg/ml leupeptin,
2 μg/ml aprotinin, 1 mM phenylmethylsulphonyl fluoride,
100 mM sodium fluoride and 1 mM sodium vanadate,
pH 7.5. After standing for 20 min on ice, the protein
supernatant was collected by centrifugation at 13,000 x g
for 20 min. Twenty micrograms of protein were analysed
by Western blotting with the ECL kit (Amersham, Little
Chalfont, UK) using the following antibodies to probe the
Western membrane after stripping: mouse anti-paxillin IgG1
antibody clone 165, mouse anti-FAK IgG1 antibody clone
77, and mouse anti-ß1-integrin IgG1 antibody clone 18 (all
from BD Biosciences). The relative protein expression level
was determined by densitometry measurement of the band
intensity and normalisation to ß-actin.
Statistical analysis. All experiments consisted of at least
three replicates. Statistical comparison between two groups
was performed by the Student's t-test, and among three
groups by one-way analysis of variance (ANOVA) with
Tukey's post test using GraphPad Prism v4.03 for Windows
(GraphPad Software, San Diego, CA). The Wilcoxon matched
pairs test was used for comparison of clinical samples.
Statistical significance was defined as a p-value of <0.05.
Results
Expression of heparan sulphate in breast cancer tissues. To
determine if heparan sulphate is differentially expressed
between breast carcinoma and non-cancerous breast
tissues, we examined the expression of the 10E4 epitope in
both epithelial and stromal compartments of 32 samples
of invasive ductal carcinoma and paired non-cancerous
mammary tissues from the corresponding patients. The
mouse monoclonal antibody 10E4 is a well-established
anti-heparan sulphate antibody, and requires the presence
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Table I. Intron-spanning primers used in real-time RT-PCR analysis.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene RefSeq No. Primer sequence Product (bp)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
ITGB1 NM_002211 Forward: 5'-CTGCGAGTGTGGTGTCTGTAA-3' 162
Reverse: 5'-GAACATTCCTGTGTGCATGTG-3'
FAK NM_005607 Forward: 5'-TGGACGATGTATTGGAGAAGG-3' 175
Reverse: 5'-ATGAGGATGGTCAAACTGACG-3'
PXN NM_002859 Forward: 5'-CCACACATACCAGGAGATTGC-3' 189
Reverse: 5'-GGGTTGGAGACACTGGAAGTT-3'
RPLP0 NM_001002 Forward: 5'-CTGTTGCATCAGTACCCCATT-3' 103
Reverse: 5'-GCCTTGACCTTTTCAGCAAG-3'
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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of the sulphate moiety on heparan sulphate for binding to
its epitope (20,27,28). The mean age of the patients in the
sample population was 60.4 years. As shown in Fig. 1,
upregulated expression of the sulphated 10E4 epitope was
detected in both the epithelial and stromal compartments
of breast cancer compared with normal mammary tissues.
Significantly, the mean immunoreactivity score of the cancer
samples was 2.8 times higher than that of normal breast
tissues, suggesting that heparan sulphate would be a useful
biomarker for breast invasive ductal carcinoma.
Sulphate group in heparan sulphate is involved in regulating
breast cancer cell adhesion. To determine if the sulphate
group of heparan sulphate affects breast cancer cell adhesion,
we cultured MCF-7 breast cancer cells in the presence of
30 mM chlorate. Chlorate is a widely used and well-known
competitive inhibitor of glycosaminoglycan sulphation. It
acts as a sulphate analogue in the cellular synthesis of the
sulphate donor 3'-phosphoadenosine 5'-phosphosulphate,
which is required for glycosaminoglycan sulphation
(5,20,29-32). Previous studies involving breast cancer cell
cultures and other biological systems have shown no
significant effects on glycosaminoglycan chain or protein
synthesis or on cell viability when chlorate was used at
concentrations of up to 30 mM.
When 30 mM chlorate was added to the culture medium,
MCF-7 cells showed an increase in cell adhesion, suggesting
that glycosaminoglycan sulphation regulates breast cancer
cell adhesion (Fig. 2A). A similar increase was also seen when
MDA-MB-231 human breast cancer cells were cultured in
medium containing 30 mM chlorate (Fig. 2B). Furthermore,
supplementation of chlorate-containing culture medium
with exogenous sulphate blocked the increase in cell
adhesion, thus confirming that the increase was indeed due
to competitive inhibition of glycosaminoglycan sulphation
(Fig. 2A). To further verify that glycosaminoglycan sul-
phation was reduced by chlorate treatment, we extracted and
measured the amount of sulphated glycosaminoglycans
produced by the cancer cells using the Blyscan dye-binding
assay. As shown in Fig. 2C, chlorate administration resulted
in 38.4% reduction in glycosaminoglycan sulphation. A
decrease in sulphation of heparan sulphate was confirmed by
fluorescence immunocytochemical staining of chlorate-
treated cells using the 10E4 anti-heparan sulphate antibody
(Fig. 2D).
Comparative effects of differentially sulphated heparan
sulphate species on cancer cell adhesion. Chlorate inhibits
sulphation of all glycosaminoglycans and does not act
specifically on heparan sulphate. Thus, to determine if the
chlorate-induced increase in cancer cell adhesion was due to
a reduction in sulphation of heparan sulphate molecules,
bovine kidney-derived heparan sulphate was added to MCF-7
cells grown in chlorate-containing medium. As shown in
Fig. 3A, supplementation of the culture medium with
adequately sulphated heparan sulphate molecules completely
abolished the effect of chlorate on cell adhesion, suggesting
that the sulphation status of heparan sulphate is important in
regulating cancer cell adhesion. To investigate this further,
we repeated the above experiment but added porcine intestine-
derived heparan sulphate to the chlorate-containing culture
medium instead of the bovine kidney-derived species.
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Figure 1. Expression of heparan sulphate in 32 archival breast cancer
specimens and paired non-cancerous breast tissues from corresponding
patients. Immunohistochemical staining of (A) normal breast tissues and
(B) paired invasive ductal carcinoma samples obtained from the
corresponding patients was carried out using the 10E4 antibody. A negative
control section where the primary antibody was omitted is shown in (C).
Statistical comparison using the Wilcoxon matched pairs test showed
(D) significantly higher immunoreactivity scores (IRS) in the epithelial
compartment of the carcinoma samples (p=0.0482), as well as (E) increased
staining intensity in the stromal compartment (p=0.0067). Values represent
mean ± SEM. Scale bars, 100 μm.
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Heparan sulphate from porcine intestines possesses a lower
degree of sulphation compared to that obtained from bovine
kidney (33,34). We hypothesised that it may thus be less
effective in blocking the effect of chlorate on cell adhesion.
Indeed, as shown in Fig. 3B, addition of porcine intestine-
derived heparan sulphate resulted in only a partial, instead of
complete, block of the chlorate-induced increase in cell
adhesion.
We also examined the effect of inhibiting glycosami-
noglycan sulphation on the expression of paxillin (PAX),
focal adhesion kinase (FAK) and ß1-integrin (ITGB1) in
chlorate-treated MCF-7 cells. Paxillin and FAK are key
regulatory components in cell adhesion and cell movement
(35-37). We have previously shown that ß1-integrin (ITGB1)
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Figure 2. Effect of chlorate treatment on breast cancer cell adhesion. (A)
MCF-7 cells were cultured in DMEM with 7.5% FBS in the presence of
PBS (control), 30 mM chlorate (ClO3) or 30 mM chlorate plus 10 mM
sulphate (SO4). Comparison among all three groups using one-way ANOVA
showed a statistically significant difference (p<0.0001), with the chlorate-
alone treated group having greater cell adhesion compared to the control
and the chlorate plus sulphate groups (Tukey's post test; p<0.001). (B)
MDA-MB-231 cells cultured in chlorate-containing medium also showed an
increase in cell adhesion (Student's t-test; p<0.0001). (C) Chlorate treatment
resulted in a significant reduction in sulphation of glycosaminoglycans
produced by MCF-7 cells (Student's t-test; p=0.0005). (D) Immunofluo-
rescence staining using the 10E4 anti-heparan sulphate antibody showed
reduced staining intensity of chlorate-treated MCF-7 cells, demonstrating
a decrease in sulphation of heparan sulphate molecules. Values represent
mean ± SEM of at least three replicates. Scale bars, 20 μm.
Figure 3. Sulphation status of heparan sulphate regulates breast cancer
cell adhesion. MCF-7 cells were cultured in serum-containing medium
supplemented with PBS (control), 30 mM chlorate (ClO3), (A) 30 mM
chlorate plus 100 ng/ml bovine kidney-derived heparan sulphate (HS-BK),
or (B) 30 mM chlorate plus 100 ng/ml porcine intestine-derived heparan
sulphate (HS-PI). Comparison among all three groups in each panel using
one-way ANOVA showed a statistically significant difference (p<0.0001),
with an increase in cell adhesion in the group treated with chlorate
alone compared against the control group (Tukey's post test; p<0.001).
Supplementation with HS-BK completely abolished the effect of chlorate
on cell adhesion, with cells in this group possessing a similar degree of
adhesion compared with those in the control group (p>0.05). In contrast,
HS-PI was only able to partially block the effect of chlorate, and cells in this
group were more adherent compared against the control group (p<0.01).
Values represent mean ± SEM of at least three replicates.
Figure 4. Effects of reduced glycosaminoglycan sulphation on ITGB1, FAK
and paxillin expression. MCF-7 cells were cultured for 48 h in medium
supplemented with PBS (control group) or 30 mM chlorate. (A) Gene
transcript levels of ITGB1, FAK and PXN were measured using real-time
RT-PCR. Chlorate treatment significantly upregulated the expression of
FAK (p=0.0375) and PXN (p=0.0440). (B) Representative Western blot of
three independent experiments. (C) Analysis by densitometry measurements
showed increased levels of ITGB1 (p=0.0016), FAK (p=0.0002) and PXN
(p=0.0003). Values represent mean ± SEM of three replicates.
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influences the activity of FAK and paxillin, with resultant
effects on breast cancer cell adhesion and spreading (23).
Using real-time RT-PCR, reduction in glycosaminoglycan
sulphation was shown to significantly increase the expression
of FAK and PXN by 1.9X and 1.7X respectively (Fig. 4A).
The expression of ITGB1 was also upregulated, although
this did not reach statistical significance. The changes in
gene transcript levels were accompanied by similar up-
regulation in protein levels, as determined by Western blotting
(Fig. 4B and C). Expressions of ITGB1, FAK and PXN
proteins in chlorate-treated cells were increased by 1.3X,
3.1X and 1.6X respectively. Using fluorescence immuno-
cytochemistry, cells in the treatment group were found to
possess an increase in focal adhesion formation together
with stronger staining intensities for PXN and FAK proteins
compared against those in the control group (Fig. 5).
Contrasting effects of different heparan sulphate species on
cancer cell migration. To determine if the increase in cell
adhesion due to reduced glycosaminoglycan sulphation
would affect cancer cell migration, we cultured MCF-7 cells
(Fig. 6A) and MDA-MB-231 cells (Fig. 6B) in the presence
of chlorate, and measured the distance migrated by the
cells across a wound gap over an 18-h period. In both cases,
inhibition of glycosaminoglycan sulphation resulted in a
significant decrease in cell migration. This chlorate-induced
reduction in cell migration could be completely ablished
by supplementation of the culture medium with porcine
intestine-derived heparan sulphate (Fig. 6A). However,
in contrast to what was observed in the cell adhesion
experiments (Fig. 3), addition of bovine kidney-derived
heparan sulphate to the chlorate-containing culture medium
led to a significant further decrease in cell migration instead
of blocking the effect of chlorate (Fig. 6C). This suggests
that differentially sulphated heparan sulphate species have
diametrically opposite effects on breast cancer cell migration.
To examine if changes in cell proliferation as a result of
chlorate treatment would confound the interpretation of the
wound gap cell migration data, we cultured MCF-7 cells in
medium supplemented with chlorate and measured the effect
on cell growth. Despite treating the cells with chlorate for
72 h, cell proliferation was reduced by only 11% (Fig. 6D).
Although this was statistically significant, the small change
in cell proliferation makes it unlikely to be an important
confounding factor in interpreting the 42% decrease in
cell migration resulting from chlorate treatment (Fig. 6A).
Chlorate-treated cells did not show any chromatin
condensation, suggesting that reducing glycosaminoglycan
sulphation did not result in apoptosis (Fig. 6E).
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Figure 5. Fluorescence confocal microscopic analysis of focal adhesion
formation. MCF-7 cells were cultured in medium supplemented with PBS
(control) or 30 mM chlorate, and immunocytochemically examined for the
expression of (A) paxillin (red) or (B) FAK using the respective antibodies.
Actin fibres were stained using phalloidin (green). Panels shown are
representative of triplicate experiments. Scale bars, 20 μm.
Figure 6. Effects of differentially sulphated heparan species on breast cancer
cell migration. MCF-7 cells (A, C, D and E) and MDA-MB-231 cells (B)
were cultured in serum-containing medium in the presence of PBS (control),
30 mM chlorate (ClO3), or 30 mM chlorate plus (A) 100 ng/ml porcine
intestine-derived heparan sulphate (HS-PI) or (C) bovine kidney-derived
heparan sulphate (HS-BK). Comparison of cell migration among all
three groups in (A) and (C) using one-way ANOVA showed a statistically
significant difference (p<0.01), with a decrease in cell migration in the
group treated with chlorate alone compared against the control group
(Tukey's post test; p<0.05). Supplementation of the chlorate-containing
culture medium with porcine intestine-derived heparan sulphate completely
blocked the effect of chlorate (p<0.05). In contrast, addition of bovine
kidney-derived heparan sulphate resulted in a further reduction in cell
migration (p<0.05). (B) As in the case of MCF-7 cells, inhibition of
glycosaminoglycan sulphation in MDA-MB-231 cells resulted in reduced
cell migration (Student's t-test; p<0.01). (D) Chlorate treatment decreased
cell proliferation (p<0.05), but did not induce cell apoptosis (E). Values
represent mean ± SEM of at least three replicates. Scale bars, 20 μm.
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Discussion
We have investigated the use of heparan sulphate glycosami-
noglycan as a biomarker of invasive breast ductal carcinoma
in patient samples, and compared the effects of differentially
sulphated porcine intestine- and bovine kidney-derived
heparan sulphate species on cancer cell adhesion and
migration. Adhesion of cancer cells to the extracellular
matrix is an important determinant of local tumour invasion
and distant metastasis (38-41). Changes in cell adhesion
enable tumour cells to invade into surrounding tissues and
spread to distant sites, contributing significantly to patient
morbidity and mortality.
Studies on heparanase, an endoglucuronidase that
hydrolyses heparan sulphate, suggest that degradation of
heparan sulphate leads to enhanced breast cancer growth
and invasion (42,43). Upregulated expression of heparanase,
with a consequential reduction in heparan sulphate level, has
been reported in breast cancer with a larger primary tumour
size and distant metastasis (44). These studies suggest that
heparan sulphate glycosaminoglycan chains are involved
in breast carcinogenesis and that their presence implies a
poorer prognosis for patients. Indeed, in the present study,
upregulated expression of the sulphated 10E4 epitope in
heparan sulphate was seen in the epithelial and stromal
compartments of invasive ductal carcinoma compared with
the corresponding normal breast tissues.
However, recent studies have shown that not all heparan
sulphate chains are bad, and that the sulphation status of
different heparan sulphate species is an important determinant
of the biological effects of these molecules on cancer cells.
This has been highlighted in the past few years in reports on
the SULF-1 gene, which codes for the enzyme sulfatase-1
that removes 6-O-sulphate groups from heparan sulphate
(45-47). Loss of 6-O-sulphate groups was shown to inhibit
growth of breast, pancreatic and hepatocellular cancers. In
contrast, absence of SULF-1 resulted in chemoresistance.
Our experiments with chlorate, which competitively inhibits
glycosaminoglycan sulphation and thus mimics over-
expression of sulphatase-1 in the loss of 6-O-sulphate groups,
showed an increase in cell adhesion and a reduction in cell
proliferation. This phenomenon could be blocked by addition
of adequately sulphated heparan sulphate to the culture
medium, with bovine kidney-derived heparan sulphate
containing a larger number of sulphate groups being more
efficacious than porcine intestine-derived heparan sulphate
(Fig. 3).
Interestingly, heparan sulphate regulation of breast cancer
cell migration appears to be affected not only by the number
of sulphate groups present but also by the position of the
sulphate groups. Thus, inhibition of heparan sulphation, as
well as the presence of highly sulphated bovine kidney-
derived heparan sulphate, both led to a significant reduction
in cell migration (Fig. 6). In contrast, optimally sulphated
porcine intestine-derived heparan sulphate was able to block
the effect of chlorate treatment. The results are in agreement
with the recently proposed concept of a ‘heparanome’, in
which differentially sulphated sugar sequences regulate
the biological activities of different heparan sulphate species
(8,48).
Heparan sulphate has been shown to affect cancer cellular
behaviour through several mechanisms (9,49). It is able to
bind to and interact with a multitude of growth factors and
signalling proteins, resulting in stimulation of growth and
metastasis of cancer cells (7). Heparan sulphate in the extra-
cellular matrix also acts as a reservoir for aggregation of
growth and angiogenic factors. Furthermore, binding of
heparan sulphate to these molecules could protect them from
degradation and thus prolong their effects on cancer cells. In
breast cancer cells, fibroblast growth factor-2 (FGF-2) binds
to heparan sulphate and stimulates cellular proliferation.
Degradation of heparan sulphate by heparinase treatment
abolished binding of the growth factor as well as the FGF-2-
induced tumour growth (30). Down-regulation of SULF-1
in MDA-MB-468 breast cancer cells, with the resultant
persistent presence of 6-O-sulphate groups on heparan
sulphate molecules, increases autocrine activation of the
epidermal growth factor receptor-extracellular signal-
regulated kinase (EGFR-ERK) pathway, mediated via
amphiregulin and heparin-binding EGF-like growth factor
(HB-EGF) (50). In addition, loss of SULF-1 has been shown
to increase cell proliferation in tumour-associated
angiogenesis through FGF-2, hepatocyte growth factor, and
vascular endothelial growth factor (VEGF) signalling.
Heparan sulphate is capable of binding to fibronectin and
many other components of the extracellular matrix, and helps
to regulate cell adhesion (7). Integrin-mediated cell adhesion
leads to recruitment of the cytoplasmic protein tyrosine kinase
FAK to focal adhesion sites, and the phosphorylation of both
FAK and paxillin (36,51-55). The transmembrane heparan
sulphate proteoglycan syndecan-4 is an essential element
in the formation of focal adhesions (56-58). Expression of
syndecan-4 in Chinese hamster ovary (CHO) cells resulted
in increased numbers of focal adhesion complexes (56). On
the other hand, CHO cell mutants deficient in glycosami-
noglycans showed reduced focal adhesion formation when
cultured on a fibronectin substrate (59). In our experiments,
reduction in heparan sulphation in MCF-7 breast cancer cells
was shown to increase cancer cell adhesion and upregulate
FAK and paxillin at both gene transcript and protein levels,
and this could be completely blocked by exogenous heparan
sulphate.
Heparan sulphate has been shown to be a key player in a
number of signalling pathways in cell migration. It has been
reported to modulate transendothelial migration of mono-
cytes by regulating G-protein-dependent signalling (60).
HT1080 fibrosarcoma cells that overexpressed the heparan
sulphate proteoglycan syndecan-2 showed activation of the
small GTPase Rac and increased cell migration (61).
Furthermore, in addition to acting as a co-receptor in FGF
signalling, heparan sulphate may act as a direct receptor in
the FGF-2 activation of ERK1/2, which is required for
bronchial epithelial and corneal epithelial cell migration
(62-64).
In conclusion, we have shown that heparan sulphate is a
useful biomarker of breast invasive ductal carcinoma, and is
involved in regulating cancer cell adhesion, migration and
focal adhesion complex formation through different sulphation
patterns on its sugar residues. A better understanding of the
effects of differentially sulphated heparan sulphate species
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on cancer cell behaviour is important for the development
of these molecules into therapeutic targets for breast cancer.
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